CA2319077A1 - Chemokine receptor antagonists and methods of use therefor - Google Patents

Chemokine receptor antagonists and methods of use therefor Download PDF

Info

Publication number
CA2319077A1
CA2319077A1 CA002319077A CA2319077A CA2319077A1 CA 2319077 A1 CA2319077 A1 CA 2319077A1 CA 002319077 A CA002319077 A CA 002319077A CA 2319077 A CA2319077 A CA 2319077A CA 2319077 A1 CA2319077 A1 CA 2319077A1
Authority
CA
Canada
Prior art keywords
group
substituted
aromatic
aliphatic group
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002319077A
Other languages
French (fr)
Inventor
Yoshisuke Nakasato
Jay R. Luly
Etsuo Ohshima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Millennium Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/148,823 external-priority patent/US6613905B1/en
Application filed by Individual filed Critical Individual
Publication of CA2319077A1 publication Critical patent/CA2319077A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/12—[b,e]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Abstract

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by structural formula (I) and physiologically acceptable salts thereof.

Description

CHEMOKINE RECEPTOR ANTAGONISTS
AND METHODS OF USE THEREFOR
RELATED APPLICATIONS
This application is a continuation-in-part of U.S.
Serial No. 09/148,823, filed September 4, 1998, which is a continuation-in-part of U.S. Serial No. 09/010,320, filed January 21, 1998, now abandoned, the entire teachings of wrich aYe incorporated herein by reference:
BACKGROUND OF THE INVENTION
Chemoattractart cytokines or chemckines are a family o' proirflammatory mediators that promote recruitment and activation of multiple lineages of leukocytes and lymphccytes. They can be released by many kinds of tissue
-2-cells after activation. Continuous release of chemokines at sites of inflammation mediates the ongoing migration of effector cells in chronic inflammation. The chemokines characterized to date are related in primary structure.
They share four conserved cysteines, which form disulfide bonds. Based upon this conserved cysteine motif, the family is divided into two main branches, designated as the C-X-C
chemokines (a-chemokines), and the C-C chemokines ((3-chemokines), in which the first two conserved cysteines are separated by an intervening residue, or adjacent respectively (Baggiolini, M. and Dahinden, C. A., Immunology Today, 15:127-133 (1994)).
The C-X-C chemokines include a number of potent chemoattractants and activators of neutrophils, such as interleukin 8 (IL-8), PF4 and neutrophil-activating peptide-2 (NAP-2). The C-C chemokines include RANTES
($egulated on 8ctivation, Normal T Expressed and secreted), the macrophage inflammatory proteins la and 1(3 (MIP-la and MIP-1(3), eotaxin and human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2, MCP-3), which have been characterized as chemoattractants and activators of monocytes or lymphocytes but do not appear to be chemoattractants for neutrophils. Chemokines, such as RANTES and MIP-la, have been implicated in a wide range of human acute and chronic inflammatory diseases including respiratory diseases, such as asthma and allergic disorders.
The chemokine receptors are members of a superfamily of G protein-coupled receptors (GPCR) which share
-3-structural features that reflect a common mechanism of action of signal transduction (Gerard, C. and Gerard, N.P., Annu Rev. Immunol., 12:775-808 (1994); Gerard, C. and Gerard, N. P., Curr. Opin. Immunol., 6:140-145 (1994)).
Conserved features include seven hydrophobic domains spanning the plasma membrane, which are connected by hydrophilic extracellular and intracellular loops. The majority of the primary sequence homology occurs in the hydrophobic transmembrane regions with the hydrophilic regions being more diverse. The first receptor for the C-C
chemokines that was cloned and expressed binds the chemokines MIP-la and RANTES. Accordingly, this MIP-la/RANTES receptor was designated C-C chemokine receptor 1 (also referred to as CCR-1; Neote, K., et al., Cell, 72:415-425 (1993); Horuk, R. et al., WO 94/11504, May 26, 1994; Gao, J.-I. et al., J. Exp. Med., 177:1421-1427 (1993)). Three receptors have been characterized which bind and/or signal in response to RANTES: CCR3 mediates binding and signaling of chemokines including eotaxin, RANTES, and MCP-3 (Ponath et al., J. Exp. Med., 183:2437 (1996)), CCR4 binds chemokines including RANTES, MIP-la, and MCP-1 (Power, et al., J. Biol. Chem., 270:19495 (1995)), and CCRS binds chemokines including MIP-la, RANTES, and MIP-1(3 (Samson, et al., Biochem. 35: 3362-3367 (1996)). RANTES is a chemotactic chemokine for a variety of cell types, including monocytes, eosinophils, and a subset of T-cells. The responses of these different cells may not all be mediated by the same receptor, and it is possible that the receptors CCR1, CCR4 and CCR5 will show ~4-some selectivity in receptor distribution and function between leukocyte types, as has already been shown for CCR3 (Ponath et al.). In particular, the ability of RANTES to induce the directed migration of monocytes and a memory population of circulating T-cells (Schall, T. et al., Nature, 347:669-71 (1990)) suggests this chemokine and its receptors) may play a critical role in chronic inflammatory diseases, since these diseases are characterized by destructive infiltrates of T cells and monocytes.
Many existing drugs have been developed as antagonists of the receptors for biogenic amines, for example, as antagonists of the dopamine and histamine receptors. No successful antagonists have yet been developed to the receptors for the larger proteins such as chemokines and CSa. Small molecule antagonists of the interaction between C-C chemokine receptors and their ligands, including RANTES
and MIP-la, would provide compounds useful for inhibiting harmful inflammatory processes "triggered" by receptor ligand interaction, as well as valuable tools for the investigation of receptor-ligand interactions.
SUMMARY OF THE INVENTION
It has now been found that a class of small organic molecules are antagonists of chemokine receptor function and can inhibit leukocyte activation and/or recruitment.
An antagonist of chemokine receptor function is a molecule which can inhibit the binding and/or activation of one or more chemokines, including C-C chemokines such as RANTES, WO 99/37651 PC'T/US99/01266 MIP-la, MCP-2, MCP-3 and MCP-4 to one or more chemokine receptors on leukocytes and/or other cell types. As a consequence, processes and cellular responses mediated by chemokine receptors can be inhibited with these small organic molecules. Based on this discovery, a method of treating a disease associated with aberrant leukocyte recruitment and/or activation is disclosed as well as a method of treating a disease mediated by chemokine receptor function. The method comprises administering to a subject in need an effective amount of a compound or small organic molecule which is an antagonist of chemokine receptor function. Compounds or small organic molecules which have been identified as antagonists of chemokine receptor function are discussed in detail hereinbelow, and can be used for the manufacture of a medicament for treating or for preventing a disease associated with aberrant leukocyte recruitment and/or activation. The invention also relates to the disclosed compounds and small organic molecules for use in treating or preventing a disease associated with aberrant leukocyte recruitment and/or activation. The invention also includes pharmaceutical compositions comprising one or more of the compounds or small organic molecules which have been identified herein as antagonists of chemokine function and a suitable pharmaceutical carrier. The invention further relates to novel compounds which can be used to treat an individual with a disease associated with aberrant leukocyte recruitment and/or activation and methods for their preparation.

BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a schematic showing the preparation of the compounds represented by Structural Formula (I).
Figure 2 is a schematic showing the preparation of the compounds represented by Compound (VI-b).
Figure 3 is a schematic showing the preparation of the compounds represented by Structural Formula (I) Figure 4 is a schematic showing the preparation of the compounds represented by Structural Formula (I), wherein Z
is represented by Structural Formula (III) and wherein Ring A and/or Ring B in Z is substituted with R°o.
Figure 5 is a schematic showing the preparation of the compounds represented by Structural Formula (I), wherein Z
is represented by Structural Formula (III) and wherein Ring A and/or Ring H in Z is substituted with - (O) u- (CHz) t-COORz°, - (O) "- (CHz) t-OC (O) Rz°, - (O) u- (CHz) t-C (O) -NRzlRzz or' - (O) "- (CHz) t-NHC (O) O-Rz° .
Figures 6A-6Z show the structures of exemplary compounds of the present invention.
Figure 7 shows the preparation of compounds represented by Structural Formula (I), where in Z is represented by Structural Formulas (III) and wherein Ring A
or Ring B in Z is substituted with R4o.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to small molecule compounds which are modulators of chemokine receptor function. In a preferred embodiment, the small molecule compounds are antagonists of chemokine receptor function.

Accordingly, processes or cellular responses mediated by the binding of a chemokine to a receptor can be inhibited (reduced or prevented, in whole or in part), including leukocyte migration, integrin activation, transient increases in the concentration of intracellular free calcium [Ca"]i, and/or granule release of proinflammatory mediators.
The invention further relates to a method of treatment, including prophylactic and therapeutic treatments, of a disease associated with aberrant leukocyte recruitment and/or activation or mediated by chemokines or chemokine receptor function, including chronic inflammatory disorders characterized by the presence of RANTES, MIP-la, MCP-2, MCP-3 and/or MCP-4 responsive T cells, monocytes and/or eosinophils, including but not limited to diseases such as arthritis (e. g., rheumatoid arthritis), atherosclerosis, arteriosclerosis, ischemia/reperfusion injury, diabetes mellitus (e. g., type 1 diabetes mellitus), psoriasis, multiple sclerosis, inflammatory bowel diseases such as ulcerative colitis and Crohn's disease, rejection of transplanted organs and tissues (i.e., acute allograft rejection, chronic allograft rejection}, graft versus host disease, as well as allergies and asthma. Other diseases associated with aberrant leukocyte recruitment and/or activation which can be treated (including prophylactic treatments) with the methods disclosed herein are inflammatory diseases associated with Human Immunodeficiency Virus (HIV) infection, e.g., AIDS
associated encephalitis, AIDS related maculopapular skin eruption, AIDS related interstitial pneumonia, AIDS related enteropathy, AIDS related periportal hepatic inflammation and AIDS related glomerulo nephritis. The method comprises administering to the subject in need of treatment an effective amount of a compound (i.e., one or more compounds) which inhibits chemokine receptor function, inhibits the binding of a chemokine to leukocytes and/or other cell types, and/or which inhibits leukocyte migration to, and/or activation at, sites of inflammation.
The invention further relates to methods of antagonizing a chemokine receptor, such as CCR1, in a mammal comprising administering to the mammal a compound as described herein.
According to the method, chemokine-mediated chemotaxis and/or activation of pro-inflammatory cells bearing receptors for chemokines can be inhibited. As used herein, "pro-inflammatory cells" includes but is not limited to leukocytes, since chemokine receptors can be expressed on other cell types, such as neurons and epithelial cells.
While not wishing to be bound by any particular theory or mechanism, it is believed that compounds of the invention are antagonists of the chemokine receptor CCR1, and that therapeutic benefits derived from the method of the invention are the result of antagonism of CCR1 function. Thus, the method and compounds of the invention can be used to treat a medical condition involving cells which express CCR1 on their surface and which respond to signals transduced through CCR1, as well as the specific conditions recited above.

_g_ In one embodiment, the antagonist of chemokine receptor function is represented by Structural Formula (I):
Z
(C~rr- N M
(I) and physiologically acceptable salts thereof.
Z is a cycloalkyl or non-aromatic heterocyclic ring group fused to one, two or more aromatic rings, wherein each ring in Z is independently substituted or unsubstituted.
n is an integer, such as an integer from one to about four. Preferably, n is one, two or three. More preferably n is two. In alternative embodiments, other aliphatic or aromatic spacer groups (L) can be employed for (CH2) ".
M is >NRZ or >CR1R2 . M is preferably >C (OH) Rz .
R1 is -H, -OH, -N3, a halogen, an aliphatic group, -O-(aliphatic group), -O-(substituted aliphatic group), -SH, -S-(aliphatic group), -S-(substituted aliphatic group), -OC(O)-(aliphatic group), -O-C(O)-(substituted aliphatic group), -C(O)O-(aliphatic group), -C(O)O-(substituted aliphatic group), -COOH, -CN, -CO-NR'R', -NR3R4; or R1 can be a covalent bond between the ring atom at M and an adjacent carbon atom in the ring which contains M. R1 is preferably -H or -OH.

RZ is -H, -OH, an acyl group, a substituted acyl group, -NRSR6, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group, a substituted benzyl group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group. RZ is preferably an aromatic group or a substituted aromatic group.
R', R4, RS and R6 are independently -H, an acyl group, a substituted acyl group, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group, a substituted benzyl group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group.
R1 and R2, R' and R°, or RS and R6 taken together with the atom to which they are bonded, can alternatively form a substituted or unsubstituted non-aromatic carbocyclic or heterocyclic ring.
In embodiments where M is >CR1R~ and R1 is a covalent bond between the carbon atom at M and an adjacent carbon atom in the ring which contains M, the antagonist of chemokine function can be represented by Structural Formula (Ia) .
(CHZ~N C R2 Z
( Ia) Z, n and R2 are as described in Structural Formula (I).

In one preferred embodiment, Z is a tricyclic ring system comprising two carbocyclic aromatic groups fused to a six, seven or eight membered cycloalkyl group or to a non-aromatic heterocyclic ring. In one example, Z is represented by Structural Formula (II):
(II) The phenyl rings in Structural Formula (II), labeled with an "A" and "B", are referred to herein as "Ring A" and "Ring B", respectively. The central ring, labeled with a "C", is referred to as "Ring C" and can be, for example, a six, seven or eight membered non-aromatic carbocyclic ring (e. g., a cycloheptane or cyclooctane ring) or a non-aromatic heterocyclic ring. When Ring C is a non-aromatic heterocyclic ring, it can contain one or two heteroatoms such as nitrogen, sulfur or oxygen. When Z is represented by Structural Formula (II), the tricyclic ring system can be connected to the remainder of the molecule by a covalent double bond between a carbon atom in Ring C and the carbon atom which, as depicted in Structural Formula (I), is bonded to Z.
Ring A and/or Ring B in Structural Formula (II) can be unsubstituted. Alternatively, Ring A and/or Ring B can have one or more substituents. Suitable substituents are as described hereinbelow. In one example, Ring A or Ring B
is substituted with - (O) "- (CHZ) t-C (O) ORZO, - (O) u- (CH2) t-OC (O) RZ°, _ (O) u- (CHZ) t-C (O) -NR21Ra2 or - (O) u- (CHZ) t-NHC (0) 0-RZ°.
a is zero or one.
t is an integer, such as an integer from zero to about three, and the methylene group -(CHZ)t- can be substituted or unsubstituted.
RZ°, RZ1 or R22 are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group. Alternatively, Rzl and RZ2, taken together with the nitrogen atom to which they are bonded, can form a non-aromatic heterocyclic ring.
Ring C optionally contains one or more substituents, as described hereinbelow.
Examples of suitable tricyclic ring systems, Z, are provided by Structural Formula (III):
i ~i (III) Ring A and Ring B in Structural Formula (III) are as described for Structural Formula (II).
X1 is -S-, -CHZ-, -CHz-CH2-, -CHZ-S-, -S-CHZ-, -O-CH2-, -CHz-0-, -NR~-CHZ-, -CHz-NR~-, -SO-CH2-, -CHZ-SO-, -S (0) 2-CHz-, -CHz-S (O) Z-, -CH=CH-, -NR~-CO- or -CO-NR~-.
Preferably X1 is -CHZ-O-, -CHZ-CHZ-, -CHz-S- , -NR~-CO- or -CO-NR~- .
R~ is hydrogen, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic l0 group, a benzyl group or a substituted benzyl group.
In one example, R~ is - (CHz) s-COOR'°, - (CHZ) e-C (O) -NR'1R'2 or - (CHZ) e-NHC (O) -O-R3°, wherein s is an integer, such as an integer from one to about three;
Rao~ R31 and R32 are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group. Alternatively, R31 and R'2, taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring.
Other examples of suitable tricyclic ring systems for Z include benzodiazepines, benzooxazepines, benzooxazines, phenothiazines and groups represented by the following structural formulas:

\ S I \ ( \ I \
/ / ~ /
S
\ ~ \ \ \
/ I / ,I /
, S O
\ \ \ \
I~/ ~ / ,~ / ~ / , \ \
/
S
In another preferred embodiment, Z is a tricyclic ring system comprising two aromatic groups fused to a seven or eight membered cycloalkyl group or to a non-aromatic heterocyclic ring, wherein at least one of the aromatic groups is a heteroaryl group. In one example, Z is represented by Structural Formula (IV):
x~
(IV) Ring A in Structural Formula (IV) can be a substituted or unsubstituted heteroaryl group. Ring B in Structural Formula (IV) can be a substituted or unsubstituted aromatic group, e.g., a heteroaryl group or carbocyclic aryl group.
Suitable substituents are as described hereinbelow. In one example, Ring A and/or Ring B is substituted with - (O) "- (CH2) c-C (O) ORZ°, - (O) "- (CHZ) c-OC (O) RZ°, - (O) "- (CHZ) t-C (O) -NRZ1R~2 or - (O) "- (CH2) t-NHC (O) O-R2° as described above. u, t, RZ°, R21, and R22 are as described above. X1 and R~ can be as described above for Structural Formula ( I I I ) .
In another embodiment of the present invention Z is represented by Structural Formula (IV), wherein Ring A is a pyridyl group and Ring B is an aromatic or heteroaromatic group. In this embodiment Ring A and Ring B are independently substituted or unsubstituted, and Ring B is preferably a phenyl group. X1 and R~ can be as described above for Structural Formula (III).
In another embodiment of the present invention Z is represented by Structural Formula (V):
1A1 ~ IB
(V) Ring A and Ring B can be independently substituted or unsubstituted as described above in Structural Formula (II), and X1 can be as described above for Structural Formula (III).
In a preferred embodiment, Ring B in Structural Formula (V) is substituted para to the carbon atom of Ring B which is bonded to X1 of Ring C, and Z is represented by Structural Formula (VI):
Rao I A I C I B
N~ 'X~
(VI) X1 can be as described above in Structural Formula (II) . Preferably X, is -CHz-O-, -CHZ-CHz- or -CHZ-S-.
R4° is a substituent as described hereinbelow.
Preferably R4° is an aliphatic group, substituted aliphatic group, -O-(aliphatic group) or -O-(substituted aliphatic group). More preferably R4° is an -O-alkyl, such as -O-CH3, -O-CZHS, -O-C3H, or -O-C4H9.
In another embodiment, the antagonist of chemokine activity can be represented by Structural Formula (VII):

( C~'~-N M
Z
(VII) and physiologically acceptable salts thereof.
n and M are as described in Structural Formula (I).
Z is as described herein, preferably as described in Structural Formula (V) or (VI).
q is an integer, such as an integer from zero to about three, and the ring containing M can be substituted or unsubstituted.
Thus, the antagonist of chemokine function can be represent by, for example, Structural Formulas (VIIa)-(VIId) ~(CHZ n M
~(CFh n M
Z
Z
(VIIa) (VIIb) WO 99/37651 PCT/US99/O1?.66 ~ R2 C
M c c~z n CFiz n Z
Z
(VIII) (VIId) and physiologically acceptable salts thereof, wherein Z, n and M are as described in Structural Formula (VII), and the ring which contains M is substituted or unsubstituted.
Another embodiment of the present invention includes novel compounds employed in these methods.
The compounds disclosed herein can be obtained as E-and Z-configurational isomers. It is expressly pointed out that the invention includes compounds of the E-configuration and the Z-configuration around the double bond connecting Ring C of Z to the remainder of the molecule, and a method of treating a subject with compounds of the E-configuration', the Z-configuration, and mixtures thereof. Accordingly, in the structural formulas presented herein, the symbol:
is used to represent both the E-configuration and the Z-configuration. Preferably Ring A and the alkylene chain bonded to Ring C are in the cis configuration. For example, the compounds can have the configuration of:

f It is understood that one configuration can have greater activity than another. The desired configuration can be determined by screening for activity, employing the methods described herein.
Additionally, certain compounds of the invention may be obtained as different sterioisomers (e. g., diastereomers and enantiomers). It is pointed out that the invention includes all isomeric forms and racemic mixtures of the disclosed compounds and a method of treating a subject with both pure isomers and mixtures thereof, including racemic mixtures. Again, it is understood that one sterioisomer may be more active than another. The desired isomer can be determined by screening.
Also included in the present invention are physiologically acceptable salts of the compounds represented by Structural Formulas (I) through (VIId).
Salts of compounds containing an amine or other basic group can be obtained, for example, by reacting with a suitable organic or inorganic acid, such as hydrogen chloride, hydrogen bromide, acetic acid, citric acid, perchloric acid and the like. Compounds with a quaternary ammonium group also contain a counteranion such as chloride, bromide, iodide, acetate, perchlorate and the like. Salts of compounds containing a carboxylic acid or other acidic functional group can be prepared by reacting with a suitable base, for example, a hydroxide base. Salts of acidic functional groups contain a countercation such as sodium, potassium, ammonium, calcium and the like.
As used herein, aliphatic groups include straight chained, branched or cyclic C1-Czo hydrocarbons which are completely saturated or which contain one or more units of unsaturation. For example, suitable aliphatic groups include substituted or unsubstituted linear, branched or cyclic C1-C2o alkyl, alkenyl or alkynyl groups.
Aromatic groups include carbocyclic aromatic groups such as phenyl, 1-naphthyl, 2-naphthyl, 1-anthracyl and 2-anthracyl, and heterocyclic aromatic or heteroaryl groups such as N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 2-thienyl, 3-thienyl, 2-furanyl, 3-furanyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-pyrimidyl, 3-pyridazinyl, 4-pyridazinyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 2-pyrazinyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 5-tetrazolyl, 2-oxazolyl, 4-oxazolyl and 5-oxazolyl. Where these rings are fused, for example, to Ring C, the stated point of attachment can be either of the two fused bonds.
Aromatic groups also include fused polycyclic aromatic ring systems in which a carbocyclic aromatic ring or heteroaryl ring is fused to one or more other rings.

Examples include tetrahydronaphthyl, 2-benzothienyl, 3-benzothienyl, 2-benzofuranyl, 3-benzofuranyl, 2-indolyl, 3-indolyl, 2-quinolinyl, 3-quinolinyl, 2-benzothiazolyl, 2-benzooxazolyl, 2-benzimidazolyl, 2-quinolinyl, 3-quinolinyl, 1-isoquinolinyl, 3-quinolinyl, 1-isoindolyl, 3-isoindolyl, acridinyl, 3-benzisoxazolyl, and the like.
Also included within the scope of the term "aromatic group", as it is used herein, is a group in which one or more carbocyclic aromatic rings and/or heteroaryl rings are fused to a cycloalkyl or non-aromatic heterocyclic ring, for example, benzocyclopentane, benzocyclohexane.
Non-aromatic heterocyclic rings are non-aromatic carbocyclic rings which include one or more heteroatoms such as nitrogen, oxygen or sulfur in the ring. The ring can be five, six, seven or eight-membered and/or fused to another ring, such as a cycloalkyl on aromatic ring.
Examples include 3-1H-benzimidazol-2-one, 3-1-alkyl-benzimidazol-2-one, 3-1-methyl-benzimidazol-2-one, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahyrothiophenyl, 3-tetrahyrothiophenyl, 2-morpholino, 3-morpholino, 4-morpholino, 2-thiomorpholino, 3-thiomorpholino, 4-thiomorpholino, 1-pyrrolsdinyl, 2-pyrrolidinyl, 3-pyrrolsdinyl, 1-piperazinyl, 2-piperazinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl,
4-thiazolidinyl, diazolonyl, N-substituted diazolonyl, 1-phthalimidyl, 1-3-alkyl-phthalimidyl, benzoxane, benzopyrolidine, benzopiperidine, benzoxolane, benzothiolane, benzothiane, WO 99!37651 PCT/US99/01266 o ~ o p s / \ / \ / \ / \ / \ / \ / 1 / \
-, . ~ . ,.. . ~ .~ . ~ .
° p ° p °
° ° /off 0 ~'O NH NH NH N
HN fW O
/ \ / \ / \ \ / \ / \ / \ / \
Cl ~ Cl ~ ~ ~ ~ ~ ~ ~ ~ , ~ and ~
Suitable substituents on an aliphatic group, aromatic group (carbocyclic and heteroaryl), non-aromatic heterocyclic ring or benzyl group include, for example, an electron withdrawing group, a halogen, azido, -CN, -COOH, -OH, -CONRz°Rzs ~ -NRa4Rzs ~ _OS (O) ,NRz4Rzs ~ -S (O) a~zaRzs ~ -S03H
-S (O) zNH" guanidino, - (O) "- (CHz) t-C (O) ORzo, - (O) "- (CHz) t-OC (0) Rzo ~ _ (O) "- (CHz) t-C (O) -NRzlRzz - (O) "- (CHz) t-NHC (O) O-Rz°, -Q-H, -Q- (aliphatic group) , -Q-{substituted aliphatic group), -Q-(aryl), -Q-(aromatic group), -Q-(substituted aromatic group), -Q-(CHz)p-{substituted or unsubstituted aromatic group) (p is an integer from 1-5), -Q-(non-aromatic heterocyclic group) or -Q-(CHz)p-(non-aromatic heterocyclic group).
Rz°, Rzl or Rzz are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a non-aromatic heterocyclic group, -NHC(O)-O-(aliphatic group), -NHC(O)-O-(aromatic group) or -NHC(O)-O-(non-aromatic heterocyclic group) and wherein R21 and R2z, taken together with the nitrogen atom to which they are bonded, can form a non-aromatic heterocyclic ring.
t is an integer from zero to about three, and the methylene group, -(CHZ)t-, can be substituted or unsubstituted.
a is zero or one.
Q is -O-, -S-, -S (O) -, -S (O) a-, -OS (O),-, -C (O) -, -OC (O) -, -C (O) O-, -C (O) C (O) -O-, -O-C (O) C (O) -, -C (O) NH-, -NHC (O) -, -OC (O) NH-, -NHC (O) O-, -NH-C (O) -NH-, -S (O) zNH-, -NHS (O),-, -N (RZ') -. -C (NR") NHNH-, -NHNHC (NR~') -, -NRZ'C (O) -or -NR2'S (O) 2- .
R~' is -H, an aliphatic group, a benzyl group, an aryl group or non-aromatic heterocyclic group.
RZ' and RZS are independently -H, -OH, an aliphatic group, a substituted aliphatic group, a benzyl group, an aryl group or non-aromatic heterocyclic group.
A substituted non-aromatic heterocyclic ring, benzyl group or aromatic group can also have an aliphatic or substituted aliphatic group, as a substituent. A
substituted aliphatic group can also have an oxo group, epoxy group, non-aromatic heterocyclic ring, benzyl group, substituted benzyl group, aromatic group or substituted aromatic group as a substituent. A substituted non-aromatic heterocyclic ring can also have =O, =S, =NH or =N(aliphatic, aromatic or substituted aromatic group) as a substituent. A substituted aliphatic, substituted aromatic, substituted non-aromatic heterocyclic ring or substituted benzyl group can have more than one substituent.
Acyl groups include substituted and unsubstituted aliphatic carbonyl, aromatic carbonyl, aliphatic sulfonyl and aromatic sulfonyl.
Suitable electron withdrawing groups include, for example, alkylimines, alkylsulfonyl, carboxamido, carboxylic alkyl esters, -CH=NH, -CN, -NOZ and halogens.
In the structural formulas depicted herein, the single or double bond by which a chemical group or moiety is connected to the remainder of the molecule or compound is indicated by the following symbol:
"
For example, the corresponding symbol in Structural Formulas (II), (III) and (IV) indicates the double bond by which the central ring of the tricyclic ring system is connected to the remainder of the molecule represented by Structural Formula (I).
A "subject" is preferably a bird or mammal, such as a human, but can also be an animal in need of veterinary treatment, e.g., domestic animals (e.g., dogs, cats, and the like), farm animals (e. g., cows, sheep, fowl, pigs, horses, and the like) and laboratory animals (e. g., rats, mice, guinea pigs, and the like).
An "effective amount" of a compound is an amount which results in the inhibition of one or more processes mediated by the binding of a chemokine to a receptor in a subject with a disease associated with aberrant leukocyte recruitment and/or activation. Examples of such processes include leukocyte migration, integrin activation, transient increases in the concentration of intracellular free calcium [Ca2'] i and granule release of proinflammatory mediators. Alternatively, an "effective amount" of a compound is a quantity sufficient to achieve a desired therapeutic and/or prophylactic effect, such as an amount which results in the prevention of or a decrease in the symptoms associated with a disease associated with aberrant leukocyte recruitment and/or activation.
The amount of compound administered to the individual will depend on the type and severity of the disease and on the characteristics of the individual, such as general health, age, sex, body weight and tolerance to drugs. It will also depend on the degree, severity and type of disease. The skilled artisan will be able to determine appropriate dosages depending on these and other factors.
Typically, an effective amount of the compound can range from about 0.1 mg per day to about 100 mg per day for an adult. Preferably, the dosage ranges from about 1 mg per day to about 100 mg per day. An antagonist of chemokine receptor function can also be administered in combination with one or more additional therapeutic agents, e.g.
theophylline, (3-adrenergic bronchodilators, corticosteroids, antihistamines, antiallergic agents, immunosuppressive agents (e. g., cyclosporin A, FK-506, prednisone, methylprednisolone) and the like.

The compound can be administered by any suitable route, including, for example, orally in capsules, suspensions or tablets or by parenteral administration. Parenteral administration can include, for example, systemic administration, such as by intramuscular, intravenous, subcutaneous, or intraperitoneal injection. The compound can also be administered orally (e. g., dietary), transdermally, topically, by inhalation (e. g., intrabronchial, intranasal, oral inhalation or intranasal drops), or rectally, depending on the disease or condition to be treated. Oral or parenteral administration are preferred modes of administration.
The compound can be administered to the individual in conjunction with an acceptable pharmaceutical or physiological carrier as part of a pharmaceutical composition for treatment of HIV infection, inflammatory disease, or the other diseases discussed above.
Formulation of a compound to be administered will vary according to the route of administration selected (e. g., solution, emulsion, capsule). Suitable carriers may contain inert ingredients which do not interact with the compound. Standard pharmaceutical formulation techniques can be employed, such as those described in Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA. Suitable carriers for parenteral administration include, for example, sterile water, physiological saline, bacteriostatic saline (saline containing about 0.9% mg/ml benzyl alcohol), phosphate-buffered saline, Hank's solution, Ringer's-lactate and the like. Methods for encapsulating compositions (such as in a coating of hard gelatin or cyclodextran) are known in the art (Baker, et al., "Controlled Release of Biological Active Agents", John Wiley and Sons, 1986).
The activity of compounds of the present invention can be assessed using suitable assays, such as receptor binding assays and chemotaxis assays. For example, as described in the Exemplification Section, small molecule antagonists of , RANTES and MIP-la binding have been identified utilizing THP-1 cells which bind RANTES and chemotax in response to RANTES and MIP-la as a model for leukocyte chemotaxis.
Specifically, a high through-put receptor binding assay, which monitors 125I-RANTES and lZSI_MIP-la binding to THP-1 cell membranes, was used to identify small molecule antagonists which block binding of RANTES and MIP-la.
Compounds of the present invention can also be identified by virtue of their ability to inhibit the activation steps triggered by binding of a chemokine to its receptor, such as chemotaxis, integrin activation and granule mediator release. They can also be identified by virtue of their ability to block RANTES and MIP-la mediated HL-60, T-cell, peripheral blood mononuclear cell, and eosinophil chemotactic response.
The compounds disclosed herein can be prepared accordingly to the schemes shown in Figures 1 - 5 and 7.
The schemes are described in greater detail below.
Figure 1 shows the preparation of compounds represented by Structural Formula ( I ) . L1 is PPh3C1, PPh3Br, PPh3I or (Et0)ZP(O), LZ is a suitable leaving group such as halogen, p-toluene sulfonate, mesylate, alkoxy, and phenoxy; Pg is a suitable protecting group such as tetrahydropyranyl; and the other symbols are as defined above.
In Step 1 of Figure 1, a Wittig reaction is carried out in a solvent such as ether, or tetrahydrofuran (THF) in the presence of a base such as sodium hydride, n-butyl lithium or lithium diisopropylamide (LDA) at 0°C up to the reflux temperature for the solvent used for 5 minutes to 72 h. Compounds represented by Formula II in Figure 1 can be prepared by methods disclosed in JP 61/152673, U.S.
Patent 5089496, WO 89/10369, WO 92/20681 and WO 93/02081, the entire teachings of which are incorporated herein by reference.
In Step 2 of Figure 1, deprotection is carried out with an acid in a solvent such as methanol at room temperature up to the reflux temperature for the solvent used for 5 minutes to 72 h. Alternatively, a compound of represented by Formula V in Figure 1 can be prepared directly from step 1 without isolating an intermediate.
The reaction mixture obtained after the work up of the reaction described in step 1 can be dissolved in the solvent and reacted with the acid.
In Step 3 of Figure 1, the hydroxy group can be converted to a leaving group by known methods. Compounds represented by Formula VI in Figure 1 can be prepared by methods disclosed in J. Med. Chem., 1992 (35) 2074-2084 and JP 61/152673.
In Step 4 of Figure 1, an alkylation reaction is carried out in a solvent such as acetone, methyl ethyl ketone, ethyl acetate, toluene, tetrahydrofuran (THF) or dimethylformamide (DMF) in the presence of a base such as potassium carbonate or sodium hydride and a catalyst such as an alkali metal iodide at room temperature up to the reflux temperature for the solvent used for 5 minutes to 72 h.
Figure 2 shows the preparation of compounds represented by Compound (VI-b). In Step 1 of Figure 2, a Grignard reaction may be carried out in a solvent such as ether, or tetrahydrofuran (THF) at 0°C up to the reflux temperature for the solvent used for 5 minuets to 72 h.
Compound VII is available commercially.
In Step 2 of Figure 2, bromination may be carried out with brominate agents such as hydrobromic acid, bromotrimethylsilane or boron tribromide-methyl sulfide complex in a solvent such as acetic acid, dichloromethane or dichloroethane at room temperature up to the reflux temperature for the solvent used for 5 minutes to 72 h.
Figure 3 shows the preparation of compounds represented by Structural Formula (I). In Figure 3, a reductive amination may be carried out with reducing regents such as sodium cyanoborohydride, sodium acetoxyborohydride or sodium borohydride in a solvent such as methanol, ethanol, tetrahydrofuran (THF), dichloromethane or dichloroethane at room temperature up to the reflux temperature for the solvent used for 5 minutes to 72 h.
Figure 4 shows the preparation of compounds represented by Structural Formula (I), where in Z is WO 99/37651 . PCT/US99/01266 represented by Structural Formulas (III) and wherein Ring A
and/or Ring B in Z is substituted with R4°. In Figure 4, the alkylation reaction can be carried out in a solvent such as acetone, methyl ethyl ketone, ethyl acetate, toluene, tetrahydrofuran (THF) or dimethylformamide (DMF) in the presence of a base such as potassium carbonate or sodium hydride and a catalyst such as an alkali metal iodide at room temperature up to the reflux temperature for the solvent used for 5 minutes to 72 h.
Figure 5 is a schematic showing the preparation of the compounds represented by Structural Formula (I), wherein Z is represented by Structural Formulas (III) and wherein Ring A and/or Ring B in Z is substituted with - (O) u- (CH2) t-COORZ°, - (O) "- (CHZ) t-OC (O) RZ°, - (O) "- (CHz) t-C (O) -NR21Rz2 or - (O) "- (CHZ) t-NHC (O) O-Rio. In Figure 5, the hydrolysis reaction may be carried out in a mixture of aqueous alkali metal hydroxide solution and a solvent such as methanol, ethanol, tetrahydrofuran (THF) or dioxane at room temperature up to the reflux temperature for the solvent used for 5 minutes to 72 h. The acylation reaction can be carried out using dicyclohexylcarbodiimide (DCC) or (1-ethyl-3-(3- dimethylaminopropyl)carbodiimide (DEC) in a solvent such as tetrahydrofuran (THF), dimethylformamide (DMF) or methylene chloride in the presence of a base such as pyridine or triethylamine (when necessary) at temperatures of 0 to 100°C for 5 minutes to 72 h.
Figure 7 shows the preparation of compounds represented by Structural Formula (I), wherein Z is represented by Structural Formulas (III) and wherein Ring A
or Ring B in Z is substituted with R'°. L4 is a suitable leaving group such as halogen or trifluoromethylsulfonate.
In Figure 7, a palladium coupling reaction such as Stille coupling, Suzuki coupling, Heck reaction, or carboxylation using carbon monoxide may be carried out using a palladium catalyst such as tetrakis(triphenylphosphine)palladium, bis(triphenylphosphine)palladium chloride, and palladium acetate in a solvent such as tetrahydrofuran (THF), 1,4-dioxane, toluene, dimethylformamide (DMF), or dimethylsufoxide (DMSO) in the presence of additive (when necessary) such as triphenylphosphine, 1,1'-bis(diphenylphosphino)ferrocene, triethylamine, sodium bicarbonate, tetraethylammonium chloride, or lithium chloride at room temperature up to the reflux temperature for the solvent used for 5 minutes to 72 h.
Compounds represented by Structural Formula (I), wherein Z is represented by Structural Formulas (III) or (IV) , X is -CO-NR~- and R~ is - (CHZ) $-COORS°, - (CHZ) 9-C (O) -~31R32 or - (CHZ) $-NHC (O) -O-R3°, can be prepared by suitable modification of the scheme shown in Figure 1-5 and 7. One modification utilizes the starting material shown in Figure 1, wherein X is -CO-NH-. The amide is then alkylated with L3- (CH2.) 9-COORS°, wherein L' is a suitable leaving group, using the alkylation procedures described above. The remainder of the synthesis is as described in Figures 1 - 5 and 7.

Although Figures 1 - 5 and 7 show the preparation of compounds in which Rings A and H are phenyl rings, analogous compounds with heteroaryl groups for Rings A and B can be prepared by using starting materials with heteroaryl groups in the corresponding positions. These starting materials can be prepared according to methods disclosed in JP 61/152673, U.S. Patent 5089496, WO
89/10369, WO 92/20681 and WO 93/02081.
The invention is illustrated by the following examples which are not intended to be limiting in any way.
EXEMPLIFICATION
Example 1 - 4-(4-Chlorophenyl)-1-[3-(10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-ylidene)propyl]piperidin-4-of To a solution of 5-(3-bromopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene (described in JP
48-030064)(200mg) in DMF (lOml) were added 4-(4-chlorophenyl)-4-hydroxypiperidine (230mg), potassium carbonate (360mg), and potassium iodide (50mg). The mixture was stirred at 70°C for 24 hours. Water and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate. The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with ethyl acetate-hexane (1:1) to give the titled compound (250mg) . 1H-NMR (CDC13) 8: 1.65-2.11 (SH,m) , 2.32-3.10 (8H,m) , 3.22-3.67(4H,m), 5.87(lH,t), 7.03-7.44(l2H,m). MS m/z:
444 (M+1 ) .

Example 2 - 4-(4-Chlorophenyl)-1-[3-(6,11-dihydrodibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of Example 1, but replacing 5-(3-bromopropylidene)-I0,11-dihydro-5H-dibenzo[a,d]cycloheptene with 11-(3-bromopropylidene)-6,11-dihydrodibenz[b, e]
oxepine. 1H-NMR (CDC13) 8: 1.61-2.16 (SH,m) , 2.37-2.80(8H,m), 5.22(2H,brs), 5.70(0.6x1H,t), 6.03(0.4xIH,t), 6.73-6.90(2H,m), 7.09-7.45(lOH,m). MS m/z:
446(M+1) Example 3 - Membrane Preparations for Chemokine Binding and Binding Assays Membranes were prepared from THP-1 cells (ATCC
#TIB202). Cells were harvested by centrifugation, washed twice with PBS (phosphate-buffered saline), and the cell pellets were frozen at -70 to -85°C. The frozen pellet was thawed in ice-cold lysis buffer consisting of 5 mM HEPES
(N-2-hydroxyethylpiperazine-N~-2-ethane-sulfonic acid) pH
7.5, 2 mM EDTA (ethylenediaminetetraacetic acid), 5 ~.g/ml each aprotinin, leupeptin, and chymostatin (protease inhibitors), and 100 ~,g/ml PMSF (phenyl methane sulfonyl fluoride - also a protease inhibitor), at a concentration of 1 to 5 x 10' cells/ml. This procedure results in cell lysis. The suspension was mixed well to resuspend all of the frozen cell pellet. Nuclei and cell debris were removed by centrifugation of 400 x g for 10 minutes at 4°C.
The supernatant was transferred to a fresh tube and the membrane fragments were collected by centrifugation at WO 99/37651 PC'T/US99/01266 25,000 x g for 30 minutes at 4°C. The supernatant was aspirated and the pellet was resuspended in freezing buffer consisting of 10 mM HEPES pH 7.5, 300 mM sucrose, l~cg/ml each aprotinin, leupeptin, and chymostatin, and 10 /cg/ml PMSF (approximately 0.1 ml per each 108 cells). All clumps were resolved using a minihomogenizer, and the total protein concentration was determined using a protein assay kit (Bio-Rad, Hercules, CA, cat #500-0002). The membrane solution was then aliquoted and frozen at -70 to -85°C
until needed.
Binding Assays utilized the membranes described above.
Membrane protein (2 to 20 dug total membrane protein) was incubated with 0.1 to 0.2 nM l2sl-labeled RANTES or MIP-la with or without unlabeled competitor (RANTES or MIP-la) or various concentrations of compounds. The binding reactions were performed in 60 to 100 ~C1 of a binding buffer consisting of 10 mM HEPES pH 7.2, 1 mM CaCl2, 5 mM MgCl2, and 0.5~ BSA (bovine serum albumin}, for 60 min at room temperature. The binding reactions were terminated by harvesting the membranes by rapid filtration through glass fiber filters (GF/B or GF/C, Packard) which were presoaked in 0.3~ polyethyleneimine. The filters were rinsed with approximately 600 ~.1 of binding buffer containing 0.5 M
NaCl, dried, and the amount of bound radioactivity was determined by scintillation counting in a Topcount beta-plate counter.
The activities of test compounds are reported in the Table below as ICso values or the inhibitor concentration required for 50~ inhibition of specific binding in receptor binding assays using 1251-RANTES or lzsMIP-la as ligand and THP-1 cell membranes. Specific binding is defined as the total binding minus the non-specific binding; non-specific binding is the amount of cpm still detected in the presence of excess unlabeled Rantes or lzsMIP-la.

Table BIOLOGICAL DATA
~s o-LI'IM

1 <1 2 <1 8 <1 12 <1 17 <10 18 <1 19 <1 21 <1 22 <1 23 <1 24 <10 25 <1 26 <1 27 <1 28 <1 29 <1 30 <1 31 <1 32 <1 33 <1 34 <1 35 <1 36 <1 38 <1 39 <10 40 <1 41 <1 42 <1 43 <10 44 <1 45 <1 46 <1 47 <1 48 <1 49 <1 BIOLOGICAL DATA (cont.) ~so~-52 <1 53 <1 54 <1 55 <1 56 <1 57 <10 59 <1 60 <1 61 <10 62 <10 63 <10 64 <I

65 <1 66 <1000 67 <1 68 <10 69 <1 71 <1 72 <10 73 <10 74 <1000 75 <10 76 <10 77 <1 78 <1 79 <1 83 <1000 85 <1 86 >10 89 >10 90 <1 91 <1 111 <1 114 <1 117 <1 118 <1 128 <1 130 <1 WO 99/37651 PC'T/US99/01266 BIOLOGICAL DATA (cont.) ~F~. ~so-.~-I1M) 131 <1 132 <1 133 <1 134 <1 135 <1 138 <1 I39 <1 140 >10 141 <1 142 <10 143 <1 144 <1 145 <10 146 >10 147 <10 148 <10 149 <1000 150 <10 151 <1 152 <1 153 <1 154 <1 155 <1 158 <1 159 <1 160 <1 161 <10 162 <1 163 <1 166 <10 167 >1 173 <1 174 <1 175 <1 176 <1 178 <1 181 <1 BIOLOGICAL DATA (cont.) S~so-~.I1M
182 <1 183 <1 184 <10 185 <1000 186 <1 187 <1 188 >10 190 >10 191 >10 192 >10 193 <1 194 <1 195 <10 197 <1 199 <1 248 <10 Example 8 - 4-(4-Chlorophenyl)-1-[3-(6,11-dihydro-dibenz[b,e]thiepin-11-ylidene)propyl]piperidin-4-of Step 1 11-(3-Bromopropylidene)-6,11-dihydrodibenz[b,e]thiepine was prepared by following the procedure of example 45, step 1 and 2, but replacing 5,11-dihydro-7-methoxypyrido[2,3-c][1]benzoxepin-~5-one with 6,11-dihydrodibenz[b,e]thiepin-11-one.
1H-NMR (CDC13) 8: 2.50-2.64 (2H,m) , 3.36-3.47 (3H,m} , 4.99 (lH,d) , 5.94 (1H, t) , 6. 98-7.31 (8H,m) .

Step 2 The titled compound was prepared by following the procedure of example 45, step 3 but replacing 5-(3-bromopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene with the product of step 1.
1H-NMR (CDC13) b: 1.65-1.80(3H,m), 1.95-2.70(lOH,m), 3.35 (lH,d) , 4.98 (lH,d) , 5.96 (lH,t) , 7.09-7.43 (l2H,m) .
MS m/z: 462(M+1) Example 12 - 1-[3-(5-Benzyl-6,11-dihydro-6-oxo-5H-dibenz[b,e]azepin-11-ylidene)propyl]-4-(4-chlorophenyl)-piperidin-4-of To a solution 4-(4-chlorophenyl)-1-[3-(6,11-dihydro-6-oxo-5H-dibenz[b,e]azepin-11-ylidene)propyl]piperidin-4-of hydrochloride (Example 39)(300mg) in DMF (5m1) were added sodium hydride (60~ in oil, 200mg), benzyl bromide (0.15m1) and the mixture was stirred at room temperature for 1 hour.
Water and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate.
The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with ethyl acetate to give the titled compound (I80mg).
~H-NMR (CDC13) b: 1.62-1.67 (2H,m) , 1.99-2.20 (3H,m) , 2.33-2 . 65 ( 8H, m) , 5 . 10 ( 1H, d) , 5 . 75 ( 1H, d) , 5 . 94 ( 1H, t ) , 7 .

7 . 42 ( 16H, m) , 7 . 91 ( 1H, dd) .
MS m/z: 549(M+1) Example 17 - 1-[3-(5-Carboxymethyl-6,11-dihydro-6-oxo-5H-dibenz[b,e]azepin-11-ylidene)propyl]-4-(4-chlorophenyl)-piperidin-4-of 4-(4-Chlorophenyl)-1-[3-(6,11-dihydro-5-ethoxycarbonymetyl-6-oxo-5H-dibenz[b,e]azepin-11-ylidene)propyl]piperidin-4-of (Example 18)(l.Og) was solved in 1M hydrogen chloride in diethyl ether and stirred at room temperature for 24 hours. Aqueous sodium hydroxide and ethyl acetate were added to the reaction mixture, the aqueous layer was separated and neutralized with dilute hydrochloric acid. The precipitation was filtered to give the titled compound (250mg).
1H-NMR (DMSO-d6) 8: 1. 44-1. 61 (2H, m) , 2 . 07-2 . 17 ( 1H, m) , 2 . 35-3.01 (9H,m) , 4.28 (lH,d) , 4.59 (lH,d) , 5.83 (1H, t) , 7.18-7 . 71 ( 12H, m) .
MS m/z: 517(M+1) Example 18 - 4-(4-Chlorophenyl)-1-[3-(6,11-dihydro-5-ethoxycarbonymetyl-6-oxo-5H-dibenz[b,e]azepin-11-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 1, but replacing 5-(3-bromopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene with 11-(3-bromopropylidene)-5-ethoxycarbonymetyl-6-oxo-5H-dibenz[b,e]azepine.
1H-NMR {CDC13) b: 1 .30 {3H, t) , 1 . 64-1 .69 (2H,m) , 1. 97-2.10 (3H,m) , 2.38-2.71 (BH,m) , 4.27 (2H,q) , 4.32 (lH,d) , 4.84{lH,d), 5.88{lH,t), 7.16-7.45(llH,m), 7.88(lH,dd).
MS m/z: 545(M+1) Example 19 - 4-(4-Chlorophenyl)-1-[3-(6,11-dihydro-
5-methyl-6-oxo-5H-dibenz(b,e]azepin-11-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of Example 1, but replacing 5-(3-bromopropylidene)-10,11-dihydro-5H-dibenzo [a, d] cycloheptene with 11-(3-bromopropylidene)-5-methyl-6-oxo-5H-dibenz[b,e]azepin.
1H-NMR (CDC13) &: 1.58-2.06 (5H,m) , 2.39-2.75 (BH,m} , 3 .53 (3H, s) , 5. 84 (1H, t) , 7. 10-7.44 (llH,m) , 7. 85-7.89 (lH,m) .
MS m/z: 473 (M+1) .
Example 21 - 4-(4-Chlorophenyl)-1-[3-(5H-dibenzo[a,d]cycloheptene-5-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 1, but replacing 5-(3-bromopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene with 5-(3-bromopropylidene)-5H-dibenzo[a,d]cycloheptene.
1H-NMR (CDC13) S: 1.58-1.63 (2H,m) , 2.00-2.05 (2H,m) , 2.26-2 .46 (6H,m) , 2.62-2 . 66 (2H,m) , 5.55 (1H, t) , 6.85 (2H, s) , 7.24-7.40 (l2H,m) .
MS m/z: 442 (M+1) .

Example 22 - 4-{4-Chlorophenyl)-1-[3-(6,11-dihydro-2-methoxycarbonyldibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 1, but replacing 5-(3-bromopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene with 11-(3-bromopropylidene)-6,11-dihydro-2-methoxy-carbonyldibenz[b,e]oxepine.
FH-NMR {CDC13) b: 1.65-1.70 (2H,m) , 2.01-2.13 (3H,m} , 2.41-2.80 (7H,m) , 3.85 (3H, s} , 5.40 {2H,brs) , 5.73 (0.6x1H, t) ,
6.09(0.4x1H,t), 6.76(0.6x1H,d), 6.82(0.4x1H,d), 7.21-
7 . 43 ( 8H, m) , 7 . 73 ( 1H, dd) , 7 . 87 ( 0 . 6xlH, d) , 7 . 97 ( 0 .
4xlH, d) .
MS m/z: 504 (M+1) .
Example 23 - 1-[3-(2-Butoxycarbonyl-6,11-dihydrodibenz [b, e] oxepin-11-ylidene) propyl] -4- (4-chlorophenyl)piperidin-4-of The titled compound was prepared by following the procedure of example 1, but replacing 5-(3-bromopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene with 11-(3-bromopropylidene)-2-butoxy-6,11-dihydrodibenz [b, e] oxepine .
1H-NMR (CDC13) 8: 0.96 (3H, t) , 1.53 (2H,q) , 1.70-1.77 (3H,m) , 2.02-2 . 14 (3H,m) , 2.39-2.78 (SH,m) , 4.27 (2H, t) , 5.27 (2H,brs) , 5.75(0.8x1H,t}, 6.10(0.2x1H,t), 6.78(lH,d), 7.27-7 . 43 ( 8H, m) , 7 . 76 { 1H, dd} , 7 . 89 ( 0 . 8xlH, d) , 7 . 98 ( 0 .
2xlH, d) .
MS m/z: 546 (M+1}.

Example 24 - 1-[3-(2-Carboxyl-6,11-dihydrodibenz(b,e]oxepin-11-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-of To a solution of 4- (4-Chlorophenyl) -1- [3- (6, 11-dihydro-2-methoxycarbonyldibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-of (Example 22)(100mg) in ethanol (3m1) were added 15% sodiun hydroxide agueous solution (0.6m1) and the mixture was heated to reflux for 12 hours. The solvent was distilled off under reduced pressure. Water and ethyl acetate were added to the reaction mixture, the aqueous layer was separated and neutralized with dilute hydrochloric acid. The precipitation was filtered to give the titled compound (80mg) .
1H-NMR (CD30D) b: 1.73-1.79 (2H,m) , 2.14-2.19 (2H,m) , 2.80-2.93 (3H,m) , 3.02-3.11 (3H,m) , 3.24-3.29 (2H,m) , 5.25(2H,brs), 5.61(0.7x1H,t), 6.05(0.3x1H,t), 6.72 (IH,d) ,7.22-7.40 (BH,m) , 7.52-7.65 (lH,m) , 7.75 (0.7x1H,d) , 7.80 (0.3x1H,d) .
MS m/z: 490 (M+1).
Example 25 - 4-(4-Chlorophenyl)-1-[3-(6,11-dihydro-2-dimethylaminocarbonyldibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 1, but replacing 5-(3-bromopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene with 11-(3-bromopropylidene)-2-dimethylaminocarbonyl-6,11-dihydrodibenz[b,e]oxepine.

1H-NMR (CDC13) 8: 1.62-1.67 (2H,m) , 2.00-2.12 (2H,m) , 2.37-2.47 (BH,m) , 2.89 (6H, s) , 5.25 (2H,brs) , 5.68 (0.7x1H,t) , 6.03 (0.3x1H,t), 6.71(0.3xIH,d), 6.78(0.7x1H,d), 7.13-7.40 ( l OH, m) .
MS m/z: 517 (M+1) .
Example 26 - 4-(4-Chlorophenyl)-1-[3-(6,11-dihydro-2-hydroxymethyldibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-0l To a solution of (4-chlorophenyl) -1- [3- (6, 11-dihydromethoxycarbonyldibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-of (110mg) in THF (8m1) were added lithium aluminum hydride (1.OM, 0.42m1) dropwise at 0 °C, and the mixture was stirred at room temperature for 1 hour. Aqueous sodium hydroxide (1M) was added to the reaction mixture to stir for 30 minutes, then ethyl acetate and brine was added to the mixture. The organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate. The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with dichloromethane-methanol (10:1) to give the titled compound ( 90mg) .
'H-NMR (CDC13) 8: 1.61-1.66 (2H,m) , 1.98-2.03 (2H,m) , 2.39-2.48 (3H,m) , 2.57-2.79 (6H,m) , 4.52 (2H,s) , 5.20 (2H,brs) , 5.66(0.8x1H,t), 6.01(0.2x1H,t), 6.67(0.2x1H,d), 6.79 (0.8x1H,d) , 7.06 (lH,dd) , 7.15-7.37 (9H,m) .
MS m/z: 476 (M+1).

WO 99/37651 PG"f/US99/01266 Example 27 - 4-(4-Chlorophenyl)-1-[3-(6,11-dihydro-2-(1-hydroxy-1-methyl)ethyldibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-of To a solution of 4- (4-chlorophenyl) -1- [3- (6, 11-dihydro-2-methoxycarbonyldibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-of (60mg) in THF (6m1) were added methylmagnesium chloride (3.OM, 0.16m1) dropwise at 0 °C, and the mixture was stirred at room temperature for 2 hour, the reaction mixture was quenched by saturated ammonium aqueous, then ethyl acetate and water was added to the mixture. The organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate. The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with ethyl acetate-methanol (95:5) to give the titled compound (20mg).
1H-NMR (CDC13) 8: 1 . 54 (0 . 7x6H, s) , 1. 62 (0 .3x6H, s) , 1 . 63-1.70(2H,m), 2.03-2.10(3H,m), 2.38-2.49 (3H,m), 2.62-2.82 (4H,m) , 5.17 (2H,brs) , 5.68 (0.7x1H,t) , 6.05 (0.3x1H,t) , 6.75(0.3x1H,d), 6.83(0.7x1H,d), 7.18-7.43(lOH,m).
MS m/z: 504 (M+1).
Example 28 - 4-(4-Chlorophenyl)-1-[3-(2-cyano-6,11-dihydrodibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 1, but replacing 5-(3-bromopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene with 11-(3-bromopropylidene)-2-cyano-6,11-dihydrodibenz[b,e]oxepine.

WO 99/37651 PC1'/US99/01266 1H-NMR (CDC13) 8: 1.67-1.72 (2H,m) , 2.02-2.13 (2H,m) , 2.37-2.77 (BH,m), 5.35 (2H,brs), 5.75(0.7x1H,t), 6.07(0.3x1H,t), 6.78 (0.3x1H,d) , 6.82 (0.7x1H,d) , 7.25-7.51 (lOH,m) .
MS m/z: 471 (M+1) .
Example 29 - 1-(3-(2-Aminomethyl-6,I1-dihydrodibenz [b , a ] oxepin-11-yl idene ) propyl ] -4 - ( 4 -chlorophenyl)piperidin-4-of To a solution of 4-(4-chlorophenyl)-1-[3-(2-cyano-6,11-dihydrodibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-0l (380mg) in EtOH (20m1) were added Raney nickel (50~
slurry in water, 60 mg), and the mixture was hydrogenated at 15 psi for 2 hours. The mixture was filtered through the celite and distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with dichloromethane-methanol-aqueous ammonium (95:5:1) to give the titled compound (130mg).
1H-NMR (CDC13) 8: 1.76-1.94 (3H,m) , 2.18-2.34 (2H,m) , 2.85-3.10 (BH,m) , 3.88 (2H,s) , 5.30 (2H,brs) , 5.59 (lH,t) , 6.78(lH,d), 7.13-7.40(lOH,m).
MS m/z: 475 (M+1).
Example 30 - 4-(4-Chlorophenyl)-1-[3-(6,11-dihydro-2-nitrodibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 1, but replacing 5-(3-bromopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene with 11-(3-bromopropylidene)-6,11-dihydro-2-nitorodibenz[b,e]oxepine.

1H-NMR (CDC13) 8: 1.62-1.67 (2H,m) , 1.80-2.12 (3H,m) , 2.28-2.78(8H,m), 5.05(0.3x2H,brs), 5.40(0.7x2H,brs), 5.90(0.7x1H,t), 6.17(0.3x1H,t), 6.82(0.3x1H,d), 6.92(0.7x1H), 7.28-7.41(BH,m), 7.82(lH,dd), 8.15(0.7x1H,d),
8 . 22 ( 0 . 3xlH, d) .
MS m/z: 491 (M+1) .
Example 31 - 1-[3-(2-Amino-6,11-dihydrodibenz[b,e]oxepin-11-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-of To a solution of 4- (4-chlorophenyl) -1- [3- (6, 11-dihydro-2-nitrodibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-of (120mg) in EtOH (15m1) were added tin (II) chloride (190mg), and the mixture was heated to reflux for 1 hour. The was distilled off under reduced pressure. The residue was added ethyl acetate and sodium aqueous to neutralize. The organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate. The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with dichloromethane-methanol (95:5) to give the titled compound (70mg).
1H-NMR (DMSO-ds} s: 1.54-1.60 (2H,m} , 1.85-2.00 (2H,m) , 2.30-2 .80 (8H,m) , 3.88 (2H, s) .5. 07 (2H,brs) , 5.66 (1H, t) , 6.41-6.46 (2H,m) , 6.59 (lH,d) , 7.24-7.49 (8H,m) .
MS m/ z : 4 61 ( M+ 1 ) .

Example 32 - 4-(4-Chlorophenyl)-1-[3-(6,11-dihydro-2-hydroxydibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-of Step 1 11-(3-Bromopropylidene)-6,11-dihydro-2-hydroxydibenz[b,e]oxepine was prepared by following the procedure of example 45, step 1 and 2, but replacing 5,11-dihydro-7-methoxypyrido[2,3-c][1]benzoxepin-5-one with 6,11-dihydro-2-hydroxydibenz[b,e]oxepin-11-one.
1H-NMR (CDC13) S: 2 . 69 (2H, q) , 3 .39 (2H, t) , 5 .20 (2H, brs) , 5.92(lH,t), 6.50-6.81(4H,m), 7.I7-7.37(4H,m).
Step 2 The titled compound was prepared by following the procedure of example 45, step 3, but replacing 5-(3-bromopropylidene)-10,11-dihydro-SH-dibenzo[a,d]cycloheptene with the product of step 1.
1H-NMR (CDC13) 8: 1.60-1.75 (3H,m) , 1.95-2.10 (2H,m) , 2.35-2.80(BH,m), 5.10(2H,brs), 5.93(lH,t), 6.56(2H,brs), 6.71 (lH,brs) , 7.11-7.35 (BH,m) .
MS m/z: 462(M+1) Example 33 - 4-(4-Chlorophenyl)-1-[3-(6,11-dihydro-2-methoxydibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-of Step 1 11-(3-Bromopropylidene)-6,11-dihydro-2-methoxydibenz[b,e]oxepine was prepared by following the procedure of example 45, step 1 and 2, but replacing 5,11-dihydro-7-methoxypyrido[2,3-c](1]benzoxepin-5-one with 6,11-dihydro-2-methoxydibenz[b,e]oxepin-11-one.

1H-NMR (CDC13) d: 2 . 74 (2H, q) , 3 .43 (2H, t) , 3 . 77 (3H, s) , 5.10 (2H,brs) , 6.02 (lH,t) , 6.70-6.83 (3H,m) , 7.21-7.38 (4H,m) .
Step 2 The titled compound was prepared by following the procedure of example 45, step 3, but replacing 5-(3-bromopropylidene}-10,11-dihydro-5H-dibenzo[a,d]cycloheptene with the product of step 1.
1H-NMR (CDC13} 8: 1.59-1.65 (2H,m) , 1.95-2.66 (llH,m) , 3 . 75 (3H, s) , 5 . 10 (2H, brs) , 6 . 03 (1H, t) , 6 . 69 (2H, brs) , 6.82 (lH,brs) , 7.20-7.40 (BH,m) .
MS m/z: 476(M+1) Example 34 - 4-(4-Chlorophenyl)-1-[3-(6,11-dihydro-2-ethoxydibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-of To a solution of 4-(4-chlorophenyl)-1-[3-(6,11-dihydro-2-hydroxydibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-of (Example 32)(200mg) in DMF (5m1) were added sodium hydride (60g in oil, 25mg), ethyl iodide (0.052m1) and the mixture was stirred at room temperature for 1 hour. Water and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate.
The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with ethyl acetate-hexane (1:1) to give the titled compound (170mg).

1H-NMR (CDC13) 8: 1.37 (3H, t) , 1 . 60-1 . 65 (2H,m) , 1 . 95-2 . 08 (3H,m) , 2 .28-75 (8H, m) , 3 . 96 (2H, q) , 5 . 15 (2H, brs) , 6.02 (1H, t) , 6.68 (2H,brs) , 6.82 (lH,brs) , 7.19-7.42 (8H,m) .
MS m/z: 490 (M+1) Example 35 - 1-[3-(3-Bromo-6,11-dihydrodibenz[b,e]oxepin-11-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-of Step 1 3-Bromo-11-(3-bromopropylidene)-6,11-dihydrodibenz[b,e]oxepine was prepared by following the procedure of example 45, step 1 and 2, but replacing 5,11-dihydro-7-methoxypyrido[2,3-c][1]benzoxepin-5-one with 3-bromo-6,11-dihydrodibenz[b,e]oxepin-11-one.
1H-NMR (CDC13} b: 2 . 74 (2H, q) , 3 .43 (2H, t) , 3 . 77 (3H, s) , 5.10 (2H,brs) , 6.02 (lH,t) , 6.70-6.83 (3H,m) , 7.21-7.38 (4H,m) .
Step 2 The titled compound was prepared by following the procedure of example 45, step 3, but replacing 5-(3-bromopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene with the product of step 1.
1H-NMR (CDC13) b: 1.63-1.70 (3H,m) , 1.96-2.10 (2H,m) , 2.32-2.69 (8H,m) , 5.20 (2H,brs) , 6.00 (1H, t) , 6.92-7.00 (2H,m) , 7.11-7.14{lH,m), 7.24-7.42(8H,m).
MS m/z: 524, 526(M+1) Example 36 - 4-(4-Chlorophenyl)-1-[3-(6,11-dihydrodibenz[b,e]oxepin-11-ylidene)propyl]-4-methoxypiperidine To a solution of 4-(4-chlorophenyl)-1-[3-(6,11-dihydro-2-methoxydibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-of (Example 2)(400mg) in DMF
(5m1) were added sodium hydride (60°s in oil, 50mg), methyl iodide (0.07m1) and the mixture was stirred at room temperature for 1 hour. Water and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate. The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with ethyl acetate-hexane (1:1) to give the titled compound (100mg).
1H-NMR (CDC13) 8: 1.90-2.04 (4H,m) , 2.34-2.62 (SH,m) , 2 . 93 (3H, s) , 5.25 (2H, brs) , 6. 04 (1H, t) , 6 . 75-6. 91 (3H, m) , 7.09-7.37(9H,m).
MS m/z: 460 (M+1) Example 37 - 4-Acetoxy-4-(4-chlorophenyl)-1-[3-(6,11-dihydrodibenz[b,e]oxepin-11-ylidene)propyl]piperidine To a solution of 4- (4-chlorophenyl) -1- [3- (6, 11-dihydro-2-methoxydibenz[b,e]oxepin-lI-ylidene)propyl]piperidin-4-of (Example 2)(200mg) in dichloromethane (5m1) were added acetyl chloride (0.06m1), triethylamine (0.19m1) and the mixture was stirred at room temperature for 1 hour. Aqueous sodium bicarbonate and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate.
The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with ethyl acetate-hexane (1:4) to give the titled compound (190mg) .
1H-NMR (CDC13) 8: 1 . 98-2 .85 (l2H,m) , 2 . 02 (3H, s) , 2 . 93 (3H, s) , 5.23(2H,brs), 6.01(lH,t), 6.73-6.90(3H,m), 7.11-7.40(9H,m).
MS m/z: 488(M+1) Example 38 - 1-[3-(8-Bromo-4,10-dihydrothieno[3,2-c] [1] benzoxepin-10-ylidene) propyl] piperidin-4- (4-chlorophenyl)-4-0l Step 1 8-Bromo-10-(3-bromopropylidene)-4,10-dihydrothieno[3,2-c](1]benzoxepine was prepared by following the procedure of example 45, step 1 and 2, but replacing 5,11-dihydro-7-methoxypyrido[2,3-c][1]benzoxepin-5-one with 4,10-dihydrothieno[3,2-c][1]benzoxepin-10-one.
1H-NMR (CDC13) b: 2 . 84 (2H, q) , 3 .45 (2H, t) , 5 . 10 (2H, s) , 6.11 (1H, t) , 6.65 (lH,d) , 7.03-7.08 (2H,m) , 7.38-7.43 (2H,m) .
Step 2 The titled compound was prepared by following the procedure of example 45, step 3, but replacing 5-(3-bromopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene with the product of step 1.
1H-NMR (CDC13) 8: 1.66-1.75(3H,m), 2.03-2.16(2H,m), 2.40-2 .86 (8H,m) , 5. 09 (0 . 7x2H, s) , 5. 14 (0 .3x2H, s) , 5. 90 (0.3x1H, t) , 6.10(0.7x1H,t), 6.64(0.7x1H,d), 6.75(0.3x1H,d), 6.90 (0.3x1H,d) , 7.03-7.09 (2H,m) , 7.21-7.45 (6H,m) .
MS m/z: 532(M+1) Example 39 - 4-(4-Chlorophenyl)-1-[3-(6,11-dihydro-6-oxo-5H-dibenz[b,e]azepin-11-ylidene)propyl]piperidin-4-of Step 1 11-(3-Bromopropylidene)-6,11-dihydro-6-oxo-5H-dibenz[b,e]azepine was prepared by following the procedure of example 45, step 1 and 2, but replacing 5,11-dihydro-7-methoxypyrido[2,3-c][1]benzoxepin-5-one with 6,11-dihydro-6-5H-dibenz[b,e]azepin-6,11-dione.
1H-NMR (CDC13) 8: 2.70-2.92(2H,m), 3.45 (2H,t), 5.92(lH,t), 7.08-7.58(7H,m), 8.05(lH,dd), 9.00(lH,brs).
Step 2 The titled compound was prepared by following the procedure of example 45, step 3, but replacing 5-(3-bromopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene with the product of step 1.
1H-NMR (CDC13) b: 1.61-1.66 (2H,m) , 1.97-2.20 (3H,m) , 2.35-2.68(8H,m), 5.80(lH,t), 7.03-7.53(llH,m), 8.02(lH,dd),
9.27 (lH,brs) .
MS m/z: 459 (M+1}

Example 40 - 4-(4-Chlorophenyl)-1-[3-(6,11-dihydro-5-ethyl-6-oxo-5H-dibenz[b,e]azepin-11-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 12, but replacing benzyl bromide with ethyl iodide.
1H-NMR (CDC13) b: 1.19-1.28 (3H,m) , 1.63-1.69 (2H,m) , 1.99-2.16(3H,m), 2.37-2.70(BH,m), 3.77-3.85(lH,m), 4.40-4.48 (lH,m) , 5.85 (lH,t) , 7.12-7.45 (llH,m) , 7.85 (lH,dd) .
MS m/z : 487 (M+1) Example 41 - 1-[3-(5-n-Hutyl-6,11-dihydro-6-oxo-5H-dibenz[b,e]azepin-11-ylidene)propyl]-4-(4-chlorophenyl)-piperidin-4-of The titled compound was prepared by following the procedure of example 12, but replacing benzyl bromide with n-butyl iodide.
1H-NMR (CDC13) 8: 0.90-0.98 (3H,m) , 1.25-2.20 (9H,m) , 2.40-2.87 (BH,m) , 3.62-3.72 (lH,m) , 4.52-4.64 (lH,m) , 5.85 (lH,t) , 7.16-7.45(llH,m), 7.88(IH,dd).
MS m/z: 515 (M+1) Example 42 - 4-(4-Chlorophenyl)-1-[3-(6,11-dihydro-5-(3-hydroxypropyl)-6-oxo-5H-dibenz[b,e]azepin-11-ylidene)propyl]piperidin-4-of To a solution 4-(4-chlorophenyl)-1-[3-(6,11-dihydro-6-oxo-5H-dibenz[b,e]azepin-11-ylidene)propyl]piperidin-4-of hydrochloride (Example 39)(500mg) in DMF (8m1) were added sodium hydride (60~ in oil, 200mg), 2-(3-bromopropoxy)tetrahydro-2H-pyran (0.5m1) and the mixture WO 99/37651 PC'f/US99/01266 was stirred at room temperature for 6 hours. Water and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate.
The solvent was distilled off under reduced pressure. The r residue was solved in 1M hydrogen chloride in diehyl ether and stirred at room temperature for 1 hour. Aqueous sodium bicarbonate and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate. The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with ethyl acetate to give the titled compound (250mg).
1H-NMR (CDC13) 8: 1.25-2.87 (lSH,m) , 3.51-3 .56 (2H,m) , 3.76-3.82(lH,m), 4.81-4.87(lH,m), 5.86(lH,t), 7.16-7.45(llH,m), 7 . 82 ( 1H, dd) .
MS m/z: 517(M+1) Example 43 - 1-[3-(5-tert-Butoxycarbonymethyl-6,11-dihydro-6-oxo-5H-dibenz[b,e]azepin-11-ylidene)propyl]-4-(4-chlorophenyl)-piperidin-4-of The titled compound was prepared by following the procedure of example 12, but replacing benzyl bromide with tert-butyl bromoacetate.
1H-NMR (CDC13) 8: 1.50(9H,s), 1.65-1.70(2H,m), 1.95-2 . 10 ( 3H, m) , 2 . 42 -2 . 75 ( 8H, m) , 4 . 24 ( 1H, d) , 4 . 75 ( 1H, d) , 5.88(lH,t), 7.16-7.46(llH,m), 7.90(lH,dd).
MS m/z: 573 (M+1) Example 44 - 4-(4-Chlorophenyl)-1-[3-{5,11-dihydro-7-hydroxy [1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-of Step 1 To a solution of the product of example 45, step 1 (4.3g) in dichloroethane (100m1) was added boron tribromide-methyl sulfide complex (19.3g) and the mixture was heated to reflex for 3 hour. Water and ethyl acetate were added to the reaction mixture and neutralized with dilute NaOH solution. The organic layer was separated and washed with saturated aqueous sodium chloride, and dried over magnesium sulfate. The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with ethyl acetate-hexane (1:2) to give 5-(3-bromopropylidene)-5,11-dihydro-7-hydroxy [1J benzoxepino [2 , 3-b] pyridine (3 . 2g) .
1H-NMR {CDC13) b: 2.72 (2H,q) , 3.45 (2H,t) , 5.28 (2H,brs) , 6.03(lH,t), 6.66-6.80(3H,m), 7.26(lH,dd), 7.58{lH,dd), 8 . 51 ( 1H, dd) .
Step 2 The titled compound was prepared by following the procedure of example 45, step 3, but replacing 5-(3-bromopropylidene)-5,11-dihydro-7-methoxy [1]benzoxepino[2,3-b)pyridine with the product of step 1.
1H-NMR (DMSO-d6) 8: 1.46-1.51(2H,m), 1.74-1.85(2H,m), 2.29-2.51(SH,m), 5.15(2H,brs), 6.07(lH,t), 6.61-6.70(3H,m), 7.33-7.48 (SH,m) , 7.73 (lH,dd) , 8.47 (lH,dd) , 9.06 (1H, s) .
MS m/z: 463 (M+1) Example 45 - 4-(4-Chlorophenyl)-1-E3-(5,11-dihydro-7-methoxy [1] benzoxepino [2, 3-b] pyridin-5-ylidene)propyl]piperidin-4-of Step 1 To a solution of 5,11-dihydro-7-methoxy [1]benzoxepino[2,3-b]pyridin-5-one (5.Og) in THF (50m1) was added 1.1M cyclopropylmagnesium bromide THF solution (25m1) at 0°C. The reaction mixture was warmed to room temperature, and stirred for 30 minutes. Aqueous ammonium chloride and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate. The solvent was distilled off under reduced pressure. The residue was filtered and washed with ethyl acetate-hexane (1:2) to give 5-cyclopropyl-5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-of (5.Og).
Step 2 To a solution of the product of step 1 (4.3g) in acetic acid (30m1) was added 48% aqueous HBr (25m1) at
10°C. The reaction mixture was warmed to room temperature, and stirred for 12 hours. Water and ethyl acetate were added to the reaction mixture and neutralized with dilute NaOH solution. The organic layer was separated and washed with saturated aqueous sodium chloride, and dried over magnesium sulfate. The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with ethyl acetate-hexane (1:4) to give 5-(3-bromopropylidene}-5,11-dihydro-7-methoxy [1] benzoxepino [2, 3-b] pyridine (5 . 6g) .
1H-NMR (CDC13) 8: 2 . 74 (2H, q) , 3 .46 (2H, t) , 3 . 78 (3H, s) , 5.25(2H,brs), 6.07(lH,t), 6.72-6.82(3H,m), 7.21-7.42(SH,m), 7.56 (lH,dd) , 8.45 (lH,dd) .
Step 3 To a solution the product of step 2 (l.lg) in DMF
(15m1) were added 4-(4-chlorophenyl)-4-hydroxypiperidine (0.81g) and potassium carbonate (0.53g) and the mixture was stirred at room temperature for 3 hours. Water and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate. The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with methylene chloride-methanol (10:1) to give the titled compound as major regioisomer (0.86g) and minor one ( 0 . 05g) .
Major isomer 1H-NMR (CDC13) 8: 1.64-1.69 (2H,m) , 1.91-2. 08 (3H,m) , 2.34-2.69(BH,m), 3.77(3H,s), 5.25(2H,brs), 6.07(lH,t), 6.72-6.82 (3H,m) , 7.21-7.42 (SH,m) , 7.56 (lH,dd) , 8.45 (lH,dd) .
MS m/z: 477 (M+1) Minor isomer 1H-NMR (CDC13) 8: 1.65-1.79(3H,m), 2.01-2.13(2H,m), 2.35-2 .76 (BH,m) , 3 .76 (3H, s) , 5.22 (2H,brs) , 5. 95 (1H, t) , 6.72-6.80 (2H,m) , 7.06 (lH,d) , 7.16 (lH,dd) , 7.28 (2H,d} , 7.42 (2H,d) , 7.66 (lH,dd) , 8.39 (lH,dd) .

MS m/z: 477(M+1) Example 46 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-ethoxy [1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-0l The titled compound was prepared by following the procedure of example 34, but replacing. 4-(4-chlorophenyl)-1-[3-(6,11-dihydro-2-hydroxydibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-of with 4-(4-chlorophenyl)-1-[3-(5,11-dihydro-7-hydroxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-of (example 44).
1H-NMR (CDC13) 8: 1.38 (3H,t) , 1.67-1.72 (3H,m) , 2.05-2.16 (2H,m) , 2.40-2.80 (BH,m) , 3.99 (2H,q) , 5.26 (2H,brs) , 6.05(lH,t), 6.71-6.82(3H,m), 7.23-7.43(SH,m), 7.57(lH,dd), 8.47 (lH,dd) .
MS m/z: 491(M+1) Example 47 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-isopropoxy [1] benzoxepino [2, 3-b] pyridin-5-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 46, but replacing ethyl iodide with isopropyl bromide.
1H-NMR (CDC13) 8: 1.30 (6H,d) , 1.60-1.70 (3H,m) , 1 .99-2.09 (2H,m) , 2.33-2.69 (BH,m) , 4.37-4.48 (lH,m) , 5.26 (2H,brs) , 6.06(lH,t), 6.73-6.82(3H,m}, 7.21-7.43(SH,m), 7.55(lH,dd), 8.47 (lH,dd) .
MS m/z: 505(M+1) Example 48 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-ethoxycarbonylmethyloxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 46, but replacing ethyl iodide with ethyl bromoacetate.
1H-NMR (CDC13) 8: 1.28 (3H,t) , 1.63-1.68 (2H,m) , 1.97-2.02 (3H,m) , 2.33-2.68 (BH,m) , 4.24 (2H,q) , 4.55 (2H,s) , 5.26 (2H,brs) , 6.06 (lH,t) , 6.73-6.88 (3H,m) , 7.21-7.42 (5H,m) , 7.55(lH,dd), 8.44(lH,dd).
MS m/z: 549(M+1) Example 49 - 4-(4-Chlorophenyl)-1-[3-(7-cyanomethyloxy-5, 11-dihydro [1] benzoxepino [2, 3-b] pyridin-5-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 46, but replacing ethyl iodide with bromoacetonitrile.
1H-NMR (CDC13) d: 1.62-1.67 (2H,m) , 1.94-2.06 (2H,m) , 2.21 (lH,brs) , 2.34-2.66 (BH,m) , 4.70 (2H,s) , 5.26 (2H,brs) , 6.10 (lH,t) , 6.80 (2H,brs) , 6.92 (lH,brs) , 7.22-7.41 (SH,m) , 7 . 56 ( IH, dd) , 8 . 44 ( 1H, dd) .
MS m/z: 502(M+1) Example 50 - 1-[3-(7-(2-Acetoxyethyl)oxy-5,11-dihydro [1] benzoxepino [2, 3-b] pyridin-5-ylidene) propyl] -4- (4 chlorophenyl)piperidin-4-of The titled compound was prepared by following the procedure of example 46, but replacing ethyl iodide with 2-bromoethyl acetate.
1H-NMR (CDC13) 8: 1.65-1.72 (3H,m) , 1.97-2.09 (SH,m) , 2.37-2.70 (BH,m) , 4.11-4.14 (2H,m) , 4.37-4.41 (2H,m) , 5.25 (2H,brs) , 6.07(lH,t), 6.75-6.84(3H,m), 7.23-7.43(SH,m), 7.56(lH,dd), 8.47 (lH,dd) .
MS m/z: 549(M+1) Example 51 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2-hydroxyethyl) oxy [1] benzoxepino [2, 3-b] pyridin-5-ylidene)propyl]piperidin-4-of To a solution of 1-[3-(7-(2-acetoxyethyl)oxy-5,11-[1] benzoxepino [2, 3-b]pyridin-5-ylidene) propyl] -4- (4-chlorophenyl)piperidin-4-of (Example 50)(140mg) in ethanol (5m1) were added 15~ sodiun hydroxide aqueous solution (2m1) and the mixture was heated to reflux for 1 hour.
Water and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate.
The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with methylene chloride-methanol (10:1) to give the titled compound (120mg).
1H-NMR (CDC13) 8: 1.64-1.69 (2H,m) , 1.98-2.10 (3H,m) , 2.36-2.79 (SH,m) , 3.89-3.94 (2H,m) , 3.99-4.04 (2H,m) , 5.24 (2H,brs) , 6.04 (1H, t) , 6.71-6.84 (3H,m) , 7.23-7.41 (SH,m) , 7.54 (lH,dd) , 8.43 (lH,dd) .
MS m/z: 507 (M+1) Example 52 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2-morphol inoethyl ) oxy [ 1 ] benzoxepino [2 , 3 -b] pyridin- 5 -ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 46, but replacing ethyl iodide with 4-(2-chloroethyl)morpholine hydrochloride.
1H-NMR (CDC13) 8: 1.62-1.67(2H,m), 1.95-2.08(2H,m), 2.20 2.67 (l3H,m) , 2.74 (2H,t) , 3.67-3.71 (4H,m) , 4.04 (2H,t) , 5.23 (2H,brs) , 6.05 (1H, t) , 6.73-6.82 (3H,m) , 7.20-7.41 (SH,m) , 7 . 53 ( 1H, dd) , 8 . 42 ( 1H, dd) .
MS m/z: 576 (M+1) Example 53 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro [1] benzoxepino [2 , 3-b] pyridin-5-ylidene) propyl] piperidin-4-0l Step 1 5-(3-Bromopropylidene)-5,11-dihydro [1]benzoxepino[2,3-b]pyridine was prepared by following the procedure of example 45, step 1 and 2, but replacing 5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with 5,11-dihydro [1] benzoxepino [2, 3-b] pyridin-5-one.
1H-NMR (CDC13) b: 2.71 (2H,q) , 3.46 (2H,t) , 5.33 (2H,brs) , 6.04(lH,t), 7.01-7.17(3H,m), 7.29(lH,dd), 7.56(lH,dd), 8 . 53 ( 1H, dd) .

Step 2 The titled compound was prepared by following the procedure of example 45, step 3, but replacing 5-(3-bromopropylidene}-5,11-dihydro-7-methoxy [1]benzoxepino[2,3-b]pyridine with the product of step 1.
'H-NMR (CDC13) 8: 1.66-1.71(2H,m), 2.00-2.20(3H,m), 2.36-2.69(8H,m), 5.34(2H,brs), 6.10(lH,t), 6.83-6.96(3H,m}, 7.17-7.44 (6H,m) , 7.60 (lH,dd) , 8.46 (IH,dd) .
MS m/z: 447(M+1) Example 54 - 1- [3- (8-Bromo-5, 11-dihydro [1] benzoxepino [2, 3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-0l Step 1 8-Bromo-5-(3-bromopropylidene)-5,11-dihydro[1]benzoxepino[2,3-b]pyridine was prepared by following the procedure of example 45, step 1 and 2, but replacing 5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with 8-bromo-5,11-dihydro [1] benzoxepino [2, 3-b] pyridin-5-one.
1H-NMR (CDC13) 8: 2.75 (2H,q) , 3.50 (2H,t) , 5.38 (2H,brs) , 6.08(lH,t), 6.85-6.98(2H,m), 7.18-7.35(3H,m), 7.59(lH,dd), 8 . 54 ( 1H, dd) .
Step 2 The titled compound was prepared by following the procedure of example 45, step 3, but replacing 5-(3-bromopropylidene)-5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridine with the product of step 1.

1H-NMR (CDC13) b: 1.64-1.69 (2H,m) , 1.90-2.07 (3H,m) , 2.30-2.67 (8H,m) , 5.30 (2H,brs) , 6.08 (lH,t) , 7.00-7.07 (2H,m) , 7.13 (lH,d) , 7.25-7.42 (SH,m) . 7.56 (lH,dd) , 8.47 (lH,dd) .
MS m/z: 525, 527(M+1) Example 55 - 4-(4-Chlorophenyl)-1-[3-(10,11-dihydro-10-oxo-5H-pyrido [2, 3-c] [2] benzazepin-5-ylidene) propyl] piperidin-4-0l Step 1 5-(3-Bromopropylidene)-10,11-dihydro-10-oxo-5H-pyrido[2,3-c][2]benzazepine was prepared by following the procedure of example 45, step 1 and 2, but replacing 5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with 10,11-dihydro-5H-pyrido[2,3-c][2]benzazepin-5,10-dione.
1H-NMR (CDC13) 8: 2.75-2.90 (2H,m) , 3.45 (2H,t) , 5.92 (lH,t) , 7.04-7.70 (5H,m) , 8.10 (lH,dd) , 8.48 (lH,dd) , 10.00 (lH,brs) .
Step 2 The titled compound was prepared by following the procedure of example 45, step 3, but replacing 5-(3-bromopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene with the product of step 1.
1H-NMR (CDC13) 8: 1.64-1.69 (3H,m) , 2.00-2 .12 (2H,m) , 2.35-2.70 (BH,m) , 5.82 (lH,t) , 7.08 (lH,dd) , 7.23-7.62 (8H,m) , 8.04(lH,dd}, 8.32(lH,dd), 8.76(lH,brs).
MS m/z: 460(M+1) WO 99/37651 PC"T/US99/01266 Example 56 - 4-(4-Chlorophenyl)-1-[3-(10,11-dihydro-11-methyl-10-oxo-5H-pyrido[2,3-c1[2]benzazepin-5-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 36, but replacing of 4-(4-chlorophenyl)-1-[3-(6,11-dihydro-2-methoxydibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-of with 5-(3-bromopropylidene)-10,11-dihydro-10-oxo-5H-pyrido [2, 3-c] [2] benzazepine.
1H-NMR (CDC13) b: 1.64-1.70 (3H,m) , 2. .00-2.10 (2H,m) , 2.41-2 . 69 (BH,m) , 3 .62 (3H, s) , 5.82 (1H, t) , 7. 07 (lH,dd) , 7.25-7 . 54 ( 8H, m) , 7 . 91 ( 1H, dd) , 8 . 34 ( 1H, dd) .
MS m/z : 474 (M+1) Example 57 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-methoxy [1] benzoxepino [2, 3-b] pyridin-5-ylidene)ethyl]piperidin-4-of Step 1 To a solution of methyltriphenylphosphonium bromide (2.2g) in THF (20m1) was added 1.6M n-butyl lithium hexane solution (2.9m1) at 0°C for 30 minutes. To the reaction mixture cooled to 0°C was added 5,11-dihydro-7-methoxy [1] benzoxepino [2, 3-b] pyridin-5-one (1 . Og) dropwise as THF solution (5m1), and the mixture was warmed to room temperature, and stirred for 3 hours. Aqueous ammonium chloride and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate. The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with ethyl acetate-hexane (1:4) to give 5,11-dihydro-7-methoxy-5-methylenepyrido[2,3-c] [1]benzoxepine (0.14g) .
Step 2 To a solution of DMF (0.54m1) was added phosphorus oxychloride (0.41m1) at 0°C for 10 minutes. To the reaction mixture was added the product of step 1 (210mg) in carbontetrachloride (Sml) and the mixture was heated to reflux for 5 hours. Aqueous sodium bicarbonate and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate. The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with ethyl acetate-hexane (1:4) to give 3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)acetaldehyde (130mg) .
1H-NMR (CDC13) 8: 3.77(0.7x3H,s),3.79(0.3x3H, s), 5.31(2H,s), 6.46(0.7x1H,d), 6.52(0.3x1H,d), 6.78-7.40 {4H,m) , 7.68 (0.3x1H,dd) , 7.78 (0.7x1H,dd) , 8.55(0.7x1H,dd), 8.64(0.3x1H,dd), 9.62(0.3x1H,d), 9 . 79 ( 0 . 7xlH, d) .

Step 3 The titled compound was prepared by following the procedure of example 58, step 2, but replacing of 3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-S-ylidene)propanaldehyde with product of step 2.
1H-NMR (CDC13) 8: 1.64-1.82(2H,m), 1.92-2.22(3H,m), 2.43-2.58 (2H,m) , 2.79-3.45 (6H,m) , 3.68 (0.3x3H, s) , 3.70(0.7x3H,s), 5.24(2H,brs), 6.18(0.7x1H,t), 6.21(0.3x1H,t), 6.72-7.42(8H,m), 7.78(0.3x1H,dd), 7. 85 (0 . 7xlH, dd) , 8 .42 (0 . 7xlH, dd) , 8 .46 (0 . 3xlH, dd) .
MS m/z: 463 (M+1) .
Example 58 - 4-(4-Chlorophenyl)-1-[4-(5,11-dihydro-7-methoxy [1] benzoxepino [2 , 3-b] pyridin-5-ylidene)butyl]piperidin-4-of Step 1 3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propenaldehyde was prepared by following the procedure of example 57, step 2, but replacing 5,11-dihydro-7-methoxy-5-methylene[1]benzoxepino[2,3-b]pyridine with 5,11-dihydro-7-methoxy-5-(propyl-1-ene) [1]benzoxepino[2,3-b]pyridine (by-product of example 45, step 3 ) .
1H-NMR (CDC13} 8: 3.78(0.3x3H,s), 3.80(0.7x3H,s), -5.32(2H,brs), 6.34-6.39(lH,m), 6.72-7.38 (6H,m), 7.58(0.7x1H,dd), 7.77(0.3x1H,dd), 8.49(0.3x1H,dd), 8 . 60 ( 0 . 7xlH, dd) , 9 . 51 ( 0 . 7xlH, d) , 9 . 54 ( 0 . 3xlH, d) .

Step 2 To a solution of the product of step 1 (90mg) in dichloromethane (6m1) were added sodium triacetoxyborohydride (170mg), 4-(4-chlorophenyl)-4-hydroxypiperidine (70mg) and acetic acid (0.02m1) and the mixture stirred at room temperature for 24 hour. Water and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate.
The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with dichloromethane-methanol (95:5) to give 4-(4-chlorophenyl)-1-[4-(5,11-dihydro-7-methoxyEllbenzoxepinoE2,3-b]pyridin-5-ylidene)buten-2-yl]piperidin-4-of (110mg).
1H-NMR (CDC13) 8: 1.68-1.73 (2H,m) , 2.04-2.16 (2H,m) , 2.43-2.72 (3H,m) , 2.77-2.81 (2H,m) , 3.08-3.13 (2H,m) , 3 .73 (0 .3x3H, s) , 3 .77 (0 .7x3H, s) , 5.20 (2H,brs) , 5. 98-6.05 (lH,m) , 6.23-7.43 (lOH,m) , 7.58 (0.7x1H,dd) , 7.65(0.3x1H,dd), 8.37(0.3x1H,dd), 8.45(0.7x1H,dd).
MS m/z: 489 (M+1) .
Step 3 To a solution of the product of step 2 (8mg) in ethanol (2m1) were added 10% Pd-C (2mg) was stirred under hydrogen (under a balloon) at room temperature for 1 hour. The mixture was filtered through the celite and distilled off under reduced pressure to give the titled compound (6mg).

1H-NMR (CDC13) b: 1.68-3.00 (l5H,m) , 3.77 (3H, s) , 5. 18-5.35(2H,m), 5.94(0.4H,t, E isomer), 6.06(0.6H,t, Z isomer), 6.65-6.88(3H,m), 7.05-7.73(6H,m), 8.30-8.56(lH,m).
MS m/z: 491 (M+1) Example 59 - 1-[3-(5,11-Dihydro-7-methoxy [1] benzoxepino (2, 3-b] pyridin-5-ylidene)propyl]piperidin-4-phenyl-4-of The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-phenyl-4-hydroxypiperidine.
1H-NMR (CDC13) d: 1.68-1.73 (2H,m) , 2.02-2.15 (3H,m) , 2.38-2.72(8H,m), 3.77(3H,s), 5.26(2H,brs), 6.08(lH;t), 6.72-6.83 (3H,m) , 7.21-7.36 (4H,m) , 7.46-7.49 (2H,m) , 7.58 (lH,dd) , 8 .46 (1H, dd) .
MS m/z: 443 (M+1) .
Example 60 - 4-(4-Bromophenyl)-1-(3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(4-bromophenyl)-4-hydroxypiperidine.
1H-NMR (CDC13) b: 1.65-1.69 (2H,m) , 2.00-2.10 (3H,m) , 2.37-2.71(8H,m), 3.76(3H,s), 5.24(2H,brs), 6.05(lH,t), 6.70-6 . 82 (3H, m) , 7 .24 (1H, dd) , 7 .38 (2H, d) , 7 . 44 (2H, s) , 7 . 52 ( 1H, dd} , 8 . 44 ( 1H, dd) .

MS m/z: 521,523 (M+1) .
Example 61 - 1-[3-(5,11-Dihydro-7-methoxy [1] benzoxepino [2, 3-b] pyridin-5-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-hydroxypiperidine.
1H-NMR (CDC13) 8: 1.43-1.60 (2H,m) , 1.80-1.98 (2H,m) , 2.00-2.18(3H,m), 2.34-2.48 (4H,m), 2.63-2.76(2H,m), 3.64-3.73 (lH,m) , 3.70 (3H,s) , 5.35 (2H,brs) , 6.06 (lH,t) , 6.74-6.84 (3H,m) , 7.25 (lH,dd) , 7.60 (lH,dd) , 8.50 (lH,dd) .
MS m/z: 367 (M+1) .
Example 62 - 4-Benzyl-1-[3-(5,11-dihydro-7-methoxy [1] benzoxepino [2, 3-b] pyridin-5-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-benzyl-4-hydroxypiperidine.
1H-NMR (CDC13) 8: 1.42-1.57 (3H,m) , 1.62-1.75 (2H,m) , 2.22-2 .70 (BH,m) , 2 . 79 (2H, s) , 3 . 80 (3H, s) , 5.25 (2H,brs) , 6.08 (lH,t) , 6.73-6.84 (3H,m) . 7.18-7.24 (6H,m) , 7.57 (lH,dd) , 8.50 (lH,dd) .
MS m/z: 457 (M+1).

Example 63 - 4-Cyano-1-[3-(5,11-dihydro-7-methoxy [1] benzoxepino [2, 3-b] pyridin-5-ylidene) propyl] -4-phenylpiperidine The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-cyano-4-phenylpiperidine.
1H-NMR (CDC13) b: 1.97-2.06(4H,m), 2.37-2.60(6H,m), 2.85-2.90 (2H,m) , 3.79 (3H, s) , 5.27 (2H,brs) , 6.08 (1H, t) , 6.72-6.84 (3H,m) , 7.24-7.58 (7H,m) , 8.49 (lH,dd) .
MS m/z : 452 (M+1) .
Example 64 - 1-[3-(5,11-Dihydro-7-methoxy [1] benzoxepino [2, 3-b] pyridin-5-ylidene) propyl] -4-phenylpiperidine The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-phenylpiperidine.
~H-NMR (CDC13) b: 1.73-1.79 (4H,m) , 1.96-2.03 (2H,m) , 2.37-2 . 52 (5H, m) , 2 . 86-2 . 94 (2H, m) , 3 . 77 (3H, s) , 5 . 26 (2H, brs) .
6. 08 (1H, t) , 6.72-6.83 (3H,m) , 7.17-7. 31 (6H,m) , 7.56 (1H, dd) , 8 .49 (1H, dd) .
MS m/z 426 (M+1) .

Example 65 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-methoxy (1] benzoxepino [2 , 3-b] pyridin-5-ylidene)propyl]piperidine The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(4-chlorophenyl)piperidine.
1H-NMR (CDC13) 8: 1.68-1.74(4H,m), 1.96-2.03(2H,m), 2.36-2.48 (5H,m) ,2.89-2.94 (2H,m) , 3.77 (3H, s) , 5.27 (2H,brs) , 6.07 (lH,t) , 6.73-6.83 (3H,m) , 7.10-7.27 (SH,m) , 7.57 (lH,dd) , 8 . 48 (1H, dd) .
MS m/z: 461 (M+1) .
Example 66 - 1-[3-(5,11-Dihydro-7-methoxy [1] benzoxepino [2, 3-b] pyridin-5-ylidene)propyl]-4-piperidinopiperidine The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-piperidinopiperidine.
1H-NMR (CDC13) b: 1.40-2.00(l2H,m), 2.15-2.60(9H,m), 2.80-2.92 (2H,m) , 3.80 (3H,s) , 5.28 (2H,brs) , 6.05 (lH,t) , 6.75-6.86 (3H,m) , 7.30 (lH,dd) , 7.55 (lH,dd) , 8.46 (lH,dd) .
MS m/z 434 (M+1).

Example 67 - 1-[3-(5,11-Dihydro-7-methoxy [1] benzoxepino [2, 3-b] pyridin-5-ylidene) propyl] -4-(2-keto-1-benzimidazolinyl)piperidine The titled compound was prepared by following the S procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(2-keto-1-benzimidazolinyl)piperidine.
1H-NMR (CDC13) 8: 1.75-1.79 (2H,m) , 2.03-2.15 (2H,m) , 2.38-2.52 (6H,m) , 2.93-2.98 (2H,m) , 3.78 (3H, s) , 4.30-4.38 (lH,m) , 5.30(2H,brs), 6.10(lH,t), 6.73-6.84(3H,m), 7.01-7.03 (3H,m) , 7.21-7.28 (2H,m) , 7.59 (lH,dd) , 8.48 (lH,dd) .
MS m/z: 483 (M+1).
Example 68 - 1-[3-(5,11-Dihydro-7-methoxy [1] benzoxepino [2 , 3-b] pyridin-5-ylidene) propyl] -4-(2-keto-3-methyl-1-benzimidazolinyl)piperidine The titled compound was prepared by following the procedure of example 36, but replacing of 4-(4-chlorophenyl)-1-[3-(6,11-dihydro-2-methoxydibenz[b,e]oxepin-11-ylidene)propyl]piperidin-4-of with 1- (3- (5, 11-dihydro-7-methoxy(1] benzoxepino [2, 3-b]pyridin-5-ylidene)propyl]-4-(2-keto-1-benzimidazolinyl)piperidine.
1H-NMR (CDC13) 8: 1.72-1.76 (2H,m) , 2.09-2.14 (2H,m) , 2.23-2 .54 (6H,m) , 2 . 91-2 . 96 (2H,m) , 3 .38 (3H, s) , 3 .77 (3H, s) , 4 .30-4.37 (lH,m) , 5.27 (2H,brs) , 6.08 (lH,t) , 6.71-6.83 (3H,m) , 6.93-7.06 (3H,m) , 7.23-7.60 (2H,m) , 8.08 (lH,dd) , 8.48 (lH,dd) .
MS m/z: 497 (M+1).

Example 69 - 8-[3-(5,11-Di.hydro-7-methoxy [1] benzoxepino [2, 3-b] pyridin-5-ylidene) propyl] -1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one.
'H-NMR (CDC13) 8: 1.65-1.70 (2H,m) , 2.36-2.41 (2H,m) , 2.53-2.79 (8H,m) , 3.76 (3H, s) , 4 .70 (2H, s) , 5.25 (2H,brs) , 6.10(lH,t), 6.71-6.88(6H,m), 7.21-7.27(3H,m), 7.58-7.61 (2H,m) , 8.48 (lH,dd) .
MS m/z: 497 (M+1) .
Example 70 - 4-Anilino-4-carbamyl-1-[3-(5,11-dihydro-7-methoxy [ 1 ] benzoxepino [2 , 3 -b] pyridin- 5 -ylidene)propyl]piperidine The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-anilino-4-carbamylpiperidine.
1H-NMR (CDC13) b: 1.85-1.90(2H,m), 2.03-2.08(2H,m), 2.19 2.46 (6H,m) , 2.62-2 .67 (2H,m) , 3 .75 (3H, s) , 3.97 (lH,brs) , 5 .27 (2H, brs) , 5 .53 (1H, brs) , 6. 03 (1H, t) , 6 . 60 (2H, d) , 6 . 70-6.85 (4H,m) , 7.12-7.25 (4H,m) , 7.53 (lH,dd) , 8.46 (lH,dd) .
MS m/z 485 (M+1) .

Example 71 - 1-(4-Chlorophenyl)-4-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperazine The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 1-(4-chlorophenyl)piperazine.
1H-NMR (CDC13) 8: 2.36-2.53 (8H,m) , 3.07-3 .09 (4H,m) , 3.76(3H,s), 5.26(2H,brs), 6.08(lH,t), 6.72-6.81(SH,m), IO 7.16-7.28 (3H,m) , 7.56 (lH,dd) , 8.49 (lH,dd) .
MS m/z: 462 (M+1) .
Example 72 - 1-[3-(5,11-Dihydro-7-methoxy [ 1 ] benzoxepino [2 , 3 -b] pyridin- 5 -yl idene ) propyl ] -4-(2-pyrimidyl)piperazine The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 1-(2-pyrimidyl)piperazine.
'H-NMR (CDC13) b: 2.37-2.53 (BH,m) , 3.74-3.83 (7H,m) , 5.27(2H, brs), 6.08(lH,t), 6.45(lH,t), 6.72-6.83(3H,m), 7 .25 (1H, dd) , 7 . 56 (1H, dd) , 8.27 (2H, d) , 8 .49 (1H, dd) .
MS m/z: 430 (M+1) .

_77_ Example 73 - 1-Cyclohexyl-4-[3-(5,11-dihydro-7-methoxy [1] benzoxepino [2, 3-b] pyridin-5-ylidene)propyl]piperazine The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 1-cyclohexylpiperazine.
1H-NMR (CDC13) 8: 1.12-1.27(6H,m), 1.74-1.86(6H,m), 2.18-2.52 (llH,m), 3.76(3H,s), 5.26(2H,brs), 6.04(lH,t), 6.74-6 . 81 ( 3H, m) , 7 . 23 ( 1H, dd) , 7 . 55 ( 1H, dd) , 8 . 48 ( 1H, dd) .
MS m/z: 434 (M+1) .
Example 74 - 1-[3-(5,11-Dihydro-7-methoxy [1] benzoxepino (2, 3-b] pyridin-5-ylidene) propyl] -4-(2-furoyl)piperazine The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 1-(2-furoyl)piperazine.
1H-NMR (CDC13) 8: 2 .34-2 .48 (BH,m) , 3 . 71-3 .74 (7H, s) , 5.24 (2H,brs) , 6.05 (lH,t) , 6.42 (lH,dd) , 6.70-6.80 (3H,m) , 6 . 93 ( 1H, d) , 7 . 23 ( 1H, dd) , 7 . 42 ( 1H, d) , 7 . 53 ( 1H, dd) , 8.46 (IH,dd) .
MS m/z: 446 (M+1).

Example 75 - 4-(3-Chlorophenyl)-1-[3-(5,11-dihydro-7-methoxy [1] benzoxepino [2, 3-b] pyridin-5-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(3-chlorophenyl)-4-hydroxypiperidine.
1H-NMR (CDC13) 8: 1.61-1.75 (2H,m) , 1.98 (lH,brs) , 1 . 99 (2H,dt) , 2.25 (3H, s) , 2.30-2 .76 (BH,m) , 3.73 (3H, s) , 5.22(2H,brs), 5.95(O.lH,t, E isomer), 6.04(0.9H,t, Z
isomer) , 6.71-6.89 (3H,m) , 6.95 (lH,dd) , 7.15-7.20 (0.3H,m, E
isomer),7.21-7.35(2.7H,m, Z isomer), 7.53(0.9H,dd, Z
isomer), 7.65(O.lH,dd, E isomer), 8.35(O.lH,dd, E isomer), 8.45 (0.9H,dd, Z isomer) .
MS m/z: 477(M+1) Example 76 - 4-(2-Chlorophenyl)-1-[3-(5,11-dihydro-7-methoxy [1] benzoxepino [2, 3-b] pyridin-5-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(2-chlorophenyl)-4-hydroxypiperidine.
1H-NMR (CDC13) b: 1.98-2.08 (2H,m) , 2.24 (2H,dt) . 2.38-2.78 (9H,m) , 3 .77 (3H, s) , 5.27 (2H,brs) , 6.08 (1H, t) , 6.82-6.75(3H,m), 7.28-7.19(3H,m), 7.33(lH,dd), 7.49(lH,dd), 7.58(lH,dd), 8.40(O.lH,dd, Z isomer), 8.47(0.9H,dd, E
isomer) .
MS m/z: 477(M+1) WO 99/37b51 PCT/US99/01266 Example 77 - 1-[3-(5,11-Dihydro-7-methoxy [1] benzoxepino [2, 3-b] pyridin-5-ylidene) propyl] -4-(4-fluorophenyl)piperidin-4-of The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(4-fluorophenyl)-4-hydroxypiperidine.
1H-NMR (CDC13) 8: 1.58-1.72 (2H,m) , 2.04 (2H,dt) , 2.22-2 . 78 (9H, m) , 3 . 75 (3H, s) , 5.26 (2H, brs) , 6 . 09 (1H, t) , 6 . 70-6 . 88 (3H, m) , 7 . 00 (2H, dd} , 7 . 23 (1H, dd) , 7 .42 (2H, dd) , 7 . 56 (1H, dd) , 8 .41 (1H, dd) .
MS m/z: 461(M+1) Example 78 - 1-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(p-tolyl)piperidin-4-of The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(p-tolyl)-4-hydroxypiperidine.
1H-NMR (CDC13) b: 1.65-1.78 (2H,m) , 2.02 (2H, dt) , 2 .31 (3H, s} , 2.24-2 .75 (9H,m) , 3.75 (3H, s) , 5.25 (2H,brs) , 6.07 (1H, t} , 6.72-6.84 {3H,m) , 7.13 (2H,d) , 7.23 (lH,dd) , 7.34 (lH,d) , 7.56 (lH,dd) , 8.43 (lH,dd) .
MS m/z: 457(M+1) Example 79 - 4-(3,4-Dichlorophenyl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydrvxypiperidine with 4-(3,4-dichlorophenyl)-4-hydroxypiperidine.
1HNMR (CDC13) b: 1.58-1.72 (2H,m) , 1.84 (lH,brs) , 2 . 02 (2H, td) , 2 .32-2 . 72 (8H, m) , 3 . 76 (3H, s) , 5.27 (2H,brs) , 5.95(O.lH,t, E isomer), 6.07(0.9H,t, Z isomer), 6.72-6.85 (3H,M) , 7.12-7.20 (0.2H,m, E isomer) , 7.21-7.32 (0.18H,m, Z
isomer), 7.32-7.45(lH,m), 7.52-7.56(2H,m), 8.37(0.9H,dd, E
siomer), 8.45(O.lH,dd, Z isomer).
MS m/z: 512(M+1) Example 83 - 4-(5-Chloropyridin-2-yl)-1-[3-(5,11-dihydro-7-methoxy [ 1 ] benzoxepino [2 , 3 -b] pyridin- 5 -ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(5-chloropyridin-2-yl)-4-hydroxypiperidine.
1H-NMR (CDC13) 8: 1.77-1.82 (2H,m) , 2.36-2.94 (llH,m) , 3.77 (3H,brs) , 5.26 (2H,brs) , 6.07 (lH,t) , 6.76-6.84 (3H,m) , 7.26(lH,dd), 7.57(lH,dd), 8.49-7.48(lH,d), 8.42-8.53 (3H,m) .
MS m/z: 478~(M+1) _81_ Example 85 -4-(5-Chloro-2-keto-1-benzimidazolinyl)-1- [3- (5, 11-dihydro-7-methoxy [1] benzoxepino [2, 3-b] pyridin-5-ylidene)propyl]piperidine The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(5-chloro-2-keto-1-benzimidazolinyl)piperidine.
1H-NMR (CDC13) 8: 1.68-1.72(2H,m), 2.03-2.60(8H,m), 2.90-3.02 (2H,m) , 3.78 (3H, s) , 4.32-4.21 (lH,m) , 5.29 (2H,brs) , 5.95(O.lH,t, E siomer), 6.08(0.9H,t, Z isomer), 6.70-6.92 (3H,m) , 7.02 (lH,dd) , 7.08-7.20 (lH,m) , 7.26 (lH,dd) , 7.58(0.9H,dd, Z isomer), 7.70(O.lH,dd, E isomer), 8.42(O.lH,dd, E isomer), 8.48(0.9H,dd, Z isomer), 10.5(lH,s). (NH is not observed in the spectrum) MS m/z: 517(M+1) Example 86 - 4-(p-Chloroanilino)-1-[3-(5,11-dihydro-7-methoxy [1] benzoxepino [2, 3-b] pyridin-5-ylidene)propyl]piperidine The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(p-chloroanilino}piperidine.
1H-NMR (CDC13) 8: 1.20-1.54(2H,m), 1.85-2.20(4H,m), 2.24-2 . 60 (4H, m) , 2 . 73 (2H, m) , 3 .18 ( 1H, m) , 3 . 77 ( 3H, s) , 5.27 (2H,brs) , 6.06 (1H, t) , 6.47 (2H,m) , 6.68-6. 90 (3H,m) , 7 . 07 (2H, m) , 7 . 24 ( 1H, dd) , 7 . 57 ( 1H, m) , 8 . 48 ( lHdd) . NH
signal was not observed.
MS m/z: 476(M+1) Example 89 - 1-[3-(5,11-Dihydro-7-methoxy [1] benzoxepino [2, 3-b] pyridin-5-ylidene) propyl] -4-(p-tosyl)piperazine The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 1- (p-tosyl ) piperazine .
1H-NMR (CDC13) 8: 2.20-2.54 (llH,m) , 2.82-3.10 (4H,m) , 3.73(3H,s), 5.16(2H,brs), 6.00(lH,t), 6.66-6.85(3H,m), 7 . 21 ( 1H, dd) , 7 . 31 (2H, m) , 7 . 51 ( 1H, dd) , 7 . 61 ( 2H, m) , 8 . 45 ( 1H, dd) .
MS m/z: 506 (M+1) Example 90 - 1'-E3-(5,11-Dihydro-7-methoxy [1] benzoxepino [2, 3-b] pyridin-5-ylidene)propyl]spiro[isobenzofuran-1(3H),4'-piperidine]
The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with spiro [isobenzofuran-1 (3H) , 4' -piperidine] .
1H-NMR (CDC13) S: 1.62-1.82 (2H,m) , 1.92 (2H,dt) , 2.25-2 .85 (BH,m) , 3 .76 (3H, s) , 5. 03 (2H, s) , 5.30 (2H, brs) , 6.11(lH,t), 6.68-6.90(3H,m), 7.02-7.34(SH,m), 7.58(lH,dd), 8.48 (lH,dd) .
MS m/z: 455(M+1) Example 91 - 5-Chloro-1'-[3-(5,11-dihydro-7-methoxy E1] benzoxepino [2, 3-b] pyridin-5-ylidene) propyl] spiro [isobenzofuran-1 (3H) , 4' -piperidine]
The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 5-chlorospiro[isobenzofuran-1(3H),4'-piperidine].
1H-NMR (CDC13) 8: 1.69-1.74 (2H,m) , 1.81-1.93 (2H,m) , 2.30-2.44 (4H,m) , 2.52-2.63 (2H,m) , 2.71-2.75 (2H,m) , 3 .79 (3H, s) , 5. 00 (2H, s) , 5.28 (2H,brs) , 6. 09 (1H, t) , 6.73-6.84 (3H,m) , 7.03 (lH,d) , 7.17-7.28 (3H,m) , 7.58 (lH,dd) , 8 . 49 (1H, dd) .
MS m/z: 489(M+1) Example 111 - 4- (4-Chlorophenyl) -1- (3- (5, 11-dihydro [1] benzothiepino [2, 3-b] pyridin-5-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 45, but replacing 5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with 5,11-dihydro[1]benzothiepino[2,3-b]pyridin-5-one.
1H-NMR (CDC13) 8: 1.66-1.78(3H,m), 2.04-2.65(lOH,m), 3.66(lH,brd), 5.05(lH,brd), 6.03(lH,t), 7.04-7.46(lOH,m), 8 . 44 ( 1H, dd) .
MS m/z: 463(M+1) Example 114 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-8-methoxy [1] benzoxepino [2, 3-b] pyridin-5-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 45, but replacing 5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with 5, 11-dihydro-8-methoxy [1] benzoxepino [2, 3-b] pyridin-5-one .
1H-NMR (CDC13) 8: 1.66-1.70 (3H,m) , 1.98-2.09 (2H,m} , 2.34-2.70(BH,m), 3.75(3H,s), 5.32(2H,brs), 6.02(lH,t), 6.39 (lH,d) , 6.51 (lH,dd) , 7.19-7.44 (6H,m) , 7.57 (lH,dd) , 8.49(lH,dd) .
MS m/z: 477(M+1) Example 115 - 4-(4-Chlorophenyl)-I-[3-(5,11-dihydro-7-methyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 45, but replacing 5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with 5,11-dihydro-7-methyl[1]benzoxepino[2,3-b]pyridin-5-one 1H-NMR (CDC13) b: 1.50(lH,brs), 1.66-1.70(2H,m), 1.98-2.10 (2H,m) , 2.28 (3H, s) , 2.34-2.42 (4H,m) , 2.52-2.57 (2H,m) , 2.66-2.70 (2H,m) , 5.30 (2H,brs) , 6.08 (1H, t) , 6.76(lH,d}, 6.97(lH,dd), 7.09(lH,d), 7.24-7.44(SH,m), 7. 57 (1H, dd) , 8 .49 (IH, dd) .
MS m/z: 461 (M+1) Example 117 - 1-(3-(7-Chloro-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-of The titled compound was prepared by following the procedure of example 45, but replacing 5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with 7-chloro-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-one.
1H-NMR (CDC13) S: 1.66-1.71 (3H,m) , 2.00-2.10 (2H,m) , 2.36-2 .44 (4H,m) , 2.52-2 .57 (2H,m) , 2.66-2.70 (2H,m) , 5.32 (2H,brs) , 6.13 (lH,t) , 6.78 (lH,d) , 7.11 (lH,dd) , 7.26-7.44 (SH,m) , 7.58(lH,dd), 8.51(lH,dd).
MS m/z: 481(M+1) Example 118 - 1-[3-(7-Carboxy-5,11-dihydro [1] benzoxepino [2, 3-b] pyridin-5-ylidene) propyl] -4-(4-chlorophenyl)piperidin-4-of A mixture of the product of example 169 (500 mg), potassium acetate (330 mg), palladium(II) diacetate (IO
mg), 1,1'-bis(diphenylphosphino)ferrocene (93 mg), in dimethylsulfoxide (10 ml) was purged with carbon monoxide for 5 minutes and stirred under a carbon monoxide balloon at 60°C for 3 hours. Water was added to the reaction mixture, the precipitation was filtered. The solid were dissolved with ethyl acetate and dilute sodium hydroxide solution. The aqueous layer was separated and neutralized with dilute hydrochloric acid. The precipitation was filtered to give the titled compound (250 mg).

1H-NMR (DMSO-d6) 8: 1 . 45-1. 55 (2H, m) , 1 . 75-1 . 85 (2H, m) , 2.36-2.62(BH,m}, 5.42(2H,brs), 6.21(lH,t), 6.90(lH,d), 7.40-7.52 (SH,m) , 7.75 (lH,dd) , 7.83 (lH,dd) , 7 . 95 ( 1H, d) , 8 . 56 ( 1H, dd) .
MS m/z: 491(M+1) Example 128 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-propoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 46, but replacing ethyl iodide with propyl iodide.
1H-NMR (CDC13) 8: 1. 03 (3H, t) , 1. 65-1. 70 (2H, m) , 1. 78 (2H, q) , 1.98-2.09 (3H,m) , 2.37-2.45 (4H,m) , 2.51-2.56 (2H,m) , 2 . 66-2 . 70 (2H,m} , 3 . 88 (2H, t) , 5.26 (2H, brs} , 6. 08 (1H, t) , I5 6 . 72-6 . 84 (3H, m) , 7 . 23-7 . 43 (5H, m) , 7 . 58 ( 1H, dd) , 8 . 43 ( 1H, dd) .
MS m/z: 505(M+1) Example I30 - 4-(4-Chlorophenyl)-1-[3-(7-cyclopropylmethyloxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 46, but replacing ethyl iodide with cyclopropylmethyl bromide.
1H-NMR (CDC13) b: 0.31-0.37 (2H,m) , 0.60-0.67 (2H,m) , 1.21-1.28 (lH,m) , 1.66-1.72 (3H,m) , 2.01-2.11 (2H,m) , 2 . 37-2 . 71 (BH,m) , 3 . 77 (2H, d) , 5 .27 (2H, brs) , 6 . 08 (IH, t) , 6.73-6.86 (3H,m) , 7.23-7.44 (SH,m) , 7.58 (lH,dd) , 8.47 (lH,dd} .
MS m/z: 517(M+1) _87_ Example 131 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2-dimetylaminoethyl)oxy)[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 46, but replacing ethyl iodide with 2-(dimethylamino)ethyl chloride hydrochloride.
1H-NMR (CDC13) 8: 1.71-1.76 (2H,m) , 2.12-2.21 (2H,m) , 2.38(6H,s), 2.40-2.79(llH,m), 4.07(2H,t), 5.28(2H,brs), 6.07(lH,t), 6.74-6.86(3H,m), 7.27-7.46(SH,m), 7.59(lH,dd), 8.49(lH,dd) .
MS m/z: 534(M+1) Example 132 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(tetrazol-5-yl)methyloxy)[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-of Step 1 4- (4-Chlorophenyl) -1- [3- (5, 11-dihydro-7- (2-triphenylmethyltetrazol-5-yl)methyloxy)[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-of was prepared by following the procedure of example 46, but replacing ethyl iodide with (2-triphenylmethyltetrazol-5-yl)methyl chloride.
1H-NMR (CDC13) 8: 1.64-1.70 {3H,m) , 2.02-2.15 (2H,m) , 2 .35-2. 71 (BH,m) , 5.29 (2H,brs) , 5.33 (2H, s} , 6.03 (lH,t) , 6.77 (lH,d) , 6.83 (lH,dd) , 6.96 (lH,d) , 7.04-7.08 (6H,m) , 7.23-7.45 (l4H,m) , 7.54 (lH,dd) , 8.50 (lH,dd) .

_88_ Step 2 A solution of the product of step 1 (530 mg) in acetone (2.5 ml), acetic acid (2.5 ml) and water (2.5 ml) was stirred at 55°C for 30 minutes. The reaction mixture was distilled off under reduced pressure. The residue was washed with methanol to give the titled compound (280 mg).
1H-NMR(DMSO-d6) b: 1.69-1.74 (2H,m) , 1.99-2.09 (2H,m) , 2.95-3.14(BH,m), 5.18(2H,brs), 5.20(2H,s), 6.14(lH,t), 6.76 (lH,d) , 6.93 (lH,dd) , 7.04 (lH,d) , 7.39-7.48 (5H,m} , 7 . 78 ( 1H, dd) , 8 . 52 ( 1H, dd) .
MS m/z: 545(M+1) Example 133 - 1-[3-(7-Carboxymethyloxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-of To a solution of product of example 48 (3.0 g) in methanol (50 ml) was added 1N sodium hydroxide solution (8 ml} and the mixture stirred at room temperature for 1 hour.
The reaction mixture was distilled off under reduced pressure. The residue was dissolved with water and neutralized with 1N hydrochloric acid. The precipitation was filtered and washed with water to give the titled compound ( 2 . 6 g ) .
1H-NMR (DMSO-d6) 8: 1.48-1.53 (2H,m) , 1.76-1.88 (2H,m) , 2.32-2.60(BH,m}, 4.60(2H,s), 5.18(2H,brs), 6.16(lH,t), 6.72-6.84 (3H,m} , 7.34-7.48 (SH,m) , 7.73 (lH,dd) , 8.50 {lH,dd) .
MS m/z: 521(M+1) Example 134 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-dimethylaminocarbonylmethyloxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-of To a solution of product of example 133 (420 mg) in dimethylformamide (17 ml) were added 1-hydroxybenzotriazol hydrate (250 mg), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (310 mg), dimethylamine hydrochloride (270 mg) and triethylamine (0.45 ml), and the mixture stirred at room temperature for 12 hours. Water and chloroform were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate.
The solvent was distilled off under reduced pressure to give the titled compound (380 mg).
1H-NMR (CDC13) b: 1.67-1.71 (2H,m) , 1.95-2.11 (3H,m) , 2 .37-2 .71 (BH,m) , 2 . 97 (3H, s) , 3 . 08 (3H, s) , 4 .64 (2H, s) , 5.27(2H,brs), 6.09(lH,t), 6.74-6.82(2H,m), 6.93(lH,d), 7.24-7.44 (SH,m) , 7.58 (lH,dd) , 8.47 (lH,dd) .
MS m/z: 548 (M+1) Example 135 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-morpholinocarbonylmethyloxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 134, but replacing dimethylamine hydrochloride with morpholine.
1H-NMR (CDC13) b: 1.67-1.71(2H,m), 1.87(lH,brs), 2.00-2.11(2H,m), 2.38-2.71(8H,m), 3.61-3.68(8H,m), 4 .65 (2H, s) , 5.27 (2H,brs) , 6. 09 (1H, t) , 6. 74-6. 83 (2H,m) , 6.90 (lH,d) , 7.25-7.44 (SH,m) , 7.58 (lH,dd) , 8.48 (lH,dd) .
MS m/z: 590 (M+1) Example 138 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(1-ethoxycarbonyl-1-methylethyl)oxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 46, but replacing ethyl iodide with ethyl 2-bromoisobutylate.
1H-NMR (CDC13) 8: 1.27 (3H, t) , 1 .56 (6H, s) , 1 .63-1 .71 (3H,m) , 2.01-2.10 (2H,m) , 2.35-2.70 (BH,m) , 4.24 (2H,q) , 5.28 (2H,brs) , 6. 05 (1H, t) , 6 . 67-6 . 75 (2H, m) , 6 . 87 (1H, d) , 7 .24-7 .44 (SH,m) , 7.56 {1H, dd) , 8.49 (lH,dd) .
MS m/z: 577(M+1) Example 139 - 1-[3-(7-(1-Carboxy-1-methylethyl)oxy-5,11-dihydro [1] benzoxepino [2, 3-b] pyridin-5-ylidene) propyl] -4-(4-chlorophenyl)piperidin-4-of The titled compound was prepared by following the procedure of example 133, but replacing product of example 48 with product of example 138.
1H-NMR (DMSO-ds) b: 1.45-1.52 (8H,m) , 1.79-1.85 (2H,m) , 2.28-2.53 (BH,m) , 5.19 (2H,brs) , 6.07 (lH,t) , 6.69-6.73 (2H,m) , 6.85 (lH,d) , 7.33-7.47 (SH,m) , 7.71 (lH,dd) , 8.48 (lH,dd) .
MS m/z: 549(M+1) Example 140 - 1-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-methoxyphenyl)piperidin-4-of The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(4-methoxyphenyl)-4-hydroxypiperidine.
1H-NMR (CDC13) 8: 1.62-1.75 (2H,m) , 2.08 (2H,dt) , 2.41-2.76 (9H,m) , 3.77 (3H,s) , 3.78 (3H,s) , 5.26 (2H,brs) , 6. 06 (1H, t) , 6.75-6.871 (SH,m) , 7 .23 (1H, dd) , 7.38 (2H, d) , 7 . 57 ( 1H, dd) , 8 . 45 ( 1H, dd) .
MS m/z: 473(M+1) Example 141 - 4-(4-Cyanophenyl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(4-cyanophenyl)-4-hydroxypiperidine.
1H-NMR (CDC13) 8: 1.58-1.70 (2H,m) , 2. 03 (2H, t) , 2.31-2.64 (7H,m) , 2.65-2.78 (2H,m) , 3.75 (3H, s} , 5.26 (2H,brs) , 5.95(O.lH,t, E isomer), 6.05(0.9H,t, Z isomer), 6.70-6.80(3H,m), 7.22(lH,dd), 7.54-7.68(SH,m), 8.31(O.lH,dd, E
iosmer), 8.39(0.9H,dd, Z isomer).
MS m/z:468(M+1) Example 142 - 1-[3-(5,11-Dihydro-7-methoxy [1] benzoxepino [2, 3-b] pyridin-5-ylidene) propyl] -4-(4-hydroxyphenyl)piperidin-4-of The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(4-hydroxyphenyl)-4-hydroxypiperidine.
1HNMR (CDC13) 8: 1.76-1.88 (2H,m) . 2.08-2.22 (2H,m) , 2.45-2.95 (9H,m) , 3 .76 (3H, s) , 5.28 (2H,brs) , 5.95 (0.3H, t, E
isomer), 6.04(0.7H,t, Z iosmer), 6.69-6.72(3H,m), 6.90(2H,d), 7.20-7.30(3H,m), 7.56(0.7H,dd, Z isomer), 7.67(0.3H,dd, E isomer), 8.46(0.7H,dd, Z isomer), 8.47(0.3H,dd, E isomer). OH signal was not observed.
MS m/z: 473(M+1}
Example 143 - 1-[3-(5,11-Dihydro-7-methoxy [1] benzoxepino [2, 3-b] pyridin-5-ylidene) propyl] -4-(4-fluoro-3-methylphenyl)piperidin-4-of The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(4-fluoro-3-methylphenyl)-4-hydroxypiperidine.
'H-NMR (CDC13) b: 1.62-1.75 (2H,m) , 2.05 (lH,brs) , 2 . 09 (2H, dt) , 2 .25 (3H, s} , 2 .30-2.76 (BH,m) , 3 . 76 (3H, s) , 5.26(2H, brs), 5.96(O.lH,t, E isomer), 6.07(0.9H,t, Z
isomer), 6.75-6.89(3H,m), 6.93(lH,t), 7.11-7.20(0.3H,m, E
isomer), 7.21-7.35(0.24H,m, Z isomer), 7.56(0.9H,dd, E
isomer), 7.67(O.1H, dd, E isomer), 8.38(O.lH,dd, E isomer), 8.45(0.9H,dd, Z isomer).

MS m/z: 475(M+1) Example 144 - 4-(3,4-difluorophenyl)-1-[3-{5,11-dihydro-7-methoxy (1] benzoxepino [2, 3-b] pyridin-5-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(3,4-difluorophenyl)-4-hydroxypiperidine.
1H-NMR (CDC13) 8: 1.58-1.72 (2H,m) , 1.96 (2H,dt) , 2.33-2 .71 (BH,m) , 3 .73 (3H, s) , 5.23 (2H,brs) , 5. 94 (0. 1H, t, E
isomer), 6.04(0.9H,t, Z isomer), 8.38-8.36(0.9H,m, Z
isomer), 6.68-6.79(3H,m), 6.98-7.38(4H,m), 7.50-7.62(0.9H,m, Z isomer), 7.63-7.68(O.lH, m, E isomer), 8.29-8.32 (O.lH,m, E isomer) , 8.32-8.44 (0.9H,m, Z isomer) . OH
I5 signal was not observed.
MS m/z: 479(M+1) Example 145 - 4-(4-Chloro-3-trifuluoromethylphenyl)-1-[3- (5, 11-dihydro-7-methoxy [1] benzoxepino [2, 3-b] pyridin-5-ylidene)propyl]piperidin-4-oI
The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(4-chloro-3-trifluaromethylphenyl)-4-hydroxypiperidine.
1H-NMR (CDC13) S: 1.62-1.74 (2H,m) , 2.10 (2H,dt) , 2.35-2.80 (8H,m) , 2.42 (1H, brs) , 3.76 (3H, s) , 5.26 (2H,brs) , 6.07(0.9H,t, Z isomer), 6.03(O.lH,t, E isomer), 6.82-6.71(3H,m), 7.24(lH,dd), 7.43(lH,d), 7.56(1.8H,dd, Z

isomer), 7.65(0.2H,dd, E isomer) 7.83(lH,d), 8.36(O.lH,dd, E isomer), 8.44(0.9H,dd, Z iosmer), MS m/z: 545(M+1) Example 146 - 4-(3,5-dichlorophenyl)-1-[3-(5,11-dihydro-7-methoxy [1] benzoxepino [2, 3-b] pyridin-5-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(3,5-dichlorophenyl)-4-hydroxypiperidine.
'H-NMR (CDC13) 8: 1.58-2.22 (SH,m) , 2.38-2.77 (BH,m) , 3.76 (3H,s) , 5.26 (2H,brs) , 5.92 (O.lH,t, E isomer) , 6.07(0.9H,t, Z isomer), 6.83-6.71(3H,m), 7.19-7.42(4H,m), 7.56(0.9H,dd, Z isomer), 7.68(O.lH,dd, E isomer), 8.38 (O.lH,dd, E isomer) , 8.45 (0.9H,dd, Z isomer) .
MS m/z: 512(M+1) Example 147 - 1-[3-(5,11-Dihydro-7-methoxy [1] benzoxepino [2, 3-b] pyridin-5-ylidene) propyl] -4-(2-pyridyl)piperidin-4-of The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(2-pyridyl)-4-hydroxypiperidine 1H-NMR (CDC13) b: 1.54-1.65 (2H,m) , 2.06 (2H,dt) , 2.07 (lH,brs) , 2.35-2.62 (7H,m) , 2.73-2.87 (2H,m) , 3 .78 (3H, s) , 5.28 (2H, brs) , 6.08 (1H, t) , 6.72-6.85 (3H,m} , 7.14-7.29 (2H,m) , 7.57 (lH,d) , 7.70 (lH,dd) , 8.48 (2H,dd) .

MS m/z: 444(M+1) Example 148 - 1-[3-(5,11-Dihydro-7-methoxy [1] benzoxepino [2, 3-b] pyridin-5-ylidene) propyl] -4-(3-pyridyl)piperidin-4-of The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(3-pyridyl)-4-hydroxypiperidine.
1H-NMR (CDC13) S: 1.65-1.78 (2H,m) , 2.08 (2H,dt) , 2.37-2.88 (7H,m) , 2 . 63-2 .79 (2H,m) , 3 .78 (3H, s) , 5.28 (2H, brs) , 6.02(O.lH,t, E isomer), 6.07(0.9H,t, Z isomer), 6.70-6.84 (3H,m) , 7.22-7.32 (3H,m) , 7.56 (lH,dd) , 7.77 (lH,dd) , 8.46 (0.9H,d) , 8.57 (O.lH,dd, E isomer) , 8.73 (lH,dd) .
MS m/z: 444(M+1) Example 149 - 1-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-pyridyl)piperidin-4-of The titled compound was prepared by following the procedure of example 45, step.3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(4-pyridyl)-4-hydroxypiperidine.
1H-NMR (CDC13) S: 1.58-1.72 (2H,m) , 2.03 (2H,dt) , 2.34-2.89 (BH,m) , 2.96 (lH,brs) , 3 .76 (3H, s) , 5.25 (2H, brs) , 6.06 (1H, t) , 6.72-6.83 (3H,m) , 7.24 (lH,dd) , 7.37 (2H,dd) , 7 . 56 ( 1H, dd) , 8 . 45 ( 1H, dd) , 8 . 48 (2H, dd) .
MS m/z: 444(M+1) Example 150 - 1-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-trifluoromethylphenyl}piperidin-4-of The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(4-trifluoromethylphenyl)-4-hydroxypiperidine.
1H-NMR (CDC13) 8: 1.64-1.75 (2H,m) , 2.01 (1H, brs) , 2.16 (2H,dt) , 2.38-2.86 (BH,m) , 3 .76 (3H, s) , 5.26 (2H,brs) , 6.04(lH,t), 6.72-6.84(3H,m}, 7.23(lH,dd), 7.56(5H,m), 8.42(lH,dd).
MS m/z: 511(M+1) Example 151 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-hydroxy [1] benzoxepino [2 , 3-b] pyridin-5-ylidene)propyl]piperidine The titled compound was prepared by following the procedure of example 44, step 2, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(4-chlorophenyl)piperidine.
1H-NMR (CDC13) b: I.62-1.92 (4H,m) , 1.94-2.18 (2H,m) , 2.28-2.64(SH,m), 2.99(2H,m), 5.25(2H,brs), 6.00(lH,t), 6.60-6.82 (3H,m) , 7.02-7.36 (SH,m} , 7.50 (lH,dd) , 8.47 (lH,dd} . OH
signal was not observed.
MS m/z: 447(M+1) Example 152 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-ethoxy [1] benzoxepino [2, 3-b] pyridin-5-ylidene)propyl]piperidine The titled compound was prepared by following the procedure of example 46, but replacing the product of example 44 with the product of example 151.
1H-NMR (CDC13) 8: 1.40 (3H, t) , 1 .52-2 .14 (6H,m) , 2 .30-2 . 57 (5H, m) , 2 . 94 (2H, m) , 4 . 00 (2H, q) , 5 . 28 (2H, brs) , 6.07 (lH,t) , 6.68-6.86 (3H,~m} , 7.05-7.36 (SH,m) , 7.58 (lH,m) , 8.49(lH,m).
MS m/z: 475(M+1) Example 153 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-ethoxycarbonylmethyloxy[1]benzoxepino[2,3-b]pyridin-5-ylidene}propyl]piperidine The titled compound was prepared by following the procedure of example 48, but replacing the product of example 44 with the product of example 151.
1H-NMR (CDC13) S: 1.29 (3H, t) , 1 .56-1. 85 (4H,m) , 1. 99 (2H, dt) , 2.28-2.55 (SH,m) , 2. 91 (2H,m) , 4.27 (2H,q) , 4.58 (2H, s) , 5.28 (2H, brs) , 6. 09 (1H, t) , 6 . 68-6. 95 (3H,m) , 7 . 07-7.32 (SH,m) , 7.58 (lH,dd) , 8.49 (lH,dd) .
MS m/z: 533 (M+1) _98_ Example 154 - 1-[3-(7-(Carboxymethyloxy-5,11-dihydro [1] benzoxepino [2, 3-b] pyridin-5-ylidene) propyl] -4-(4-chlorophenyl)piperidine The titled compound was prepared by following the procedure of example 133, but replacing the product of example 48 with the product of example 153.
1H-NMR (CD30D) 8: 1 . 82-2 . 17 (4H, m) , 2 . 69 (2H, m) , 2 . 86 ( 1H, m) , 3.07 (2H,m) , 3.30 (2H,m) , 3.57 (2H,m) , 4.57 (2H, s) , 5.21(2H,brs), 6.10(lH,t), 6.70-7.04(3H,m), 7.16-7 . 38 (4H, m) , 7 . 44 ( 1H, m) , 7 . 77 ( 1H, m) , 8 . 47 ( 1H, m) . COOH
signal was not observed.
MS m/z: 505(M+1) Example 155 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-dimethylaminocarbonylmethyloxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine The titled compound was prepared by following the procedure of example 134, but replacing the product of example 133 with the product of example 154.
1H-NMR (CDC13) 8: 1.58-1.92 (4H,m) , 2.04 (2H,m) , 2.30-2. 68 (SH,m) , 2 . 93 (2H,m) , 2 . 98 (3H, s) , 3 . 08 (3H, s) , 4.65 (2H, s) , 5.28 (2H,brs) , 6. 07 (1H, t) , 6.70-6. 98 (3H,m) , 7.08-7.36 (SH,m) , 7.60 (lH,m) , 8.50 (lH,m) .
MS m/z: 532(M+1) Example 156 - 1-[3-(7-(2-Acetoxyethyl)oxy-5,11-dihydro [ 1 ] benzoxepino [ 2 , 3 -b] pyridin- 5 -ylidene)propyl]piperidine The titled compound was prepared by following the procedure of example 50, but replacing the product of example 44 with the product of example 151.
1H-NMR (CDC13) b: 1.55-1.88 (4H,m) , 1.90-2 .32 (2H,m) , 2.10 (3H, s) , 2.28-2.60 (SH,m) , 2.82-3 .02 (2H,m) , 4.14 (2H,dd) , 4 .41 (2H, dd) , 5.29 (2H,brs) , 6.08 (1H, t) , 6.72-6. 90 (3H,m) , 7.18-7.34 (SH,m) , 7.57 (lH,m} , 8.50 (lH,m} .
MS m/z: 533(M+1) Example 157 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2-hydroxyethyl) oxy [1] benzoxepino [2, 3-b] pyridin-5-ylidene)propyl]piperidine The titled compound was prepared by following the procedure of example 51, but replacing the product of example 50 with the product of example 156.
1H-NMR (CD30D) 8: 1.66-1.98(4H,m), 2.40-2.73(SH,m), 2.82-2 . 94 (2H, m) , 3 .22 (2H, m) , 3 . 84 (2H, dd) , 4 . O1 (2H, dd) , 5.23(2H,brs), 6.13(lH,t), 6.64-6.98(3H,m), 7.13-7.34 (4H,m) , 7.45 (lH,m) , 7.77 (lH,m) , 8.47 (lH,m) . OH signal was not observed.
MS m/z: 491(M+1) Example 158 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(1-ethoxycarbonyl-1-methylethyl)oxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidine The titled compound was prepared by following the procedure of example 138, but replacing the product of example 44 with the product of example 151.
1H-rlMR (CDC13) 8: 1 .28 (3H, t) , 1 .56 (6H, s) , 1 . 56-1. 85 (4H,m) , 1.97 (2H,dt) , 2.28-2.55 (5H,m) , 2.93 (2H,m) , 4.24 (2H,q) , 5.28(2H,brs), 6.04(lH,t), 6.62-6.95(3H,m), 7.07-7 . 32 ( SH, m) , 7 . 57 ( 1H, dd) , 8 . 50 ( 1H, dd) .
MS m/z: 561(M+1) Example 159 - 1-[3-(7-(1-Carboxy-1-methylethyl)oxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidine The titled compound was prepared by following the procedure of example 133, but replacing the product of example 48 with the product of example 158.
1H-NMR (CD30D) 8: 1.50 (6H, s) , 1.82-2.18 (4H,m) , 2.70 (2H,m) , 2.87 (lH,m) , 3.12 (2H,m) , 3.30 (2H,m) , 3.60 (2H,m) , 5.25(2H,brs), 6.07(lH,t), 6.67-7.04(3H,m), 7.16-7 . 38 (4H, m) , 7 . 58 ( 1H, m) , 7 . 96 ( 1H, m) , 8 . 52 ( 1H, m) . COOH
signal was not observed.
MS m/z: 533 (M+1) Example 160 - 1-[3-(8-Bromo-5,11-dihydro [1] benzoxepino [2, 3-b] pyridin-5-ylidene) propyl] -4-(4-chlorophenyl)piperidine The titled compound was prepared by following the procedure of example 65, but replacing the product of example 45, step 2 with the product of example 54, step 1.
1H-NMR (CDC13) 8: 1.50-1.86 (4H,m) , 1.98 (2H,m) , 2.26-2.60 (SH,m) , 2.88 (2H,m) , 5.30 (2H,brs) , 6.09 (1H, t) , 6. 96-7 . 36 ( 8H, m) , 7 . 57 ( 1H, dd) , 8 . 51 ( 1H, dd) .
MS m/z: 509, 511(M+1) Example 161 - 1-[3-(8-Carboxy-5,11-dihydro [1] benzoxepino [2, 3-b] pyridin-5-ylidene) propyl] -4-(4-chlorophenyl)piperidine To a solution of 1-[3-(8-Bromo-5,11-dihydro [1] benzoxepino [2, 3-b] pyridin-5-ylidene) propyl] -4-(4-chlorophenyl)piperidine (Example 161) (130 mg) in THF(1.0 ml) was added 1.6M n-butyllithium hexane solution (0.17 ml) at -78°C. After stirring 10 minutes at the same temperature, COZ (dry-ice) was added to the mixture. After being warmed to ambient temperature, the mixture was stirred for 30 minutes at the same temperature. The mixture was concentrated in vacuo. The resulting oil was purified by silica gel chromatography eluted with dichloromethane -methanol (5:1) to give the titled compound 1H-NMR (CD30D) b: 1.55-1.95 (4H,m) , 2.17 (2H,dt) , 2.32-2.78(SH,m), 3.00(2H,m), 5.30(2H,brs), 6.19(lH,t), 7.08-7.54(BH,m), 7.76(lH,dd), 8.45(lH,dd). COOH signal was not observed (50 mg) .
MS m/z: 475 (M+1) Example 162 - 1-[3-(7-Bromo-5,11-dihydro [1] benzoxepino [2, 3-b] pyridin-5-ylidene) propyl] -4-(4-chlorophenyl)piperidin-4-of The titled compound was prepared by following the procedure of example 45, but replacing 5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with 8-bromo-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-one.
1H-NMR (CDC13) b: 1.60-1.71(3H,m), 1.98-2.09(2H,m), 2.34-2.69(8H,m), 5.32(2H,brs), 6.13(lH,t), 6.73(lH,d), 7 . 22-7 . 44 (7H, m) , 7 . 57 ( 1H, dd) , 8 . 52 ( 1H, dd) .
MS m/z: 525, 527(M+1) Example 163 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-ethyl [1] benzoxepino [2, 3-b] pyridin-5-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 45, but replacing 5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with 5,11-dihydro-7-ethyl[1]benzoxepino[2,3-b]pyridin-5-one.
1H-NMR (CDC1,) 8: 1.23 (3H,t) , 1.52 (lH,brs) , 1.66-1.71(2H,m), 1.98-2.06(2H,m), 2.35-2.70(llH,m), 5.31 (2H,brs) , 6.09 (lH,t) , 6.79 (lH,d) , 7.01 (lH,dd) , 7 . 11 ( 1H, d) , 7 . 25-7 . 44 (5H, m) , 7 . 58 ( 1H, dd) , 8 . 49 ( 1H, dd) .

WO 99/37651 PC1'NS99/01266 MS m/z: 475(M+1) Example 164 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-8-vinyl [ 1 ] benzoxepino [2 , 3 -b] pyridin-5 -ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 45, but replacing 5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with 5,11-dihydro-8-vinyl[1]benzoxepino[2,3-b]pyridin-5-one.
1H-NMR (CDC13) b: 1.66-1.71 (3H,m) , 2.00-2.10 (2H,m) , 2 . 36-2 . 70 (8H, m) , 5 . 22 (2H, d) , 5 . 34 (2H, brs) , 5 . 70 (1H, d) , 6.11(lH,t), 6.61(lH,dd), 6.89(lH,d), 6.99(lH,dd), 7.24-7.44 (6H,m) , 7.58 (lH,dd) , 8.49{lH,dd) .
MS m/z: 473(M+1) Example 165 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-8-ethyl [1] benzoxepino [2, 3-b] pyridin-5-ylidene)propyl]piperidin-4-of A mixture of the product of example 164 (100 mg) and Pd-C (20 mg) in ethanol(2 ml) stirred under a hydrogen balloon at room temperature for 1 hour. The mixture was filtered through the celite and distilled off under reduced pressure. The residue was purified by preparative thin layer chromatography eluting with chloroform-methanol (15:1) to give the titled compound (50 mg).
1H-NMR (CDC13) b: 1.22 (3H,t) , 1.55-1.77 (3H,m) , 2.00-2.13(2H,m), 2.33-2.74(lOH,m), 5.32(2H,brs), 6.07 (1H, t) , 6.70 (lH,d) , 6.78 (lH,dd) , 7.19-7.44 (6H,m) , 7.57 (lH,dd) , 8.49 (lH,dd) .
MS m/z: 475 (M+1) Example 166 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-9-methoxy [1] benzoxepino [2, 3-b] pyridin-5-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 45, but replacing 5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with 5,11-dihydro-9-methoxy[1]benzoxepino[2,3-b]pyridin-5-one.
1H-NMR (CDC13) 8: 1.65-1.70 (2H,m) , 1.95-2.06 (2H,m) , 2.15 (lH,brs) , 2.37-2.67 (8H,m) , 3.83 (3H, s) , 5.43 (2H,brs) , 6.09(lH,t), 6.79-6.91(3H,m), 7.22-7.43(5H,m), 7.57(lH,dd), 8 . 44 ( 1H, dd) .
MS m/z: 477 (M+1) Example 167 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro [1] benzoxepino [4, 3-c] pyridin-5-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 45, but replacing 5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with 5,11- dihydro[1]benzoxepino[4,3-c]pyridin-5-one.
1H-NMR (CDC13) 8: 1.67-1.71 (2H,m) , 1.97-2.08 (2H,m) , 2.16(lH,s), 2.40-2.69(8H,m), 5.16(2H,brs), 6.14(lH,t), 6.80 (lH,dd) , 6.91-6.97 (lH,m) , 7.13-7.19 (lH,m) , 7.26-7.44 (6H,m) , 7.50-8.54 (2H,m) .

MS m/z: 447(M+1) Example 168 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro [ 1 ] benzoxepino [4 , 3 -d] pyrimidin- 5 -ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 45, but replacing 5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with 5,11- dihydro[1]benzoxepino[4,3-d]pyrimidin-5-one.
1H-NMR (CDC13) 8: 1.68-1.72 (2H,m) , 1.90 (lH,brs) , 2.06-2.19 (2H,m) , 2.41-2.78 (BH,m) , 5.20 (2H, s) , 6.12 (lH,t) , 7.14-7.45 (BH,m) , 8.72 (lH,s) , 8.97 (lH,s) .
MS m/z: 448 (M+1) Example 169 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-trifluoromethanesulfonyloxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-of To a solution of product of example 44 (1.0 g) in pyridine (10 ml) was added trifluoromethanesulfonic acid anhydride (0.55 ml) at 0°C, and the mixture was stirred at room temperature for 1 hour. Water and diethyl ether were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel chromatography eluting with ethyl acetate-methanol (10:1) to give the titled compound (-1.1 g) .

IH-NMR (CDC13) 8: 1.56 (lH,brs) , 1.66-1.71 (2H,m) , 1.97-2.09 (2H,m) , 2.35-2.69 (BH,m) , 5.35 (2H,brs) 6.15 (lH,t) , 6 . 88 ( 1H, d) , 7 . 05 ( 1H, dd) , 7 . 21-7 .44 (6H, m) , 7 . 60 ( 1H, dd) , 8.54 (lH,dd) .
MS m/z: 595(M+1) Example 170 - 1-[3-(7-Allyl-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-of To a mixture of the product of example 169 (240 mg), allyltributyltin (0.19 ml), dichlorobis(triphenylphosphine)palladium(II) (30 mg), lithium chloride (76 mg), in dimethylformamide (3 ml) under argon at 120°C for 2 hours. Aqueous ammonium fluoride solution and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel chromatography eluting with chloroform-methanol (10:1) to give the titled compound (180 mg).
1H-NMR (CDC13) 8: 1.62-1.72(3H,m), 2.03-2.11(2H,m), 2.39-2.73 (8H,m) , 3.31 (2H,d) , 5.04-5.11 (2H,m) , 5.29(2H,brs), 5.87-6.02(lH,m), 6.06(lH,t), 6.77(lH,d), 6.99(lH,dd), 7.10(lH,d), 7.23-7.43(SH,m), 7.57(IH,dd), 8 . 40 ( 1H, dd) .

Example I71 - 1-[3-(7-(2-t-Butoxycarboxy)ethenyl-5,11-dihydro [1] benzoxepino [2, 3-b] pyridin-5-ylidene) propyl] -4-(4-chlorophenyl)piperidin-4-of A mixture of the product of example 169 (1.7 g), t-butyl acrylate (0.85 ml), triethylamine (2.5 ml), 1,1'-bis(diphenylphosphino)ferrocene (250 mg) and palladium(II) diacetate (33 mg) in dimethylformamide (3 ml) under argon at 90°C for 24 hours. Water ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel chromatography eluting with ethyl acetate-methanol (30:1) to give the titled compound (780 mg).
1H-NMR (CDC13) b: 1.45 (9H,s) , 1.63-1.71 (3H,m) , 1.98-2 .10 (2H,m) , 2.35-2.72 (BH,m) , 5.35 (2H,brs) 6.15 (lH,t) , 6.26 (lH,d) , 6.83 (lH,d) , 7.22-7.44 (7H,m) , 7 . 53 ( IH, d) , 7 . 58 ( 1H, dd) , 8 . 52 ( 1H, dd) .
Example 172 - 1-[3-(7-(2-Carboxy)ethenyl-5,11-dihydro [1] benzoxepino [2, 3-b] pyridin-5-ylidene) propyl] -4-(4-chlorophenyl)piperidin-4-of The product of example 171 (330 mg) was dissolved with 4N hydrochloric acid 1,4-dioxane solution (4 ml), and stirred at room temperature for 1 hour. The solvent was distilled off under reduced pressure. Water was added to the residue, and neutralized with sodium hydroxide solution. The precipitation was filtered to give the titled compound (190 mg).
1H-NMR (DMSO-ds) &: 1.45-1.52(2H,m), 1.72-1.84(2H,m), 2.25-2.58(BH,m), 5.25(2H,brs), 6.28(lH,t), 6.43(lH,d), 6.82 (lH,d) , 7.34-7.60 (BH,m) , 7.75 (lH,dd) , 8.52 (lH,dd) .
Example 173 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-propargyloxy [1] benzoxepino [2, 3-b] pyridin-5-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 46, but replacing ethyl iodide with propargyl chloride.
1H-NMR (CDC13) 8: 1.65-1.71 (2H,m) , 1.79 (lH,brs) , 1.99-2.10(2H,m), 2.35-2.71(9H,m), 4.66(2H,d), 5.28 (2H,brs) , 6.10 (lH,t) , 6.80-6.93 (3H,m) , 7.24-7.46 (SH,m) , 7.59 (lH,dd) , 8.48 (lH,dd) .
MS m/z: 501(M+I) Example 174 - 4-(4-Chlorophenyl)-1-[3-(7-cyclopentoxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 46, but replacing ethyl iodide with cyclopentyl bromide.
1H-NMR (CDC13) S: 1.54-2.18(l3H,m), 2.41-2.72(8H,m), 4.66-4.73(lH,m), 5.27(2H,brs), 6.08(lH,t), 6.70-6.87 (3H,m) , 7.23-7.44 (5H,m) , 7.58 (lH,dd) , 8.49 (lH,dd) .
MS m/z: 531 (M+1) WO 99/37651 PC"T/US99/01266 Example 175 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2-methoxyethyl) oxy) [1] benzoxepino [2, 3-b] pyridin-5-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 46, but replacing ethyl iodide with 2-methoxyethyl chloride.
IH-NMR (CDC13) 8: 1.66-1.75 (3H,m) , 2.00-2.11 (2H,m) , 2 .36-2.71 (BH,m) , 3 .45 (3H, s) , 3 . 71-3 .75 (2H,m) , 4 . 07-4 . lI (2H, m) , 5 . 27 (2H, brs) , 6 . 09 ( 1H, t) , 6.75-6.91{3H,m), 7.23-7.44(SH,m), 7.57(lH,dd), 8.48 (lH,dd) .
MS m/z: 521(M+1) Example 176 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(1-dimethyaminocarbonyl-1-methylethyl)oxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 134, but replacing the product of example 133 with the product of example 139.
1H-NMR (CDC13) 8: 1. 59 (6H, s) , 1. 67-1.72 (2H,m) , 1.99-2.09(2H,m), 2.36-2.70(9H,m), 2.96(3H,s), 3.21(3H,s), 5.25 {2H,brs) . 6.02 (1H, t) , 6.60-6.77 (3H,m) , 7 . 24 -7 . 44 ( 5H, m) , 7 . 58 ( 1H, dd) , 8 . 44 ( 1H, dd) .
MS m/z: 576{M+1) Example 177 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(1-ethoxycarbonylethyl)oxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 46, but replacing ethyl iodide with ethyl 2-bromopropionate.
1H-NMR (CDC13) 8: 1.25(3H,t), 1.59(3H,d), 1.65-1.70{2H,m), 1.98-2.08(2H,m), 2.35-2.68(BH,m), 2.80(lH,brs), 4 .21 (2H, q) , 4 . 68 (1H, q) , 5 .24 (2H, brs) , 6 . 07 (1H, t) , 6.68-6.79 (2H,m) , 6.88 (lH,d) , 7.22-7.44 (5H,m) , 7.56 (lH,dd) , 8.40(lH,dd).
Example 178 - 1-[3-(7-(1-Carboxyethyl)oxy-5,11-dihydro [1] benzoxepino (2, 3-b] pyridin-5-ylidene) propyl] -4-(4-chlorophenyl)piperidin-4-of The titled compound was prepared by following the procedure of example 133, but replacing product of example 48 with product of example 177.
1H-NMR (DMSO-ds) b: 1.46 (3H, d) , 1 . 58-1 . 63 (2H, m) , 1. 98-2.06 (2H,m) , 2.41-2.45 (2H,m) , 2 .72-2.86 (6H,m) , 4.74 (lH,q) , 5.18 (2H,brs) , 6. 11 (1H, t) . 6.73 (2H, s) , 6.84 (1H, s) , 7.36-7.47 (SH,m) , 7.73 (lH,dd) , 8.50 (lH,dd) .
MS m/z: 535{M+1) Example 179 - 4-(4-Chlorophenyl)-1-(3-(5,11-dihydro-7-(1-ethoxycarbonyl)cyclobutoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 46, but replacing ethyl iodide with ethyl 2-bromocyclobutanecarboxylate.
1H-NMR (CDC13) 8: 1.19(3H,t), 1.67-1.71(2H,m}, 1.92-2.11 (SH,m) , 2.33-2.77 (l2H,m) , 4.21 (2H,q} , 5.25(2H,brs),.6.05(lH,t), 6.47(lH,dd), 6.70(lH,d), 6 . 73 (1H, d) , 7 . 23-7 .44 (5H, m) , 7 . 55 (1H, dd) , 8 . 44 (1H, dd) .
Example 180 - 1-[3-(7-(1-Carboxy)cyclbutoxy-5,11-dihydro [1] benzoxepino [2, 3-b] pyridin-5-ylidene) propyl] -4-(4-chlorophenyl)piperidin-4-of The titled compound was prepared by following the procedure of example 133, but replacing product of example 48 with product of example 179.
1H-NMR (DMSO-d6) 8: 1.60-1.65 (2H,m) , 1.86-2.08 (4H,m) , 2.24-2.90(l2H,m), 5.17(2H,brs), 6.05(lH,t), 6.50(lH,dd), 6.66 (lH,d) , 6.73 (lH,d) , 7.37-7.48 (SH,m) , 7.74 (lH,dd) , 8.51 (lH,dd) .
MS m/z: 561(M+1) Example 181 - 1-[3-(7-Carbamoylmethyloxy-5,11-dihydro[1]benzoxepino[2,3-b]pyridin-5-ylidene}propyl]-4-(4-chlorophenyl)piperidin-4-of The titled compound was prepared by following the procedure of example 134, but replacing dimethylamine hydrochloride with ammonium hydroxide.

1H-NMR (CDC13) 8: 1.66-1.71(2H,m), 1.98-2.09(2H,m), 2.21 (lH,brs} , 2.38-2.70 (BH,m) , 4.45 (2H, s) , 5.28 (2H,brs) , 6.09(lH,t), 6.11(lH,brs), 6.58(lH,brs), 6.74-6.85(3H,m), 7.24-7.44 (SH,m) , 7.58 (lH,dd) , 8.47 (lH,dd) .
MS m/z: 520 (M+I) Example 182 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-methylaminocarbonylmethyloxy[1]benzoxepino[2,3-b]pyridin-5 -ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 134, but replacing dimethylamine hydrochloride with methylamine.
1H-NMR (CDC1~3) 8: 1.67-1.72 (2H,m) , 1.99-2.10 (2H,m) , 2 . 3&-2 . 70 (9H, m) , 2 . 89 (3H, d) , 4 .45 (2H, s) , 5 . 28 (2H, brs) , 6.08(IH,t), 6.66(lH,brs), 6.73-6.84(3H,m), 7.25-7.45 (SH,m) , 7.58 (lH,dd) , 8.47 (lH,dd) .
MS m/z: 534(M+1) Example 183 - 1-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-3-c][1]benzoxepiepin-5-ylidene)propyl]-4-(4-hydroxyphenyl)piperidine The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(4-hydroxyphenyl)piperidine.
1H-NMR (CDCL3) d: 1.52-1.88(4H,m), 2.01(2H,dt), 2.28 2.60 (5H,m) , 2.93 (2H,m) , 3.79 (3H, s) , 5.28 (2H,brs) , 6.08(lH,t), 6.68-6.88(3H,m), 7.05-7.36(SH,m), 7.58(lH,dd), 8.50(lH,dd).
MS m/z: 461(M+1) Example 184 - 1-[3-(5,11-Dihydro-7-methoxy [ 1 ] benzoxepino [2 , 3 -b] pyridin-5-yl idene ) propyl ] -4 -3-c][1]benzoxepiepin-5-ylidene)propyl]-4-(2-hydroxyphenyl)piperidine The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(2-hydroxyphenyl)piperidine.
1H-NMR (CDC13} 8: 1.78-1.92 (4H,m) , 2.12-2.25 (2H,m) , 2.32-2 .70 (4H,m) , 2 .80-2.97 {lH,m) , 3 . O1-3 . 15 {2H,m) , 3 .77 (3H, s) , 3.78 (lH,brs) , 5.28 (2H,brs) , 6.03 (lH,t) , 6.74-6.86 (4H,m) , 7.05(lH,dd), 7.11(lH,dd), 7.23-7.28(2H,m), 7.56(lH,dd), 8.48(lH,dd), OH signal was not observed.
MS m/z: 443 (M+1) Example 185 - 4-(7-Chloro-1,2-benzisoxazol-3-yl)-1-[3 (5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5 ylidene)propyl]piperidine The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(7-chloro-1,2-benzisoxazol-3-yl) piperidine. This piperidine was prepared by the same method described in J.
Med. Chem. 28:761-769 (1985).

1H-NMR (CDC13) 8: 1.94-2.20(6H,m), 2.30-2.60(4H,m), 2.86-3.14(3H,m), 3.79(3H,s), 5.29(2H,brs), 6.10(lH,t), 6.70-6.88(3H,m), 7.22(lH,t), 7.27(lH,dd), 7.50(lH,dd), 7.57-7.68 (2H,m) , 8.49 (lH,dd) .
Example 186 - 4-(7-Chloroindol-3-yl)-1-[3-(5,11-dihydro-7-methoxy [1] benzoxepino [2, 3-b] pyridin-5-ylidene)propyl]piperidine The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(7-chloroindol-3-yl)piperidine. This piperidine was prepared by the same method described in J. Med. Chem.
36:4006-4014 (1993) and following hydrogenation described in Example 58, step 3.
1H-NMR(CDC13) S: 1.66-1.88 (2H,m) , 1.92-2.22 (4H,m) , 2.32-2. 63 (4H,m) , 2.78 (lH,m) , 2.97 (2H,m) , 3 .79 (3H, s) , 5.29(2H,brs), 6.09(lH,t), 6.70-6.87(3H,m}, 6.97-7.07 (2H,m) , 7.12-7.30 (2H,m) , 7.52 (lH,m) , 7.59 (lH,dd) , 8.45(lH,brs}, 8.50(lH,dd).
Example 187 - 4-Azido-4-(4-chlorophenyl)-1-[3-(5,11-dihydro-7-methoxy [1] benzoxepino (2, 3-b] pyridin-5-ylidene)propyllpiperidine The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-azido-4-(4-chlorophenyl) piperidine.

WO 99/37651 PCT/US99/01266~

'H-NMR (CDCL3) 8: 1.88 (2H,m) , 2.55-2.85 (4H,m) , 3.00-3.30(6H,m). 3.75(3H,s), 5.19(2H,brs), 5.97(lH,t), 6.68-6.65 (3H,m) . 7.20-7.46 (5H,m) , 7.63 (lH,dd) , 8.35 (lH,dd) .
MS m/z: 477 (M+1-NZ+HZ) Example 188 - Methyl 1-(3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-4-phenylpiperidin-4-carboxylate The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with methyl 4-phenylpiperidin-4-carboxylate.
1H-NMR (CDC13) 8: 1.82-2.15 (4H,m) , 2.28-2.60 (6H,m) , 2.78-2 .82 (2H,m) , 3.62 (3H, s) , 3 .68 (3H, s) , 5.26 (2H,brs) , 5.95(O.lH,t, E isomer), 6.05(0.9H,t, Z isomer), 6.82-6.70 (3H,m) , 7.33-7.22 (6H,m) , 7.65 (O.lH;dd, Z isomer) , 7.55(0.9H,dd, Z isomer), 8.39(O.1H, E isomer), 8 .48 (0 . 9H, dd, Z isomer) .
MS m/z: 485 (M+1) Example 189 - 1-[3-(5,11-Dihydro-7-methoxy [1] benzoxepino [2, 3-b] pyridin-5-ylidene) propyl] -4-phenylpiperidin-4-carboxylic acid The titled compound was prepared by following the procedure of example 133, but replacing product of example 48 with product of example 188.
1H-NMR (CD30D) 8: 2.16-2.23 (2H,m) , 2.69-2 . 91 (4H,m) , 3 .00-3 .16 (2H,m) , 3.37-3.25 (2H,m) , 3 .68-3 .73 (2H,m) , 3 .76 (3H, s) , 5.34(2H,brs), 6.24(lH,t), 6.70-7.04(3H,m), 7.26-7.55(SH,m), 7.79-7.89(lH,m), 8.21-8.34(lH,m), 8.56-8.62(O.lH,m), 8.63-8.77(0.9H,m), MS m/z: 471(M+1) Example 190 - 1-(2-Chlorophenylsulfonyl)-4-[3-(5,11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperazine The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 1-(2-chlorophenylsulfonyl)piperazine.
1H-NMR (CDC13) 8: 2.20-2.58 (8H,m) , 3.12-3.38 (4H,m) , 3 .76 (3H, s) , 5.22 (2H, brs) , 6. 03 (1H, t) , 6.64-6.90 (3H,m) , 7.23 (lH,dd) , 7.32-7.60 (4H,m) , 8.01 (lH,dd) , 8.48 (lH,dd) .
MS m/z: 526(M+1}
Example 191 - 1- (3-Chlorophenylsulfonyl) -4- [3- (5, 11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperazine The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 1-(3-chlorophenylsulfonyl)piperazine.
1H-NMR (CDC13) 8: 2.20-2.60 (BH,m) , 2.82-3 .12 (4H,m) , 3 .76 (3H, s) , 5. 18 (2H,brs} , 6.00 (1H, t) , 6.64-6.90 (3H,m) , 7.23 (lH,dd) , 7.42-7.78 (SH,m) , 8.48 (lH,dd) .
MS m/z: 526(M+1) Example 192 - 1- (4-Chlorophenylsulfonyl) -4- [3- (5, 11-Dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperazine The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 1-(4-chlorophenylsulfonyl)piperazine.
1H-NMR (CDC13) 8: 2.20-2.56 (8H,m) , 2.82-3.10 (4H,m) , 3.76(3H,s), 5.18(2H,brs), 5.99(lH,t), 6.62-6.92(3H,m), 7.23 (lH,dd) , 7.42-7.78 (SH,m) , 8.48 (lH,dd) .
MS m/z: 526(M+1) Example 193 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-hydroxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-1,2,3,6-tetrahydropyridine The titled compound was prepared by following the procedure of example 44, step 2, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(4-chlorophenyl}-1,2,3,6-tetrahydropyridine.
1H-NMR (CDC13) 8: 2.37-2.72 (8H,m) , 3.07 (2H,m) , 5.25 (2H,brs) , 6.00 (lH,m) , 6.07 (lH,t) , 6.60-6.78 (3H,m) , 7.18-7.47(SH,m), 7.56(lH,dd}, 8.50(lH,dd). OH signal was not observed.
MS m/z: 445(M+1) Example 194 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-methoxy [ 1 ] benzoxepino [ 2 , 3 -b] pyridin- 5 -yl idene ) propyl ] -1,2,3,6-tetrahydropyridine The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(4-chlorophenyl)-1,2,3,6-tetrahydropyridine.
1H-NMR (CDC13) 8: 2.37-2.72 (BH,m) , 3.06 (2H,m) , 3 .78 (3H, s) , 5.27(2H,brs), 5.99(lH,m), 6.10(lH,t), 6.72-6.90(3H,m), 7.20-7.44(SH,m), 7.60(lH,dd), 8.50(lH,dd).
MS m/z: 459(M+1) Example 195 - 4-(7-Chloroindol-3-yl)-1-[3-(5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]-1,2,3,6-tetrahydropyridine.
The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(7-chloroindol-3-yl)-1,2,3,6-tetrahydropyridine. This piperidine was prepared by the same method described in J.
Med. Chem. 36:4006-4014 (1993).
1H-NMR (CDC13) 8: 2.37-2.76 (BH,m) , 3 .14 (2H,m) , 3.78 (3H, s) , 5.29(2H,brs), 6.02-6.23(2H,m), 6.67-6.90(3H,m), 7.05 (lH,dd) , 7.12-7.33 (3H,m) , 7.60 (lH,dd) , 7.77 (lH,m) , 8.50 (lH,dd) , 9.06 (lH,br s) .

Example 196 - 5-Chloro-1'-[3-(5,11-dihydro-7-hydroxy [ 1 ] benzoxepino [2 , 3 -b] pyridin- 5 -ylidene)propyl]spiro[isobenzofuran-1(3H),4'-piperidine]
The titled compound was prepared by following the procedure of example 44, step 2, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 5-chlorospiro[isobenzofuran-1(3H),4'-piperidine].
1H-NMR (CDC13) 8: 1.66-1.71(2H,m), 1.79-1.91(2H,m), 2 .26-2 . 73 (BH,m) , 4. 99 (2H, s) , 5.22 (2H, brs) , 6. 07 (1H, t) , 6.63-6.70 (2H,m) , 6.76 (lH,d) , 7.06 (lH,d) , 7.19-7.32 (3H,m) , 7.60 (lH,dd} , 8.47 (lH,dd) , 8.63 (lH,s) .
MS m/z: 475 (M+1) Example 197 - 5-Chloro-1'-[3-(5,11-dihydro-7-(2-methoxyethyl) oxy [1] benzoxepino [2, 3-b] pyridin-5-ylidene)propyl]spiro[isobenzofuran-1(3H),4'-piperidine]
The titled compound was prepared by following the procedure of example 175, but replacing the product of example 44 with the product of example 196.
1H-NMR (CDC13} 8: 1.69-1.74(2H,m), 1.83-1.94(2H,m), 2.31-2.76 (8H,m) , 3 .45 (3H, s) , 3 .72-3.75 (2H,m} , 4 . 08-4 . 11 (2H, m) , 5 . 00 (2H, s) , 5. 28 (2H, brs) , 6 . 09 (1H, t) , 6.74-6.82 (2H,m) , 6.89 (lH,d) , 7.04 (lH,d) , 7.17-7.28 (3H,m) , 7.57(lH,dd), 8.49(lH,dd).
MS m/z: (M+1) Example 198 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-dimethylaminocarbonyl[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-of The titled compound was prepared by following the procedure of example 134, but replacing the product of example 133 with the product of example 118.
1H-NMR (CDC13) 8: 1.65-1.70(2H,m), 1.99-2.09(3H,m), 2.32-2.69 (8H,m) , 2.17 (3H, s) , 5.35 (2H,brs) , 6.15 (1H, t} , 6.82(lH,d), 7.19(lH,dd}, 7.28-7.46(6H,m), 7.58(lH,dd), 8.49(lH,dd).
Example 199 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(1,1-dimethyl-2-hydroxyethyl)oxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-of To a solution of product of example 138 (500 mg) in methanol (5 ml) was added sodium borohydride (330 mg), and the mixture was heated to reflux for 1 hour. The mixture was distilled off under reduced pressure. Water and ethyl acetate were added to the residue, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel chromatography eluting with chloroform-methanol (10:1) to give the titled compound (440 mg).
1H-NMR (CDC13) b: 1.26(6H,s), 1.66-1.70(2H,m), 1.79(lH.brs}, 2.00-2.08(2H,m), 2.37-2.70(9H,m), 3.58 (2H,s) , 5.30 (2H,brs) , 6.05 (lH,t) , 6.75-6.84 (2H,m) , 6.91 (lH,d) , 7.26-7.44 (SH,m) , 7.58 (lH,dd) , 8.49 (lH,dd) .

MS m/z: 535 (M+1) Example 200 -4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(2,2-dimethyl-2-hydroxyethyl)oxy[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-of To a solution of product of example 48 (500 mg) in tetrahydrofuran (5 ml) was added 0.95M methylmagnesium bromide tetrahydrofuran solution (3.8 mI) at 0°C, and the mixture was stirred at room temperature for 20 minutes.
Aqueous ammonium chloride solution and ethyl acetate were added to the mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel chromatography eluting with chloroform-methanol (10:1) to give the titled compound (360 mg).
1H-NMR (CDC13) b: 1.34 (6H, s) , 1.58 (lH,brs) , 1.66-1.71(2H,m), 1.99-2.10(2H,m), 2.25(lH,brs), 2.36-2.71(8H,m), 3.77(2H,s), 5.28(2H,brs), 6.09(lH,t), 6.74-6.86 (3H,m) , 7.24-7.44 (SH,m) , 7.57 (lH,dd) , 8.49 (lH,dd) .
MS m/z: 535(M+1) Example 234 - 1-[3-(5,11-Dihydro-7-methoxy [1] benzoxepino [2, 3-b] pyridin-5-ylidine) propyl] -4-(indol-3-yl)-piperidine The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(indol-3-yl}-piperidine. This piperidine was prepared by the same method described in J. Med. Chem. 36:4006-4014 (1993) and follow hydrogenation described in Example 58, step 3.
1H-NMR(CDC1;} 8: 1.65-1.93 (2H,m) , 1.94-2.28 (4H,m) , 2.34-2 .70 (4H,m) , 2.81 (lH,m) , 2.96 (2H,m) , 3.78 (3H, s) , 5.28(2H,brs), 6.09(lH,t), 6.70-7.42(BH,m), 7.53-7.72 (2H,m) , 8.28 (lH,brs) , 8.49 (lH,m) .
Example 235 - 1-[3-(5,11-Dihydro-7-methoxy [1] benzoxepino [2, 3-b] pyridin-5-ylidine) propyl] -4-(indol-3-yl)-1,2,3,6-tetrahydropyridine.
The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(indol-3-yl)-1,2,3,6-tetrahydropyridine. This piperidine was prepared by the same method described in J. Med. Chem.
36:4006-4014 (1993).
1H-NMR (CDC13) 8: 2.35-2.77 (BH,m) , 3 .06-3 .26 (2H,m) , 3 .78 (3H, s) , 5.29 (2H,brs) , 6.05-6.22 (2H,m) , 6.70-6.88 (3H,m) , 7.07-7.38 (SH,m) , 7.60 (lH,dd) , 7.87 (lH,m) , 8.42 (lH,brs) , 8.50 (lH,m) .
Example 236 - 4-(4-Chlorophenyl)-1-[3-(5,11-dihydro-7-(3-(ethoxycarbonyl}propyloxy[1]benzoxipino[2,3-b]pyridin-5-ylidine)propyl]piperidine The titled compound was prepared by following the procedure of example 153, but replacing ethyl bromoacetate with ethyl 4-bromobutyrate.

1H-NMR (CDCL3} b: 1.26 (3H,t) , 1.56-1.85 (4H,m) , 2.01 (2H,dt} , 2.09 (2H,quint) , 2.30-2.60 (7H,m) , 2.93 (2H,m) , 3.98 (2H, t) , 4.15 (2H,q) , 5.28 (2H,brs) , 6.07 (lH,t) , 6.68-6.86 (3H,m) , 7 . 07-7 . 33 ( 5H, m) , 7 . 58 ( 1H, dd) , 8 . 50 ( 1H, dd) .
MS m/z: 561(M+1) Example 237 - 1-(3-(7-(3-Carboxypropyl)oxy-5,11-dihydro-[1] benzoxepino [2, 3-b] pyridin-5-ylidine) propyl] -4- (4-chlorophenyl}-piperidine The titled compound was prepared by following the procedure of example 133, but replacing the product of example 48 with the product of example 236.
1H-NMR (CD30D) b: 1.92-2.20(6H,m), 2.48(2H,t), 2.70-3.02 (3H,m) , 3.06-3.45 (4H,m) , 3.66 (2H,m) , 4.01 (2H,t) , 5.48 (2H,brs) , 6.36 (1H, t) , 6. 85 (2H, s) , 7. 00 (1H, s) , 7.20-7 .40 (4H,m) , 8 . 11 (1H, dd) , 8 . 64 (1H, d) , 8 . 81 (1H, d) . COOH
signal was not observed.
MS m/z: 533(M+1}
Example 248 - 1'-[3-(5,11-Dihydro-7-methoxy [1] benzoxepino [2, 3-b] pyridin-5-ylidine) propyl] -6-methylspiro(4H-3,1-benzoxazine-4,4'-piperidine]-2(1H)-one The titled compound was prepared by following the procedure of example 45, step 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 6-methylspiro[4H-3,1-benzoxazine-4,4'-piperidin]-2(1H)-one.
'H-NMR (CDC13) b: 1 . 99-2.06 (2H,m) , 2 .29 (3H, s) , 2 . 32-2.69(lOH,m}, 3.77(3H,s), 5.27(2H,brs), 6.08(lH,t), 6.69-6.83 (4H,m) , 6.94 (lH,s) , 7.02 (lH,d) , 7.25 (lH,dd) , 7.55 (lH,dd) , 8.48 (lH,dd) , 8.56 (1H, s) .
MS m/z: 498(M+1) Examples 4-7, 9-11, 13-16, 20, 80-82, 84, 87-88, 92-110, 112-113, 116, 119-127, 129, 136-137, 189, 193-195, 201-233, 236, 238-247 shown in Figure 6 can be prepared by the schemes set forth in Figures 1 - 5 and 7 and by the procedures described above.
Those skilled in the art will be able to recognize, or be able to ascertain, using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

Claims (111)

What is claimed:
1. A method of treating a disease associated with aberrant leukocyte recruitment and/or activation comprising administering to a subject in need thereof an effective amount of a compound represented by the following structural formula:
;
and physiologically acceptable salts thereof, wherein:
Z is a cycloalkyl or non-aromatic heterocyclic ring group fused to one or more aromatic rings, wherein each ring in Z is independently substituted or unsubstituted;
n is an integer from one to about four;
M is > NR2 or > CR1R2;
R1 is -H, -OH, -N3, an aliphatic group, -O-(aliphatic group), -O-(substituted aliphatic group), -SH, -S-(aliphatic group), -S-(substituted aliphatic group), -OC(O)-(aliphatic group), -O-C(O)-(substituted aliphatic group), -C(O)O-(aliphatic group), -C(O)O-(substituted aliphatic group), -CN, -COOH, -CO-NR3R4 or -NR3R4; or R1 is a covalent bond between the ring atom at M and an adjacent carbon atom in the ring which contains M
R2 is -H, -OH, an acyl group, a substituted acyl group, -NR5R6, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group, a substituted benzyl group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group; wherein:
R3, R4, R5 and R6 are independently -H, an acyl group, a substituted acyl group, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group, a substituted benzyl group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group; or R1 and R2, R3 and R4, or R5 and R6 taken together with the atom to which they are bonded, form a substituted or unsubstituted non-aromatic carbocyclic or heterocyclic ring.
2. The method of Claim 1 wherein 2 is represented by the following structural formula:
wherein:
Ring C is a substituted or unsubstituted C6, C7, or C8 non-aromatic carbocyclic ring or a substituted or unsubstituted non-aromatic heterocyclic ring; and Ring A and Ring B are independently substituted or unsubstituted.
3. The method of Claim 2 wherein Z is represented by the structural formula:
;
wherein:
X1 is -S-, -CH2-, -CH2-CH2-, -CH2-S-, -S-CH2-, -O-CH2-, -CH2-O-, -NR2-CH2-, -CH2-NR2-, -SO-CH2-, -CH2-SO-, -S(O)2-CH2-, -CH2-S(O)2-, -CH=CH-, -NR c-CO- or -CO-NR c-; wherein:
R c is -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group or a substituted benzyl group.
4. The method of Claim 3 wherein:
Ring A or Ring B is substituted with -OH, halogen, -O-(aliphatic group), -O-(substituted aliphatic group), -O-(aromatic group), -O-(substituted aromatic group), an electron withdrawing group, -(O)u-(CH2)t-C(O)OR20, - (O)u-(CH2)c-OC(O)R20, -(O)u-(CH2)t-C(O)-NR21R22 or - (O)u-(CH2)t-NHC(O)O-R20;
R20, R21 and R22 are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group; or R21 and R21, taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring;
a is zero or one; and t is an integer from 0 to about 3.
5. The method of Claim 3 wherein:
R c is -(CH2)s-COOR30, -(CH2)s-C(O)-NR31R32 or -(CH2)s-NHC(O)-O-R30;
s is an integer from 1 to about 3; and R30, R31 and R32 are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group; or R31 and R32, taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring.
6. The method of Claim 3 wherein R1 is -H or -OH.
7. The method of Claim 3 wherein:
M is > C(OH)R2; and n is two.
8. The method of Claim 7 wherein R2 is an aromatic or substituted aromatic group.
9. The method of Claim 7 wherein R2 is an aromatic group substituted with halogen.
10. The method of Claim 9 wherein R2 is a 4-chlorophenyl group.
11. The method of Claim 1 wherein Z is represented by the following structural formula:
wherein:
Ring A is a substituted or unsubstituted heteroaryl group;
Ring B is a substituted or unsubstituted aromatic carbocyclic or heteroaryl group;
X1 is -S-, -CH2-, -CH2-CH2-, -CH2-S-, -S-CH2-, -O-CH2-, -CH2-O-, -NR c-CH2-, -CH2-NR c-, -SO-CH2-, -CH2-SO-, -S(O)2-CH2-, -CH2-S(O)2-, -CH=CH-, -NR c-CO- or -CO-NR c-; wherein:
R c is -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group or a substituted benzyl group.
12. The method of Claim 11 wherein:
Ring A or Ring B is substituted with -OH, halogen, -O-(aliphatic group), -O-(substituted aliphatic group), -O-(aromatic group), -O-(substituted aromatic group), an electron withdrawing group, - (O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-OC(O)R20, -(O)u-(CH2)t-C(O)-NR21R22 or -(O)u-(CH2)t-NHC(O)O-R20; wherein:
R20, R21 or R22 are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group; or R21 and R22, taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring;
a is zero or one; and t is an integer from zero to about three.
11. The method of Claim 11, wherein:
X1 is -NR c-CH2-, -CH2-NR c-, -NR c-CO-, or -CO-NR c-;
R c is -(CH2)s-COOR30, -(CH2)s-C(O)-NR31R32 or -(CH2)s-NHC(O)-O-R30;
s is an integer from 1 to about 3;
R30, R31 and R32 are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group; a substituted aromatic group or a non-aromatic heterocyclic group; or R31 and R32, taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring.
14. The method of Claim 11 wherein Ring B is a substituted or unsubstituted heteroaryl group.
15. The method of Claim 11 wherein Ring A is a substituted or unsubstituted pyridyl group and Ring B
is a substituted or unsubstituted aromatic carbocyclic group.
16. The method of Claim 11 wherein Ring A is a substituted or unsubstituted pyridyl group and Ring B
is a substituted or unsubstituted heteroaryl group.
17. The method of Claim 11 wherein R1 is -H or -OH.
18. The method of Claim 11 wherein:
M is > C (OH) R2; and n is two
19. The method of Claim 18 wherein R2 is an aromatic or substituted aromatic group.
20. The method of Claim 18 wherein R2 is an aromatic group substituted with halogen.
21. The method of Claim 20 wherein R2 is a 4-chlorophenyl group.
22. The method of Claim 11 wherein Ring A is a substituted or unsubstituted heteroaryl group and Ring B is a substituted or unsubstituted phenyl group.
23. The method of Claim 22 wherein:
M is > C(OH)R2; and n is two.
24. The method of Claim 23 wherein R2 is a substituted or unsubstituted aromatic group.
25. The method of Claim 23 wherein R2 is an aromatic group substituted with halogen.
26. The method of Claim 25 wherein R2 is a 4-chlorophenyl group.
27. The method of Claim 22 wherein:
Ring A is a pyridyl group;
n is two;
M is > C(OH)R2; and R2 is a 4-chlorophenyl group.
28. The method of Claim 27 wherein X1 is -CH2-S- or -CH2-CH2-.
29. The method of Claim 27 wherein X1 is -CH2-O-.
30. The method of Claim 1 wherein Z is represented by the structural formula:
wherein:

Ring C is a substituted or unsubstituted C6, C7 or C a non-aromatic carbocyclic ring or a substituted or unsubstituted non-aromatic heterocyclic ring;
and Ring A and Ring B are independently substituted or unsubstituted.
31. The method of Claim 30 wherein Z is represented by the following structural formula:
wherein:
X1 is -S-, -CH2-, -CH2-CH2-, -CH2-S-, -S-CH2-, -O-CH2-, -CH2-O-, -NR c-CH2-, -CH2-NR c-, -SO-CH2-, -CH2-SO-, -S(O)2-CH2-, -CH2-S(O)2-, -CH=CH-, -NR c-CO- or -CO-NR c-; wherein:
R c is -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group or a substituted benzyl group; and Ring A and Ring B are independently substituted or unsubstituted.
32. The method of Claim 31 wherein Ring B is substituted with -OH, halogen, -O-(aliphatic group), -O(substituted aliphatic group), -O-(aromatic group), -O-(substituted aromatic group), an electron withdrawing group, -(O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-OC(O)R20, -(O)u-(CH2)t-C-C(O)-NR21R22 or -(O)u-(CH2)t-NHC(O)O-R20; wherein:
R20, R21 or R22 are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group; or R21 and R22, taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring;
a is zero or one; and t is an integer from zero to about 3.
33. The method of Claim 31 wherein X1 is -NR c-CH2-, -CH2-NR c-, -NR c-CO- Or -CONR c-;
R c is -(CH2)s-COOR30, -(CH2)s-C(O)-NR31R32 or -(CH2)s-NHC(O)-O-R30;
s is an integer from one to about three;
R30, R31 or R32 are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group; or R31 and R32, taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring.
34. The method of Claim 32 wherein Z is represented by the following structural formula:
wherein R40 is -OH, halogen, aliphatic group, substituted aliphatic group, -NR24R25, Q-(aliphqtic group), Q-(substituted aliphatic group), -O-(aliphatic group), -O-(substituted aliphatic group), -O-(aromatic group), -O-(substituted aromatic group), an electron withdrawing group, -(O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-OC(O)R20, -(O)u-(CH2)t-C(O)-NR21R22 or -(O)u-(CH2)t-NHC(O)O-R20;
R20, R21 or R22 are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group; or R21 and R22, taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring;
Q is -NR24C(O)- or -NR24S(O)2-;
R24 and R25 are independently -H, -OH, an aliphatic group or a substituted aliphatic group;
u is zero or one; and t is an integer from zero to about 3.
35. The method of Claim 34 wherein:
X1 is -NR c-CH2-, -CH2-NR c, -NR c-CO-, or -CO-NR c-;
R c is -(CH2)s-COOR30, -(CH2)s-C(O)-NR31R32 or -(CH2)s-NHC(O)-O-R30;
R30, R31 or R32 are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group; or R31 and R32, taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring; and s is an integer from one to about three.
36. The method of Claim 34 wherein R40 is -O-CH3.
37. The method of Claim 36 wherein R1 is -OH.
38. The method of Claim 36 wherein M is > C(OH)R2 and n is two.
39. The method of Claim 38 wherein R2 is a substituted or unsubstituted aromatic group.
40. The method of Claim 38 wherein R2 is an aromatic group substituted with halogen.
41. The method of Claim 40 wherein R2 is a 4-chlorophenyl group.
42. The method of Claim 41 wherein X1 is -CH2-O-.
43. The method of Claim 41 wherein X1 is -CH2-S- or -CH2-CH2-.
44. The method of Claim 1 wherein Z is represented by the following structural formula:

wherein:

Ring B is a substituted or unsubstituted aromatic carbocyclic group or heteroaryl group; and X1 is -S-, -CH2-, -CH2-CH2-, -CH2-S-, -S-CH2-, -O-CH2-, -CH2-O-, -NR c-CH2-, -CH2-NR c-, -SO-CH2-, -CH2-SO-, -S(O)2-CH2-, -CH2-S(O)2-, -CH=CH-, -NR c-CO- or -CO-NR c-; wherein:

R c is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group or a substituted benzyl group.
45. The method of Claim 44 wherein Ring B is substituted with -OH, halogen, -O-(aliphatic group), -O-(substituted aliphatic group), -O-(aromatic group), -O-(substituted aromatic group), an electron withdrawing group, -(O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-OC(O)R20, -(O)u-(CH2)t-C(O) -NR21R22 or -(O)u-(CH2)t-NHC(O)O-R20; wherein:

R20, R21 or R22 are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group; or R21 and R22, taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring;

u is zero or one; and t is an integer from zero to about three.
46. The method of Claim 44 wherein X1 is -NR c-CH2-, -CH2-NR c, -NR c-CO-, or -CO-NR c-;

R c is -(CH2)s-COOR30, -(CH2)s-C(O) -NR31R32 or -(CH2)s-NHC(O) -O-R30;

R30, R31 or R32 are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group; or R31 and R32, taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring; and s is an integer from one to about three.
47. The method of Claim 44 wherein R1 is -OH.
48. The method of Claim 44 wherein M is > C(OH)R2 and n is two.
49. The method of Claim 48 wherein R2 is a substituted or unsubstituted aromatic group.
50. The method of Claim 48 wherein R2 is an aromatic group substituted with halogen.
51. The method of Claim 50 wherein R2 is a 4-chlorophenyl group.
52. A method of treating a disease associated with aberrant leukocyte recruitment and/or activation comprising administering to a subject in need thereof an effective amount of a compound represented by the following structural formula:

and physiologically acceptable salts thereof, wherein:

n is an integer from one to about four;

M is > NR2 or > CR2;

R1 is -H, -OH, -N3, an aliphatic group, -0-(aliphatic group), -O-(substituted aliphatic group), -SH, -S-(aliphatic group), -S-(substituted aliphatic group), -OC(O)-(aliphatic group), -O-C(O)-(substituted aliphatic group), -C(O)O- (aliphatic group) , -C(O)O- (substituted aliphatic group) , -CN, -COOH, -CO-NR3R4 or -NR3R4; or R1 is a covalent bond between the ring atom at M and an adjacent carbon atom in the ring which contains M;

R2 is -H, -OH, an acyl group, a substituted acyl group, -NR5R6, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group, a substituted benzyl group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group; wherein:

R3, R4, R5 and R6 are independently -H, an acyl group, a substituted acyl group, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group, a substituted benzyl group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group; or R1 and R2, R3 and R4, or R5 and R6 taken together with the atom to which they are bonded, form a substituted or unsubstituted non-aromatic carbocyclic or heterocyclic ring;

q is zero to three;

the ring containing M is substituted or unsubstituted;

Z is represented by the following structural formula:

wherein:

X1 is -S-, -CH2-, -CH2-CH2-, -CH2-S-, -S-CH2-, -O-CH2-, -CH2-O-, -NR c-CH2-, -CH2-NR c-, -SO-CH2-, -CH2-SO-, -S(O)2-CH2-, -CH2-S (O)2-, -CH=CH-, -NR c-CO- or -CO-NR c-;

wherein:

R c is -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group or a substituted benzyl group; and Ring A and Ring B are independently substituted or unsubstituted.
53. The method of Claim 52 wherein n is two;

M is CR1R2; and R2 is a substituted aromatic group.
54. The method of Claim 53 wherein Z is represented by the following structural formula:

wherein:

R40 is -OH, halogen, aliphatic group, substituted aliphatic group, -NR24R25, Q-(aliphqtic group), Q-(substituted aliphatic group), -O-(aliphatic group), -O-(substituted aliphatic group), -O-(aromatic group), -O-(substituted aromatic group), an electron withdrawing group, -(O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-OC(O)R20, -(O)u-(CH2)t-C(O)-NR21R22 or -(O)u-(CH2)t-NHC(O)O-R20;

R20, R21 or R22 are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group; or R21 and R22, taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring;

Q is -NR24C(O)- or -NR24S(O)2-;

R24 and R25 are independently -H, -OH, an aliphatic group or a substituted aliphatic group;

u is zero or one; and t is an integer from zero to about 3.
55. The method of Claim 54 wherein R40 is -O-aliphatic group; and R1 is -OH.
56. The method of Claim 55 wherein X1 is -CH2-O-.
57. A compound represented by the following structural formula:

and physiologically acceptable salts thereof, wherein:

n is an integer from one to about four;

M is > NR2 or >CR1R2;

R1 is -H, -OH, -N3, an aliphatic group, -O-(aliphatic group), -O-(substituted aliphatic group), -SH, , -S-(aliphatic group), -S-(substituted aliphatic group), -OC(O)-(aliphatic group), -O-C(O)-(substituted aliphatic group), -C(O)O- (aliphatic group), -C(O)O-(substituted aliphatic group), -CN, -COOH, -CO-NR3R4 or -NR3R4; or R1 is a covalent bond between the ring atom at M and an adjacent carbon atom in the ring which contains M;

and R2 is -H, -OH, an acyl group, a substituted acyl group, -NR5R6, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group, a substituted benzyl group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group; wherein:

R3, R4, R5 and R6 are independently -H, an acyl group, a substituted acyl group, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group, a substituted benzyl group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group; or R1 and R2, R3 and R4, or R5 and R6 taken together with the atom to which they are bonded, form a substituted or unsubstituted non-aromatic heterocyclic ring; and Z is represented by the following structural formula:

wherein:

Ring A is a substituted or unsubstituted heteroaryl group;

Ring B is a substituted or unsubstituted aromatic carbocyclic or heteroaryl group;

wherein:

X1 is -S-, -CH2-, -CH2-CH2-, -CH2-S-, -S-CH2-, -O-CH2-, -CH2-O-, -NR c-CH2-, -CH2-NR c-, -SO-CH2-, -CH2-SO-, -S(O)2-CH2-, -CH2-S(O)2-, -CH=CH-, -NR c-CO- or -CO-NR c-; wherein:

R c is -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group or a substituted benzyl group.
58. The compound of Claim 57 wherein:

Ring A or Ring B is substituted with -(O)u-(CH2)t-C(O)OR20, -(O)u- (CH2)t-OC(O)R20, -(O)u-(CH2)t-C(O)-NR21R22 or -(O)u-(CH2)t-NHC(O)O-R20;

R20, R21 and R22 are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group; or R21 and R22, taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring;

u is zero or one; and t is an integer from 0 to about 3.
59. The compound of Claim 57 wherein:

R c is -(CH2)s-COOR30, -(CH2)s-C(O)-NR31R32 or -(CH2)s-NHC(O)-O-R30;

R30, R31 and R32 are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group; or R31 and R32, taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring; and s is an integer from one to about three.
60. The compound of Claim 57 wherein Ring B is a substituted or unsubstituted heteroaryl group.
61. The compound of Claim 57 wherein Ring A is a substituted or unsubstituted pyridyl group and Ring B
is a substituted or unsubstituted aromatic carbocyclic group.
62. The compound of Claim 57 wherein Ring A is a substituted or unsubstituted pyridyl group and Ring B
is a substituted or unsubstituted heteroaryl group.
63. The compound of Claim 57 wherein R1 is -H or -OH.
64. The compound of Claim 57 wherein M is > C(OH)R2 and n is two.
65. The compound of Claim 64 wherein R2 is an aromatic or substituted aromatic group.
66. The compound of Claim 64 wherein R2 is an aromatic group substituted with halogen.
67. The compound of Claim 66 wherein R2 is a 4-chlorophenyl group.
68. The compound of Claim 57 wherein Ring A is a substituted or unsubstituted heteroaryl group and Ring B is a substituted or unsubstituted phenyl group.
69. The compound of Claim 68 wherein:

n is two; and M is > C(OH)R2.
70. The compound of Claim 69 wherein R2 is a substituted or unsubstituted aromatic group.
71. The compound of Claim 69 wherein R2 is an aromatic group that is substituted with a halogen.
72. The compound of Claim 71 wherein R2 is a 4-chlorophenyl group.
73. The compound of Claim 68 wherein:

Ring A is a pyridyl group;

n is two;

M is > C(OH)R2; and R2 is a 4-chlorophenyl group.
74. The compound of Claim 73 wherein X1 is -CH2-S- or -CH2-CH2-.
75. The compound of Claim 73 wherein X1 is -CH2-O-.
76. A compound represented by the following structural formula:

and physiologically acceptable salts thereof, wherein:

n is an integer from one to about four;

M is > NR2 or > CR1R2;

R1 is -H, -OH, -N3, an aliphatic group, -O-(aliphatic group), -O-(substituted aliphatic group), -SH,-S-(aliphatic group), -S-(substituted aliphatic group), -OC(O)-(aliphatic group), -O-C(O)-(substituted aliphatic group), -C(O)O-(aliphatic group), -C(O)O-(substituted aliphatic group) , -CN, -COOH, -CO-NR3R4 or -NR3R4; or R1 is a covalent bond between the ring atom M and an adjacent carbon atom in the ring which contains M;

R2 is -H, -OH, an acyl group, a substituted acyl group, -NR5R6, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group, a substituted benzyl group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group; wherein:

R3, R4, R5 and R6 are independently -H, an acyl group, a substituted acyl group, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group, a substituted benzyl group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group; or R1 and R2, R3 and R4, or R5 and R6 taken together with the atom to which they are bonded, form a substituted or unsubstituted non-aromatic heterocyclic ring; and Z is represented by the following structural formula:

wherein:

X1 is -S-, -CH2-, -CH2-CH2-, -CH2-S-, -S-CH2-, -O-CH2-, -CH2-O-, -NR c-CH2-, -CH2-NR c-, -SO-CH2-, -CH2-SO-, -S(O)2-CH2-, -CH2-S(O)2-, -CH=CH-, -NR c-CO- or -CO-NR c- ; wherein:
R c is -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group or a substituted benzyl group; and Ring A and Ring B are independently substituted or unsubstituted.
77. The compound of Claim 76 wherein Ring B is substituted with -OH, halogen, -O-(aliphatic group), -O-(substituted aliphatic group), -O-(aromatic group), -O-(substituted aromatic group), an electron withdrawing group, -(O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-OC(O)R20, -(O)-(CH2)t-C(O) -NR21R22 or - (O)u-(CH2)t-NHC(O)O-R20; wherein:
R20, R21 or R22 are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group; or R21 and R22, taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring;
u is zero or one; and t is an integer from zero to about three.
78. The compound of Claim 76 wherein X1 is -NR c-CH2-, -CH2-NR c, -NR c-CO-, or -CO-NR c-;
R c is -(CH2)s-COOR30, -(CH2)s-C(O)-NR31R32 or -(CH2)c-NHC(O)-O-R30;
R30, R31 or R32 are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group); or R31 and R32, taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring; and s is an integer from one to about three.
79. The compound of Claim 76 wherein Z is represented by the following structural formula:

wherein:
R40 is -OH, halogen, aliphatic group, substituted aliphatic group, -NR24R25, Q- (aliphqtic group), Q-(substituted aliphatic group), -O-(aliphatic group), -O-(substituted aliphatic group), -O-(aromatic group), -O-(substituted aromatic group), an electron withdrawing group, -(O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-OC(O)R20, -(O)u-(CH2)t-C(O)-NR21R22 or -(O)u-(CH2)t-NHC(O)O-R20;
R20, R21 or R22 are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group; or R21 and R22, taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring;
Q is -NR24C(O)- or -NR24S(O)2-;
R24 and R25 are independently -H, -OH, an aliphatic group or a substituted aliphatic group;
a is zero or one; and t is an integer from zero to about 3.
80. The compound of Claim 79 wherein X1 is -NR c-CH2-, -CH2-NR c, -NR c-CO-, or -CO-NR c-;
R c is -(CH2)s-COOR30, -(CH2)s-C(O)-NR31R32 or -(CH2)s-NHC(O) -O-R30;
R30, R31 or R32 are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group; or R31 and R32, taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring; and s is an integer from one to about 3.
81. The compound of Claim 80 wherein R40 is -O-CH3.
82. The compound of Claim 81 wherein R1 is -OH.
83. The compound of Claim 81 wherein M is >C(OH)R2 and n is two.
84. The compound of Claim 83 wherein R2 is a substituted or unsubstituted aromatic group.
85. The compound of Claim 83 wherein R2 is an aromatic group substituted with halogen.
86. The compound of Claim 85 wherein R2 is a 4-chlorophenyl group.
87. The compound of Claim 86 wherein X1 is -CH2-O-
88. The compound of Claim 86 wherein X1 is -CH2-S- or -CH2-CH2-.
89. The compound of Claim 57 wherein Z is represented by the following structural formula:

wherein:
Ring B is a substituted or unsubstituted aromatic carbocyclic group or heteroaryl group; and X1 is -S-, -CH2-, -CH2-CH2-, -CH2-S-, -S-CH2-, -O-CH2-, -CH2-O-, -NR c-CH2-, -CH2-NR c-, -SO-CH2-, -CH2-SO-, -S(O)2-CH2-, -CH2-S(O)2-, -CH=CH-, -NR c-CO- or -CO-NR c-; wherein:
R c is -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group or a substituted benzyl group.
90. The compound of Claim 89 wherein Ring B is substituted with -OH, a halogen, -O-(aliphatic group), -O-(substituted aliphatic group), -O-(aromatic group), -O-(substituted aromatic group), an electron withdrawing group, -(O)u- (CH2)t-C(O)OR20, -(O)u-(CH2)t-OC(O)R20, (O)u-(CH2)t-C(O)-NR21R22 or -(O)u-(CH2)t-NHC(O)O-R20; wherein:
R20, R21 or R22 are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group; or R21 and R22, taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring;
u is zero or one; and t is an integer from zero to about three.
91. The compound of Claim 89 wherein X1 is -NR c-CH2-, -CH2-NR c, -NR c-CO-, or -CO-NR c-;
R c is -(CH2)s-COOR30, -(CH2)s-C(O)-NR31R31 or -(CH1)s-NHC(O)-O-R30;
R30, R31 or R32 are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group; or R31 and R32, taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring; and s is an integer from one to about three.
92. The compound of Claim 89 wherein R1 is -OH.
93. The compound of Claim 89 wherein M is >C(OH)R2 and n is two.
94. The compound of Claim 93 wherein R2 is a substituted or unsubstituted aromatic group.
95. The compound of Claim 93 wherein R2 is an aromatic group substituted with halogen.
96. The compound of Claim 95 wherein R2 is a 4-chlorophenyl group.
97. A compound represented by the following structural formula and physiologically acceptable salts thereof, wherein:
n is an integer from one to about four;
M i s >NR2 or >CR1R2;
R1 is -H, -OH, -N3, an aliphatic group, -O-(aliphatic group), -O-(substituted aliphatic group), -SH, , -S-(aliphatic group), -S-(substituted aliphatic group), -OC(O)-(aliphatic group), -O-C(O)-(substituted aliphatic group), -C(O)O-(aliphatic group), -C(O)O-(substituted aliphatic group) , -CN, -COOH, -CO-NR3R4 or -NR3R4; or R1 is a covalent bond between the ring atom M and an adjacent carbon atom in the ring which contains M;
R2 is -H, -OH, an acyl group, a substituted acyl group, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group, a substituted benzyl group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group; and Z is represented by the following structural formula:

wherein:
X1 is -S-, -CH2-, -CH2-CH2-, -CH2-S-, -S-CH2-, -O-CH2-, -CH2-O-, -NR c-CH2-, -CH2-NR c-, -SO-CH2-, -CH2-SO-, -S(O)2-CH2-, -CH2-S(O)2-, -CH=CH-, -NR c-CO- or -CO-NR c- ;
R c is -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group or a substituted benzyl group; and Ring A and Ring B are independently substituted or unsubstituted.
98. The compound of Claim 97 wherein Ring A or Ring B has at least two substituents.
99. The compound of Claim 97 wherein Ring A or Ring B is substituted with -OH, a halogen, -O-(aliphatic group), -O-(substituted aliphatic group), -O-(aromatic group), -O-(substituted aromatic group), an electron withdrawing group; (O)u-(CH2)t-C(O)OR20, -(O)u-(CH2)t-OC(O)R20, - (O)u-(CH2)t-C(O)-NR21R22 or -(O)u-(CH2)t-NHC(O)O-R20; wherein:
R20, R21 or R22 are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group; or R21 and R22, taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring;
u is zero or one; and t is an integer from zero to about three.
100. The compound of Claim 97 wherein X1 is -NR c-CH2-, -CH2-NR c, -NR c-CO-, or -CO-NR c-;
R c is -(CH2)s-COOR30, -(CH2)s-C(O)-NR31R32 or -(CH2)s-NHC(O)-O-R30;
R30, R31 or R32 are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group; or R31 and R32, taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring; and s is an integer from one to about three.
101. The compound of Claim 97 wherein:
n is two;
M is >C(OH)R2; and R2 is a substituted or unsubstituted aromatic group.
102. The compound of Claim 101 wherein R2 is an aromatic group substituted with halogen.
103. The compound of Claim 102 wherein R2 is a 4-chlorophenyl group.
104. The compound of Claim 103 wherein X1 is -CH2-S- or -CH2-CH2-.
105. The compound of Claim 103 wherein X1 is -CH2-O-.
106. A compound represented by the following structural formula:

and physiologically acceptable salts thereof, wherein:
n is an integer from one to about four;
M i s >NR2 or >CR1R2;
R1 is -H, -OH, -N3, an aliphatic group, -O-(aliphatic group), -O-(substituted aliphatic group), -SH, -S-(aliphatic group), -S-(substituted aliphatic group), -OC(O)-(aliphatic group), -O-C(O)-(substituted aliphatic group), -C(O)O-(aliphatic group) , -C(O)O-(substituted aliphatic group) , -CN, -COOH, -CO-NR3R4 or -NR3R4; or R1 is a covalent bond between the ring atom at M and an adjacent carbon atom in the ring which contains M;
R2 is -H, -OH, an acyl group, a substituted acyl group, -NR5R6, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group, a substituted benzyl group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group; wherein:
R3, R4, R5 and R6 are independently -H, an aryl group, a substituted acyl group, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group, a substituted benzyl group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group; or R1 and R2, R3 and R4, or R5 and R6 taken together with the atom to which they are bonded, form a substituted or unsubstituted non-aromatic carbocyclic or heterocyclic ring;
q is zero to three;
the ring containing M is substituted or unsubstituted;
Z is represented by the following structural formula:

wherein:
X1 is -S-, -CH2-, -CH2-CH2-, -CH2-S-, -S-CH2-, -O-CH2-, -CH2-O-, -NR c-CH2-, -CH2-NR c-, -SO-CH2-, -CH2-SO-, -S(O)2-CH2-, -CH2-S(O)2-, -CH=CH-, -NR c-CO- or -CO-NR c-;
wherein:
R c is -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group or a substituted benzyl group; and Ring A and Ring B are independently substituted or unsubstituted.
107. The compound of Claim 106 wherein n is two;
M i s CR1R2; and R2 is a substituted aromatic group.
108. The compound of Claim 107 wherein Z is represented by the following structural formula:

wherein:
R40 is -OH, halogen, aliphatic group, substituted aliphatic group, -NR24R25, Q- (aliphqtic group), Q-(substituted aliphatic group), -O-(aliphatic group), -O-(substituted aliphatic group), -O-(aromatic group), -O-(substituted aromatic group), an electron withdrawing group, - (O)u-CH2)t C(O)OR20, -(O)u-(CH2)t-OC(O)R20, -(O)u-(CH2)t-C(O)-NR21R22 or -(O)u-(CH2)t-NHC(O)O-R20;
R20, R21 or R22 are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group; or R21 and R22, taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring;
Q is -NR24C(O)- or -NR24S(O)2-;
R24 and R25 are independently -H, -OH, an aliphatic group or a substituted aliphatic group;
a is zero or one; and t is an integer from zero to about 3.
109. The compound of Claim 108 wherein R40 is -O-aliphatic group; and R1 is -OH.
110. The compound of Claim 109 wherein X1 is -CH2-O-.
111. A method of antagonizing a chemokine receptor in a mammal in need thereof comprising administering a compound of Claim 52.
CA002319077A 1998-01-21 1999-01-21 Chemokine receptor antagonists and methods of use therefor Abandoned CA2319077A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1032098A 1998-01-21 1998-01-21
US09/010,320 1998-01-21
US09/148,823 1998-09-04
US09/148,823 US6613905B1 (en) 1998-01-21 1998-09-04 Chemokine receptor antagonists and methods of use therefor
PCT/US1999/001266 WO1999037651A1 (en) 1998-01-21 1999-01-21 Chemokine receptor antagonists and methods of use therefor

Publications (1)

Publication Number Publication Date
CA2319077A1 true CA2319077A1 (en) 1999-07-29

Family

ID=26681031

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002319077A Abandoned CA2319077A1 (en) 1998-01-21 1999-01-21 Chemokine receptor antagonists and methods of use therefor

Country Status (14)

Country Link
US (1) US6329385B1 (en)
EP (1) EP1049700B9 (en)
CN (1) CN1289336A (en)
AT (1) ATE309249T1 (en)
AU (1) AU2331999A (en)
BR (1) BR9910144A (en)
CA (1) CA2319077A1 (en)
DE (1) DE69928226T8 (en)
DK (1) DK1049700T3 (en)
ES (1) ES2251176T3 (en)
HU (1) HUP0101320A3 (en)
ID (1) ID26618A (en)
IL (1) IL137266A0 (en)
WO (1) WO1999037651A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509346B2 (en) 1998-01-21 2003-01-21 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6613905B1 (en) 1998-01-21 2003-09-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6433165B1 (en) 1998-01-21 2002-08-13 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US7271176B2 (en) * 1998-09-04 2007-09-18 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
MXPA04004826A (en) * 1998-09-04 2004-08-11 Millenium Pharmaceuticals Inc Chemokine receptor antagonists and methods of use thereof.
DE19936780A1 (en) 1999-08-09 2001-02-15 Basf Ag New integrin receptor antagonists
US6740636B2 (en) * 2000-07-31 2004-05-25 Schering Aktiengesellschaft Non-peptide CCR1 receptor antagonists in combination with cyclosporin A for the treatment of heart transplant rejection
EP1448200A2 (en) * 2001-11-19 2004-08-25 Elan Pharmaceuticals, Inc. (4-phenyl)piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
JP4889920B2 (en) * 2001-11-21 2012-03-07 ミレニアム ファーマシューティカルズ， インコーポレイテッド Chemokine receptor antagonist and method of use thereof
US7541365B2 (en) 2001-11-21 2009-06-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6727241B2 (en) 2002-06-12 2004-04-27 Chemocentryx Anti-inflammatory compositions and methods of use
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
MXPA04012393A (en) 2002-06-12 2005-06-17 Chemocentryx 1-aryl-4-substituted piperazines derivatives for use as ccr1 antagonists for the treatment of inflammation and immune disorders.
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
KR100915743B1 (en) * 2002-06-12 2009-09-04 케모센트릭스, 인크. Anti-inflammatory compositions and methods of use
US7842693B2 (en) 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
AU2002354054A1 (en) * 2002-10-18 2004-05-04 Ono Pharmaceutical Co., Ltd. Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient
TWI291467B (en) * 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
CN1950082B (en) 2004-03-03 2013-02-06 凯莫森特里克斯股份有限公司 Bicyclic and bridged nitrogen heterocycles
EP1841429B1 (en) 2004-12-17 2012-04-18 Millennium Pharmaceuticals, Inc. Solid forms of a chemokine receptor antagonist and methods of use thereof
EP1866298A2 (en) * 2005-03-31 2007-12-19 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
EP2222680A1 (en) * 2007-11-30 2010-09-01 Millennium Pharmaceuticals, Inc. Process improvement
EP2231675A1 (en) * 2007-11-30 2010-09-29 Millennium Pharmaceuticals, Inc. Process for the preparation of 5-cyclopropyl-5, 11-dihydro (1) benzoxepino (3, 4-b) -pyridin-5-ol using tmeda
US20090286823A1 (en) * 2007-12-17 2009-11-19 Millennium Pharmaceuticals Inc. CCR1 Inhibitors useful for the treatment of multiple myeloma and other disorders

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD80449A (en)
GB1003292A (en) 1960-12-08 1965-09-02 Sandoz Ag Improvements in or relating to 4-azathiaxanthene derivatives
FR145F (en) 1964-06-01
CH421138A (en) 1965-11-04 1966-09-30 Wander Ag Dr A Process for the preparation of thioxanthene derivatives
US3409621A (en) 1966-04-01 1968-11-05 Schering Corp Piperazino-aza-dibenzo-[a, d]-cycloheptenes
US3625974A (en) 1967-04-28 1971-12-07 Fujisawa Pharmaceutical Co Dibenzothiazepine derivatives
NL6905642A (en) 1968-04-12 1969-10-14
GB1330966A (en) 1970-12-22 1973-09-19 Yoshitomi Pharmaceutical N-substituted piperidine compounds methods for their production and pharmaceutical compositions containing them
US3770729A (en) 1970-12-22 1973-11-06 Yoshitomi Pharmaceutical N substituted piperidine compounds
CA1010870A (en) 1972-12-08 1977-05-24 Niels Lassen Thiaxanthene derivative and method
US4250176A (en) 1976-12-21 1981-02-10 Janssen Pharmaceutica N.V. Piperazine derivatives
US4335122A (en) 1981-03-18 1982-06-15 Hoechst-Roussel Pharmaceuticals Inc. Dihydro-dibenzoxepines-thiepines and -morphanthridones, compositions and use
DE3326641A1 (en) 1982-07-27 1984-02-02 Basf Ag, 6700 Ludwigshafen 5,6-Dihydro-11H-morphanthridin-6-ones, their preparation and medicaments containing these
CA1237428A (en) 1983-06-24 1988-05-31 Hiroshi Tanaka ¬1| benzepino¬3,4-b|pyridine derivative
DE3402060A1 (en) 1984-01-21 1985-08-01 Dr. Karl Thomae Gmbh, 7950 Biberach SUBSTITUTED 5,11-DIHYDRO-6H-DIBENZ (B, E) AZEPIN-6-ONE, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
JPH0665664B2 (en) 1985-01-18 1994-08-24 大塚製薬株式会社 Morphoanthridine derivative
SE8500273D0 (en) 1985-01-22 1985-01-22 Leo Ab NEW TRICYCLIC ASSOCIATIONS, COMPOSITIONS CONTAINING SUCH ASSOCIATIONS, MANUFACTURING PROCEDURES AND METHODS OF TREATMENT
JPS6310784A (en) 1986-03-03 1988-01-18 Kyowa Hakko Kogyo Co Ltd Dibenz(b,e)oxepin derivative, antiallergic agent and anti-inflammatory agent
US5089496A (en) 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
IT8721978A0 (en) 1987-09-21 1987-09-21 Angeli Inst Spa NEW TRICYCLIC AMIDE DERIVATIVES.
US4882351A (en) 1987-10-14 1989-11-21 Roussel Uclaf Tricyclic compounds
US4994463A (en) 1987-12-14 1991-02-19 Kyowa Hakko Kogyo Co., Ltd. Tricyclic thromboxane A2 antagonists
ATE108453T1 (en) 1988-04-28 1994-07-15 Schering Corp BENZOPYRIDOPIPERIDINE, PIPERIDYLIDS AND PIPERAZINE COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USE.
CA1338625C (en) 1988-06-09 1996-10-01 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
US5242931A (en) 1988-06-09 1993-09-07 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds as TXA2 antagonists
DE3838912A1 (en) 1988-11-17 1990-05-23 Thomae Gmbh Dr K MEANS FOR THE TREATMENT OF ACUTE AND CHRONIC OBSTRUCTIVE RESPIRATORY DISEASES
JPH0694464B2 (en) 1991-01-23 1994-11-24 協和醗酵工業株式会社 Tricyclic compound and its intermediate
CA2062587A1 (en) 1991-03-11 1992-09-12 Toshiaki Kumazawa Indole derivatives
EP0515158A1 (en) 1991-05-23 1992-11-25 Schering Corporation Novel benzopyrido piperidylidene compounds, compositions, methods of manufacture and methods of use
AU2392392A (en) 1991-07-23 1993-02-23 Schering Corporation Novel benzopyrido piperylidene compounds, compositions, methods of manufacture and methods of use
US5378701A (en) 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
US5679703A (en) 1992-09-16 1997-10-21 Kyowa Hakko Kogyo, Co., Ltd. Tricyclic compounds having ACAT inhibiting activity
US5538986A (en) 1993-12-06 1996-07-23 Schering Corporation Tricyclic derivatives, compositions and methods of use
MY113463A (en) 1994-01-04 2002-03-30 Novo Nordisk As Novel heterocyclic compounds
JPH07220200A (en) * 1994-01-31 1995-08-18 Nec Software Ltd Aircraft control and authority transfer system for ocean airspace
JPH07330064A (en) * 1994-06-08 1995-12-19 Fukui Shokai:Kk Prepaid card case
JPH0849377A (en) * 1994-08-05 1996-02-20 Fuji Kogyo:Kk Method and structure of mounting solar cell module
WO1996031469A1 (en) 1995-04-07 1996-10-10 Novo Nordisk A/S N-substituted azaheterocyclic carboxylic acids and esters thereof
AU5271096A (en) 1995-04-07 1996-10-23 Novo Nordisk A/S Novel heterocyclic compounds
US5801175A (en) 1995-04-07 1998-09-01 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
UA54385C2 (en) * 1995-04-07 2003-03-17 Ново Нордіск А/С N-substituted azaheterocyclic carboxylic acids and etHers thereof, a method for THEIR PREPARATION, a pharmaceutical composition and a method for treatment
US5712280A (en) 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
JPH0940662A (en) 1995-05-24 1997-02-10 Kyowa Hakko Kogyo Co Ltd Tricyclic compound
CA2231773A1 (en) 1995-09-13 1997-03-20 Shigeru Aono Phenylpiperidine derivative
WO1997024325A1 (en) 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
WO1997044329A1 (en) 1996-05-20 1997-11-27 Teijin Limited Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists
US6281212B1 (en) 1996-07-12 2001-08-28 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6323206B1 (en) 1996-07-12 2001-11-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
EP0916668A4 (en) 1996-07-29 2000-08-16 Banyu Pharma Co Ltd Chemokine receptor antagonists
CN1104427C (en) 1996-09-13 2003-04-02 先灵公司 Tricyclic inhibitors of farnesyl protein transferase
WO1998011106A1 (en) 1996-09-13 1998-03-19 Schering Corporation Tricyclic compounds useful as fpt inhibitors
CA2264666A1 (en) 1996-09-13 1998-03-19 Schering Corporation Substituted benzocycloheptapyridine useful as inhibitors of farnesyl-protein transferase
NZ334340A (en) 1996-09-13 2000-09-29 Schering Corp Tricyclic compounds that inhibits farnesyl protein transferase I but not geranylgeranyl protein transferase I in the treatment of cancer or cancer-like conditions
ES2229340T3 (en) 1996-09-13 2005-04-16 Schering Corporation TRICICLIC ANTITUMORAL COMPOUNDS, INHIBITORS OF FARNESIL-PROTEINA-TRANFERASA.
EP0931078B1 (en) 1996-09-13 2006-11-15 Schering Corporation Novel tricyclic piperidinyl compounds useful as inhibitors of farnesyl-protein transferase
ID22156A (en) 1996-09-13 1999-09-09 Schering Corp SUBSTITUTION OF BENZOSICLOHEPTAPIRIDINA SUBSTITUTION THAT USE TO INHIBIT FERNESIL PROTEIN TRANSFERASE
HUP0000088A3 (en) 1996-10-04 2000-09-28 Novo Nordisk As N-substituted azaheterocyclic compounds, process for producing them and pharmaceutical compositions containing them
AU5604998A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
AU5522498A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
WO1998025605A1 (en) 1996-12-13 1998-06-18 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
AU5812498A (en) 1996-12-20 1998-07-17 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
WO1998043638A1 (en) 1997-03-27 1998-10-08 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for autoimmune diseases
WO1998046587A1 (en) 1997-04-15 1998-10-22 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
US5877177A (en) 1997-06-17 1999-03-02 Schering Corporation Carboxy piperidylacetamide tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US6040318A (en) 1997-06-25 2000-03-21 Novo Nordisk A/S Tricycle substituted with azaheterocyclic carboxylic acids
US6048856A (en) 1997-12-17 2000-04-11 Novo Nordisk A/S Heterocyclic compounds
US6433165B1 (en) 1998-01-21 2002-08-13 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
EP1109815A1 (en) 1998-09-04 2001-06-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor

Also Published As

Publication number Publication date
BR9910144A (en) 2002-04-02
IL137266A0 (en) 2001-07-24
AU2331999A (en) 1999-08-09
EP1049700B1 (en) 2005-11-09
CN1289336A (en) 2001-03-28
DE69928226T8 (en) 2006-10-19
ES2251176T3 (en) 2006-04-16
DE69928226D1 (en) 2005-12-15
EP1049700A1 (en) 2000-11-08
EP1049700B9 (en) 2006-05-10
DK1049700T3 (en) 2006-02-20
ID26618A (en) 2001-01-25
US6329385B1 (en) 2001-12-11
WO1999037651A1 (en) 1999-07-29
ATE309249T1 (en) 2005-11-15
HUP0101320A2 (en) 2001-12-28
HUP0101320A3 (en) 2002-11-28
DE69928226T2 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
US6329385B1 (en) Chemokine receptor antagonists and methods of use therefor
US6509346B2 (en) Chemokine receptor antagonists and methods of use therefor
JP5936669B2 (en) Chemokine receptor antagonists and methods of use thereof
JP4853934B2 (en) Chemokine receptor antagonist and method of use thereof
US20020169155A1 (en) Chemokine receptor anagonists and methods of use therefor
US9663537B2 (en) Chemokine receptor antagonists and methods of use
JP2002501072A5 (en)
WO2003045942A2 (en) Chemokine receptor antagonists and methods of use thereof
US20050070549A1 (en) Chemokine receptor antagonists and methods of use thereof
MXPA00007140A (en) Chemokine receptor antagonists and methods of use therefor

Legal Events

Date Code Title Description
FZDE Discontinued